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Zusammenfassung  
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„Selektive Markierung von Peptiden mit Organometall-Verbindungen -  Chemische und 
biologische Charakterisierung“ 
 
Referent: Prof. Dr. N. Metzler-Nolte 
Koreferent: Prof. Dr. A. Jäschke 
 
Die Kopplung von Übergangsmetall-Verbindungen an Peptide und Proteine  verleiht 
diesen biologisch aktiven Substanzen einzigartige spektroskopische Eigenschaften, wel-
che sie zu wertvollen Werkzeugen in Diagnose und Therapie machen. In dieser Arbeit 
wurden neue Methoden zur Einführung von Organometall-Verbindungen in Peptide 
entwickelt. Diese konnten an einem Pentapeptid, [Leu5]-Enkephalin, gezeigt werden, 
während Metallocenderivate als Metall-Marker zum Einsatz kamen. 
Die Synthese des Pentapeptids Enkephalin und die nachfolgende Markierung durch Fer-
rocen- bzw. Cobaltoceniumcarbonsäure wurden mittels Festphasensynthese realisiert. 
Dabei konnten die Organometall-Gruppen sowohl an den N-Terminus als auch an die 
Seitenkette eines 4-Amino-modifizierten Phenylalanins gebunden werden. Die unter-
schiedlichen Eigenschaften der jeweiligen Metallverbindungen erforderten den Einsatz 
einer Vielzahl verschiedener Harze, Linker und Schutzgruppen. 
Im zweiten Teil der Arbeit wurde mit der Sonogashira-Kopplung, einer Palladium-
katalysierten Kreuzkopplung, eine weitere Methode zur Verknüpfung eines Biomole-
küls mit einer Organometall-Verbindung vorgestellt. Diese Kopplungsreaktion veknüpft 
ein Iodaren und eine Alkinyl-Funktion und wurde zunächst an einer Reihe von Dipepti-
den getestet, welche ein 4-Iodo-Phenylalanin enthielten. Nach erfolgreicher Kopplung 
einiger Ferrocen-Alkinyl-Verbindungen wurde diese Technik auf das Neuropeptid En-
kephalin übertragen, das ebenfalls an der Phenylalanin-Seitenkette markiert werden 
konnte.  
Um den Einfluss des Metall-Markers auf die physiologischen Eigenschaften des Ziel-
moleküls zu untersuchen, wurde die Lipophilie einer Reihe von Enkephalin-Derivaten 
mit einer modernen HPLC-Methode gemessen. Zusätzlich konnte die Blut-Hirn-
Schranken-Permeabilität in einem in vitro Modell bestimmt werden, welches auf porzi-
nen Hirnkapillar-Endothelzellen basiert. Hierbei zeigte sich eine bessere Permeabilität 
für Substanzen mit höherer Lipophilie, wie es für einen reinen Diffusionsmechanismus 
erwartet werden kann. 
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„Selective Labelling of Peptides with Organometallic Compounds - Chemical and Bio-
logical Characterization“ 
 
1st  Referee: Prof. Dr. N. Metzler-Nolte 
2nd  Referee: Prof. Dr. A. Jäschke 
 
The modification of peptides and proteins with transition metal compounds is a growing 
field of interest, since it provides biologically active substances with unique spectro-
scopic properties, serving as valuable tools in diagnosis and therapy. In this work, new 
methods for the introduction of organometallic compounds into peptides have been pre-
sented, using the pentapeptide [Leu5]-Enkephalin as a model target molecule, while 
ferrocene and cobaltocenium compounds served as metal markers. 
Preparation of enkephalin and the subsequent labelling with ferrocene- and cobaltoce-
nium carboxylic acids were carried out using solid phase peptide synthesis (SPPS). 
These synthetic pathways comprised the introduction of the metal marker to the N-
terminus, as well as to the side-chain of a 4-amino modified phenylalanine residue, 
yielding mono- and di-labelled species. The different properties of the metal compounds 
used demanded the combination of diverse linkers, resins and protecting groups.  
In the second synthetic part of this work, the binding of the metal fragment by the use of 
Sonogashira coupling, a Pd catalyzed cross coupling reaction, was evaluated. As a proof 
of concept, dipeptides containing a 4-iodo-phenylalanine were synthesized and different 
alkynylated ferrocene derivatives were successfully coupled. An enkephalin derivative 
was synthesized next where the natural phenylalanine was substituted by the 4-iodo-
phenylalanine residue, to which the ferrocene-alkyne could be successfully coupled. 
To study the influence of the metal marker on the physiological properties of the target 
enkephalin molecule, the lipophilicity was determined for a selection of enkephalin 
compounds using a modern RP-HPLC method. In addition, the blood-brain-barrier 
permeation behaviour of selected compounds was tested. These transport experiments 
were conducted by means of porcine brain capillary endothelial cell (PBCEC) monolay-
ers. It was found that the more lipophilic compounds showed higher permeation, as ex-
pected for a passive diffusion mechanism.  
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General remarks 
 
In this thesis, ferrocene and cobaltocenium groups are abbreviated by Fc and Cc, re-
spectively. Both represent the (C5H5)M(C5H4) moiety, for M = Fe, Co. Within this sys-
tem ferrocene would be noted as Fc-H and cobaltocenium carboxylic acid as Cc-COOH, 
like indicated in Fig. I. 
 
 
Fe Co
H COOH
Fc-H Cc-COOH  
 
Fig. I Ferrocene and cobaltocenium carboxylic acid. Fc and Cc represent C5H5MC5H4 (M = Fe, Co) 
 
 
The nomenclature for amino acids and peptides in this thesis is as commonly used in 
peptide chemistry. It is based on the general amino acid structure shown in Fig. II. 
When bound inside a peptide or protein the amino acid residue only implies the N-
terminal NH group and the C-terminal carbonyl function. Glycine, for example, with the 
formula H2N-CH2-COOH is referred to as H-Gly-OH. 
 
 
O
OH
H
NH
H
N
O
N
H O
OMe
O
O
H-Gly-OH Boc-Gly-Ala-OMe
CH3
 
 
Fig. II Nomenclature for amino acids and peptides 
1  Introduction 
1.1 General introduction 
Only a few decades ago the classical areas of chemical research like organic, inorganic 
and biochemistry were strictly separated. Especially the field of inorganic chemistry, 
mainly being the study of (transition) metal compounds, and the discipline of biochem-
istry had been viewed as merely incompatible. This has been changing to an ever in-
creasing extend and techniques of the one field are being used with great success in the 
other. As a consequence the field of transition metal chemistry for the organic chemist 
continues to expand and have a significant role in functional group conversion and or-
ganic total synthesis.1-3 On the other hand has Merrifield’s invention of solid phase pep-
tide synthesis4 (SPPS) greatly enriched the field of biochemistry, since it provides a 
synthetic tool for small to medium sized biopolymers of high purity.5-7 With the discov-
ery of a growing number of metallo-enzymes8-10 and other transition metal containing 
biomolecules,11, 12 which play an essential role in biology, the two areas of inorganic 
chemistry and biochemistry become more related, as well. 
 
1.2 Bio-Inorganic Chemistry 
Bio-Inorganic chemistry comprises the study of the functions, processing, storage, and 
applications of metal ions and their complexes in biological systems. It is a rapidly 
growing field that combines numerous disciplines, including inorganic chemistry, bio-
chemistry, molecular and cell biology, environmental and medicinal chemistry.  
 
Alkaline and earth alkaline metals, especially Na+, K+, Ca2+ and Mg2+ have been known 
to have vital functions in life13, 14 for a very long time. These functions include the con-
struction of the skeleton, the building of membrane potentials in nerve cells, the folding 
of proteins or DNA/RNA and many more. Just lately a Nobel Prize was awarded for the 
discovery of alkaline ion channels in cell membranes.15 
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Apart from these group 1 and 2 metals we nowadays know that a number of transition 
metals are also necessary for living organisms. The versatility of these metals may be 
derived from the high number of stable oxidation states they can accept and we can find 
them in transport (haemoglobin/transferrin), catalysis (cytochrome P450) and structural 
motifs (zinc finger).  
Hemes, for example, contain iron and have been one of the centers of attention since the 
earlier days of biological inorganic chemistry.16-19 Cytochrome P450 is such a heme-
containing enzyme from the respiratory system of plants, animals and humans. Its im-
portant task is to oxidize, i.e. hydroxylate various substrates. The catalytic center of the 
enzyme consists of a low-spin Fe3+ coordinated by the porphyrine system of the heme 
and a cystein sulphur atom. After initial reduction to Fe2+ one electron is transferred 
from the iron to the binding O2 and a high-spin Fe3+ with a superoxide ligand is formed. 
After release of one oxygen atom as a water molecule and the following hydroxylation 
of the substrate the low-spin Fe2+ is restored.20, 21 Substructures of this catalytic cycle 
have been presented.22, 23  
Non-heme iron enzymes catalyze a variety of redox processes, as well.24, 25 Nitrogenase 
is such an enzyme which makes environmental dinitrogen available for biochemical 
processes through reduction to ammonia. The active site contains an iron/sulphur cluster 
and one molybdenum atom.26-28 The exact mechanism of the highly energy consuming 
process is still in the dark. 
Angiotensin converting enzyme (ACE), a carboxypeptidase, is responsible for cleaving 
the two carboxy terminal amino acids His-Leu from angiotensin I to produce angio-
tensin II, a potent vasopressor octapeptide.29 The enzyme contains a Zn2+ ion as a metal 
ion cofactor which is at the heart of the active site. The zinc ion is coordinated in a pen-
tahedral geometry first by three amino acid side chains in the active site namely through 
a nitrogen atom from histidines 69 and 196, and through two oxygen atoms from glu-
tamic acid 72. The fifth bonding position is either a water molecule or an oxygen center 
from the carbonyl group of Gly 1.30 The nucleophilic carbonyl oxygen atom of the tar-
get peptide binds to the zinc center, therefore destabilizing the Cα-N bond through a 
betain structure, enabling easy hydrolysis of the peptide.  
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1.3 Bio-Organometallic chemistry 
The metallo-enzymes mentioned above have all in common that the metal ion is coordi-
nated by classical donors like O, N and S atoms. However, enzymes with organometal-
lic moieties are also known in nature, one example thereof being cobalamin, also known 
as vitamin B12, which contains a cobalt fragment.31 
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Fig. 1.1    The structure of cobalamin, vitamin B12 
 
The Co3+ ion is coordinated by a corrine ring which is apart from a higher grade of satu-
rationsaturation and a missing methylene group very similar to the heme’s porphyrine 
ring system. The fifth ligand is a benzimidazol riboside. The synthetically obtained 
cyano cobalamin is transformed in vivo into the active compounds methyl cobalamin 
and 5’-desoxyadenosyl cobalamin, respectively.32 Vitamin B12 serves as a cofactor for 
biosynthesis of purine- and pyrimidine bases, reduction of ribonuctleotide triphosphates 
to 2-desoxyribo-nucleotide triphosphates and synthesis of methionine from homocys-
tein.33 The meta stability of the Co-C bond allows easy methylation and isomerization 
of the substrate. 
A second example is hydrogenase, a bacterial enzyme which catalyzes the reversible 
transformation of dihydrogen into protons and two electrons. Several forms are known, 
one of it being [Fe-Ni]-hydrogenase, which contains a heterobimetallic active center, 
the structure of which has recently been elucidated8 and is shown in Fig. 1.2.  
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[Fe-Ni]-hydrogenase is truly organometallic, since one carbonyl and two cyanide 
ligands are bound to the iron atom (Fig. 1.2).  
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Fig. 1.2   The catalytic center of [Fe-Ni]-hydrogenase from Desulfovibrio Gigas. The “unready” 
state (left) can be transformed into the active form (right) by a two electron H2-reduction. 
 
The crystal structure of the “unready” state of the enzyme, referred to as Ni-A, discloses 
a bridging ligand, identified as a hydroxyl group by ENDOR spectrometry.34 However, 
the Ni-A state requires prolonged hydrogen exposure to be activated and be transferred 
into Ni-C, the active form of the enzyme. Other oxidised forms which could be deduced 
from EPR spectroscopy have been presented, too.35-38 
 
1.4 Applications of bio-compatible organometallic compounds 
To the uninitiated it may seem that organometallic compounds, generally known for 
their high reactivity, have no relevance in biological or medicinal applications which 
usually take place in aqueous media and with dioxygen present. That is clearly not true 
because quite a range of organometallic substances like ferrocene39-41 and the cobalto-
cenium ion40, 41 show great stability in water at different pH values, making them first 
row candidates for biological applications (see chapter 2). Showing different properties 
and reactivity compared to donor coordinated metals, these compounds can add some 
very powerful spectroscopic probes to the shelf of the analytic scientist.  
 
1.4.1 Immunoassays 
Since the early 1960s, the use of immunological tests has revolutionized clinical chem-
istry and biochemistry. In these so-called immunoassays the selective binding of an an-
tibody to the responding antigen is exploited, with either of both being marked with a 
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detectable group. In this way the antigen-antibody adduct results in a signal which can 
be measured easily and with high precision. Possible analytes are proteins and hor-
mones or even small compounds (haptens), which have to be attached to a protein be-
forehand.42-44 In the beginning most of these assays were radio immunoassays (RIA), 
i.e. the label was a radioactive element like 125I or 3H. However, because of the hazards 
associated with the use of radioactivity, development and commercialization of a num-
ber of non-isotopic immunological methods has been driven forth. The most widespread 
methods now use enzymes45, 46, fluorescent47-49, chemi- and bioluminescent50, 51 and 
electrochemical52, 53 probes as labels associated to analytical methods such as col-
orimetry, fluorescence spectroscopy or electrochemical detection. 
 
A new interesting development in the field has been initiated  by Jaouen and co-workers 
who presented a non-isotopic immunological assay termed CMIA (carbonyl metallo 
immunoassay) that uses metal carbonyl complexes as tracers and Fourier transform in-
frared spectroscopy (FT-IR) as the detection method.54 The assay is based on the very 
strong absorption bands in the 1800-2200 cm-1 spectral range where proteins and bio-
molecules do normally not absorb.55  
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Fig. 1.3    The antiepileptic drug Phenobarbital (left) is modified with a cymantrene group (right) to 
enable infrared detection. 
 
The number of suitable metal carbonyl tracers has increased over the years and work 
with Cr(CO3), Mo2(η5-C5H5)2(CO)4, Co2(CO)6 and Re(CO3) has been published.56-62 
These are examples of the use of an organometallic probe attached to biomolecules, 
offering new ways of detection. 
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1.4.2 Radiopharmaceuticals 
Another growing and well established sector is the area of metallopharmaceuticals, 
which are applied both in diagnosis and therapy.63 Many of these drugs are used in im-
aging applications some of them being metallo-radiopharmaceuticals.  
These drugs contain radioactive material and are administered to the patient either par-
enterally or orally. After a certain time of distribution in the person’s body, an image 
with high resolution can be recorded using a so-called Anger (gamma) camera.64  
More than 80% of all radiopharmaceuticals contain technetium (99mTc), because this 
nuclide advantageously combines a short half-life of 6 h with a relatively low energy of 
emitted gamma photons (140 keV) and thus minimizes the radiation hazard for all in-
volved.  
The first organometallic 99mTc compound for use in nuclear medicine has been reported 
by Davidson et al.65 (Fig. 1.4). The monodentate, highly back-bonding, isonitrile ligand 
allows the complex to form an unstrained octahedral geometry with very strong Tc-C 
bonds as demonstrated in the crystal structure.66   
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Fig. 1.4 [Tc(tbi)6]+(left), as reported by Davidson et al. Technetium(I) in an octahedral geometry of 
six isonitrile ligands. Cardiolite (right) is the first clinically applied organometallic com-
pound in nuclear medicine. 
1.4  Applications of bio-compatible organometallic compounds 7 
This water and air-stable compound was found to be quite robust and formed readily by 
simply heating 99mTcO4- with excess isonitrile and SnCl2 as the reducing agent. Cardio-
lite and similar organometallic 99mTc compounds have been successfully used in clinical 
applications since, but the demand for a more selective enrichment in target tissues is 
still high. Therefore a system which binds the technetium compound to the targeting 
(bio)molecule is needed.  
Schubiger, Alberto and co-workers presented such a system, reporting the synthesis of 
the complex fac-[Tc(CO)3(H2O)3]+, where Tc is strongly bound to three carbonyl groups 
and only weakly connected to the water ligands, which easily exchange with a tridentate 
donor ligand.67-69 A variety of biomolecules like cobalamin (Fig. 1.1), biotin and 
[Leu5]-Enkephalin (→ chapters 4,5) have been labelled with 99mTc(CO)3 using a modi-
fied histidine ligand70, 71 (Fig. 1.5).  
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Fig. 1.5 A modified histidine linker binds the radioactive metal carbonyl moiety to the C-terminal 
end of the pentapeptide [Leu5]-Enkephalin. (from Ref. 70)   
 
 
The choice of linker depends on a number of aspects, amongst them are the strength of 
binding to the metal ion, its stability and the complexity of the synthesis.67 Also the size 
of the linker is an important issue, since the biomolecule’s original properties are influ-
enced by the linker, as well. The choice of the wrong linker might therefore result in 
loss of activity, bad solubility or aggregation.  
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1.4.3 Tumor inhibition (cytostatics)  
The anti-tumor properties of a series of bent metallocene dihalides and pseudohalides, 
[Cp2MX2] (M = Ti, Mo, Nb, C; X = F, Cl, Br, I, NCS, N3) have been reported.72-74 
Some of these (Fig. 1.6) have very high activities and are being studied in clinical tri-
als.75-77 The mechanism of the cytostatic effect is still unclear but is supposed to result 
from the interaction of a hydrolyzed metallocene species with DNA78. Several adducts 
of metallocene dihalides with DNA have been isolated and characterized, but no such 
adducts have been detected with [Cp2VCl2], the most active metallocene in vitro. Not 
only this contradiction concludes that the cytostatic mechanism is very different from 
that of cisplatin, a very active and commercially successful anti cancer drug.41, 79, 80  
 
Ti
Cl
Cl
V
Cl
Cl
Pt
Cl
H3N Cl
H3N
cisplatinmetallocene dihalides  
Fig. 1.6 Titanocene dichloride and vanadocene dichloride (left) the two most active anti-tumor 
metallocenes. On the right: Cisplatin, a highly active cytostatic, which hinders cell division 
by crosslinking the two DNA strands. 
 
Studies on the anti-tumor activity of ferrocene derivatives81-83 suggest that the oxida-
tion/reduction behaviour of this metallocene plays a key role in the mechanism of pro-
liferation inhibition, shown in many experiments.84, 85 The water solubility of these 
compounds is still in important issue, since the ferrocene moiety renders many small 
molecules insoluble due to high lipophilicity.85 
 
These promising properties of metallocenes have led to various attempts to incorporate 
metallocenes or fragments of them into peptides86-88 and proteins89-91. After Schlögel et 
al. have prepared the first ferrocene amino acid derivatives in 1957,92 many similar 
compounds have been used for labelling purposes. Cymantrenylalanine (Cym) and 
ferrocenylalanin (Fer) are two such derivatives which substitute the natural amino acid 
phenylalanine.93, 94 They can be used like a regular amino acid and are tolerant to solid 
phase synthesis conditions.  
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COOH
NH2COCOOC
COOH
NH2
 
Fig. 1.7 Molecular structures of cymantrenylalanine (Cym, left) and ferrocenylalanine (Fer, right)  
 
However, a major drawback is that racemization takes place during their synthesis. 
Thus, the isolation of the stereochemically pure product can be a very time consuming 
process.94, 95 The labelling of enkephalin by replacing the natural amino acid Phe4 with 
ferrocenylalanine (Fer) has been reported96 in 1980. Other biologically relevant peptides 
have also been marked with Fer by Tartar et al. Among these are substance P86, 97, bra-
dykinin97 and angiotensin II.98 All of these Cym and Fer containing bioconjugates have 
been synthesized under harsh conditions using TFA and HF chemistry, and could only 
be incompletely characterized by elemental analysis. It has been shown that the activity 
of Fer-labelled peptides is significantly lower compared to their wild type homo-
logues,97, 99 which is probably caused by the bulkiness and higher lipophilicity of the 
ferrocene moiety.100  
 
The labelling of biomolecules, which preferably enter specific organs and tissues, with 
anti-tumor active organometallic groups, is surely one of the most challenging tasks for 
the bio-organometallic chemist. The knowledge how to precisely deliver the pharmacon 
to the location of the disease is of great importance for modern drug design. 
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1.5  Objectives of this thesis 
 
All of the above examples show that the binding of organometallic probes to bio-
molecules opens new pathways concerning detection of the bioconjugate (diagnosis) 
and also medicinal treatment (therapy). However, the demand for methods which allow 
a selective coupling of the metal marker to the biomolecule is high. Since most of all 
synthetic peptides are realized through solid phase peptide synthesis, it is desirable to 
have the coupling of the organometallic marker to the target molecule be compatible 
with the chemical conditions applied during SPPS. This should enable a facile synthesis 
on the solid support, yielding the readily usable product. 
 
 
The aim of this thesis is to develop new methods for the selective and biocompatible 
coupling of organometallic groups to peptides on the solid phase. The use of different 
linkers, protection groups and coupling strategies should be elaborated in this context. 
The obtained bioconjugate compounds are to be fully characterized by NMR, mass 
spectrometry and electrochemical experiments. Furthermore, the impact of the metal 
label itself on the bioconjugate’s physiological properties should be studied by the de-
termination of lipophilicity values and conduction of cell permeation experiments. To 
fulfil these tasks a pentapeptide, [Leu]-Enkephalin, has been chosen as the model target 
molecule. Ferrocene and cobaltocenium, two metallocenes containing iron and cobalt, 
respectively, serve as the organometallic probes. The simplicity of synthesis, isolation 
and purification of the products is one of the main points of focus. 
2 Ferrocene / Cobaltocinium as markers 
2.1 Metallocenes 
In 1951, the compound dicyclopentadienyl iron (ferrocene) was discovered and the field 
of organometallic chemistry was thereby transformed. Two independent groups of 
chemists almost simultaneously arrived at the same conclusions, albeit accidentally. A 
reaction was carried out on cyclopentadienyl magnesium bromide with anhydrous 
iron(III) chloride in ether in an attempt to synthesize fulvalene via the oxidation of the 
cyclopentadienyl Grignard reagent (Kealy and Pauson, 1951).101 However, via reduc-
tion of the iron(III) to (II) by the Grignard species, they instead obtained orange crystals 
that analysed for C10H10Fe.  
 
3 C5H5MgBr   +   FeCl3
[(C5H5)2Fe]  +  0.5 C10H10  +  3 MgBrCl  
Fig. 2.1 An attempted formation of fulvalene that lead to the discovery of the first metallocene (from 
Ref. 41) 
 
At the same time Miller et al., who where investigating the preparation of amines, re-
ported the formation of an orange compound C10H10Fe by direct reaction of cyclopenta-
diene with iron in the presence of aluminum, potassium or molybdenum oxides at high 
temperatures102.  
 
Both groups noted that the compound was air-stable, sublimable and had a melting 
point of 173 °C, with excellent solubility in organic solvents but was insoluble in water. 
It took only short time until the unusual structure of ferrocene was disclosed. In 1952 
Wilkinson from Harvard University used chemical, physical and spectroscopic methods 
to elucidate the correct “sandwich”-like structure,103 whilst Fischer used x-ray crystal-
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lography to structurally characterize the compound.104 They both shared the Nobel Prize 
for their achievements in 1973.  
After substantial studies had been made on ferrocene, many other transition metal de-
rivatives were synthesized, and the entire class of transition metal dicyclopentadienyl 
compounds became quickly known as metallocenes. 
  
2.2 Synthesis and properties 
2.2.1 Group 8 metallocenes 
In metallocene chemistry, ferrocene is still among the main areas of interest primarily 
due to its remarkable stability and ease of preparation. The 18-electron compound, con-
sisting of a Fe2+ (d6) and two 6e- aromatic rings (C5H5-), is accessible through a variety 
of reaction pathways, with the most common being shown in Tab. 2.1. 
 
Tab 2.1 A selection of common synthesis for ferrocene 
 
1 [M(C5H5)2] (M = Li, Na, K) and anhydrous FeCl2 
2 C5H6, Et2NH, anhydrous FeCl2 or FeCl3 
3 C5H6, KOH, FeCl2·4H2O 
4 Fe, [Et2NH2]Cl, C5H6 
5 Fe (atoms), C5H6 (+Al2O3 or K2O in traces, 300° C) 
 
 
Dicyclopentadienyl ruthenium and osmium (ruthenocene, osmocene) were one of the 
first metallocenes to be formed following the discovery of ferrocene, but whilst the 
chemistry of ferrocene has flourished, much less attention has been paid to the more 
costly and synthetically more challenging group 8 homologues.105, 106 Ruthenocene can 
be formed by the reaction of Ru(acac)3 with excess [(C5H5)MgBr], from RuCl3 and so-
dium cyclopentadiene or via the ligand exchange route from ferrocene and anhydrous 
RuCl3. It is stable in air and has a high melting point of 199 °C. Osmocene is even more 
difficult to obtain but can be synthesized from OsCl4 and sodium cyclopentadiene in 
THF in low yields of below 20%. Unlike ferrocene, the higher group 8 analogues prefer 
an eclipsed conformation for the Cp-rings. This is explained by the longer distance be-
tween the two aromatic rings, caused by the increasing size of the metal ion moving 
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down-group. X-ray diffraction studies of ferrocene had indicated a staggered configura-
tion of the rings with a molecular center of symmetry (D5d), whereas gas-phase electron 
diffraction observations projected a D5h geometry with C-C distances of 144 pm and a 
Fe-C distance of 203 pm. The rotational barrier in ferrocene is quite small with 4 
kJ/mol, though107. All three compounds can be easily oxidised and show E0 values of 
+0.11 V, +0.55 V and +0.46 V for iron, ruthenium and osmium, respectively.108 While 
ferrocene exclusively undergoes one-electron reversible oxidation, the chemical and 
electrochemical oxidation of Cp2Ru and Cp2Os are still subject to controversy, since 
also two-electron irreversible processes have been reported for the latter two com-
pounds.109 Ring substituents strongly influence the energy barrier for a single electron 
removal by their electron withdrawing or releasing properties.  
 
Fe M MM = Ru, Os
d(Fe-C) 
d(Ru-C) 
d(Os-C)
= 203 pm
= 221 pm
= 222 pm
 
Fig. 2.2 Ferrocene prefers a staggered conformation, whereas its higher homologues favour the 
eclipsed geometry (left). The metal-carbon distances of Cp2Ru and Cp2Os surpass the Fe-C 
bond length by 0.2 Å (from Ref. 103) 
 
Derivatization of the Cp-rings becomes more difficult regarding the heavier metal com-
pounds. While in ruthenocene alkylation and acylation of the cyclopentadienes can still 
be applied under forcing conditions, osmocene can hardly be Friedel-Crafts mono-
acylated and no alkylation is possible at all.41 On the opposite, the exceptional feature of 
ferrocene is its ability to undergo aromatic-type (electrophilic) substitution reactions in 
analogy to benzene,39, 110 but up to 106 times faster. 
2.2.2 Group 9 metallocenes 
Cobaltocene was first synthesized by the reaction of NaCp with [Co(NCS)2(NH3)4] in 
liquid ammonia. Other routes involve using cobalt bromide or [Co(NH3)6]Cl2 giving 
improved yields.111 In concurrence with the 18-electron rule cobaltocene (d7 + 2 · 6 ele-
ctrons from 2 Cp = 19 e-) is expected to be easily oxidized to reach the inert gas con-
figuration. As a fact, cobaltocene is very rapidly oxidized in air and liberates H2 from 
water and dilute acids, producing the extremely stable cobaltocenium ion [Cp2Co]+. 
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Although the 18-electron rule does not apply to all metallocene derivatives, it serves as 
a practical tool of stability prediction.112, 113 For instance, the 18 VE ions [Cp2Rh]+ and 
[Cp2Ir]+, the heavier group 9 metallocenes, are also very stable114, as opposed to their 
neutral monomers Cp2Rh and Cp2Ir, which have only been observed so far by mass 
spectrometry from an electrochemically reduced [Cp2M]+-solution.115 The high cost and 
difficulty of synthesis has left these compounds rather unattended.  
From x-ray crystallography, Cp2Co has been shown to be isostructural with Cp2Fe. Both 
cyclopentadienyl rings are parallel and in a staggered configuration. The average C-C 
distance is 141 pm and the Co-C distance 210 pm.116 The barrier to rotation for the rings 
is with 7.5 kJ/mol slightly higher than the one in ferrocene.  
Cobaltocenium salts can be easily prepared through a variety of reactions as reported in 
numerous publications.117, 118 While these compounds are similar to ferrocene regarding 
their stability and behaviour in electrophilic substitution reactions, they show a different 
solubility due to their positive charge and a strong resistance to oxidation.  
 
X Y
CoBr2
pyrrolidine
+ + Co
X
Y0°C / 12 h
X, Y = H, CH3
Ox.
Co
COOH
COOH
Co
COOH
+Co +
 
Fig. 2.3 Synthesis of derivatized cobaltocenium salts according to Sheats et al. (from ref. 118)  
 
This fact suggests the use of cobaltocenium as a model substance for ferrocene and as a 
very robust metal marker for all sorts of applications.  
Almost every other transition metal forms cyclopentadienyl compounds, the majority of 
which are useless for the labelling of (bio)molecules, mostly due to instability, their 
tendency to form binuclear compounds, their expensive and inefficient synthesis and of 
course the high toxicity these substances often show.  
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2.2.3 Spectroscopic aspects of ferrocene/cobaltocenium 
Among the most important attributes for a marker molecule is the spectroscopic behav-
iour, which enables exact measurement of the bioconjugate in vivo and in vitro. As indi-
cated in chapter 1, organometallic compounds often show high sensitivity for various 
types of spectroscopy. As described, Jaouen et al. successfully use metal carbonyl com-
pounds, detectable by FT-IR54 while Alberto and co-workers observe their technetium 
labels via radioactive detection67. Also atomic absorption spectroscopy (AAS) is a 
common tool for the detection of metals,119 especially for exobiological species in 
cells.120-122 Cais and co-workers, for instance, have introduced metallo immunoassays 
using metal-labelled antigens and AAS detection.123 
Ferrocene and cobaltocenium, in particular, show a reversible electrochemical transition 
and can be detected down to pico-molar concentrations in solution.124-126 Apart from a 
quantitative measurement of ferrocene-labelled compounds does the electrochemical 
method reveal details on the electronical and therefore chemical environment of the 
metal ion. The high quality and of electrochemical ferrocene signals have lead to an 
introduction of ferrocene as the standard reference in electrochemistry related literature.  
 
 
Fig. 2.4 Ferrocene (left) shows reversible oxidation at about + 80 mV, whereas the oxidation resis-
tant cobaltocenium ion (right) can only be reduced in the far negative  
 
 
Cobaltocinium ions are stable towards oxidation but can be converted into cobaltocene 
at highly reductive potentials (Fig. 2.4). Samples containing ferrocene or cobaltocenium 
labels can be detected by HPLC-ECD (High Performance Liquid Chromatography with 
ElectroChemical Detection).127, 128 In view of that, ferrocene and cobaltocenium provide 
a very sensitive means for the detection of labelled species. 

3 Peptides 
3.1 General outline 
A number of very important physiological and biochemical functions of life are influ-
enced by peptides, amino acid polymers of short length. Peptides are involved as neuro-
transmitters, neuromodulators, and hormones in receptor-mediated signal transduction. 
More than 100 peptides with functions in the central and peripheral nervous system, in 
immunological processes, in the cardiovascular system and in the intestine are 
known.129  
Although the formation of a peptide bond is known to be a relatively simple chemical 
reaction, the biosynthesis of polypeptides is a very complex process. Ribosomal peptide 
synthesis involves deoxyribonucleic acid (DNA) encoding genetic information, and two 
different types of ribonucleic acids which convey (mRNA) a blue print of the genetic 
information out of the nucleus to the ribosome, and carry (tRNA) the attached amino 
acid to the ribosome for peptide bond formation (Fig. 3.1) 130 
 
 
 
Fig. 3.1 Peptide synthesis on an mRNA strand. Each amino acid, which is attached to the growing 
end of the polypeptide chain, is chosen by complementary base pairing between the anti-
codon of its attached tRNA and the next free codon on the mRNA chain (mod. from ref. 14) 
 
Each of the 21 natural amino acids is represented by three adjacent nucleotides in the 
mRNA, a so-called codon, which is recognised by the anticodon of the amino acid   
delivering tRNA molecule. This highly efficient machinery allows fast polypeptide syn-
thesis with up to 40 couplings per second.129 
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As the biosynthesis even of complicated proteins in vivo occurs within seconds or min-
utes, the relatively tedious classical chemical synthesis of peptides in the laboratory 
seems to be a rather exhausting enterprise, especially with regard to speed. Nonetheless, 
is the classical synthesis still a powerful tool compared to recombinant techniques, if the 
desired amount of substance is in the scale of milligrams or grams. Even more so, since 
solid phase peptide synthesis has reached a high grade of automation. 
 
 
3.2 Synthesis in solution 
The formation of a peptide bond, resulting in a dipeptide, is seemingly a very simple 
process. The two component amino acids are connected by a peptide (amide) bond with 
the elimination of water (Fig. 3.2) 
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Fig. 3.2 A simplified scheme of peptide bond formation 
 
The synthesis of a peptide bond under mild reaction conditions can only be achieved 
after activation of the carboxy function. If the amino function of the carboxy component 
(A) is unprotected, then formation of peptide bonds occurs in an uncontrolled manner 
and polymers are formed. Consequently, all functional groups not involved in peptide 
bond formation must be blocked temporarily. This has led to the development of a high 
number of specific amino, carboxy and side chain protecting groups. Amino acids car-
rying side chains with reactive behaviour like Tyr, Lys, Cys etc., are usually protected 
from the beginning and only freed of the blocking groups after the synthesis has been 
finished. Whether the amino or carboxy group are blocked is determined by the direc-
tion of synthesis.  
The most common method is the Nα-protection of the carboxy activated amino acid, for 
which two protection groups have become widely accepted, 9-fluorenylmethoxy-
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carbonyl (Fmoc) and tert-butoxycarbonyl (Boc). While Fmoc can be cleaved under 
mildly basic condition, using 20% piperidine or diethylamine in DMF, the Boc removal 
is performed with strong acids like HCl and TFA. More than 80% of all peptide synthe-
ses follow either of both protection strategies. 
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Fig. 3.3 Boc and Fmoc strategies. Protection groups are removed under indicated conditions after 
peptide coupling has occurred. This leaves a free amino group for succeeding coupling. 
 
Solution peptide coupling reactions have employed several types of reagents for the 
carboxy activation, such as N,N’-dicyclohexylcarbodiimide (DCC), isobutyl chlorofor-
miate (IBCF) and phosphonium salts like BOP. The dipeptides in this thesis have exclu-
sively been prepared with IBCF (chapter 5), since the by-products (CO2 and i-butanol) 
can be easily removed under reduced pressure. 
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Fig. 3.4 Activation of the carboxylic group using isobutyl chloroformiate.  
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3.3 Synthesis on a solid support 
The ingenious concept of peptide synthesis on a solid support, which is now known as 
SPPS, was developed by Robert Bruce Merrifield in 1963,4 and provided a major break-
through in peptide chemistry. In SPPS the peptide chain is assembled in the usual way, 
starting from the C-terminus. The amazingly simple concept is that the first amino acid 
of the peptide to be synthesized is connected via its carboxy group to an insoluble poly-
mer that may be easily separated from either solvents or dissolved product by the use of 
filtration. The general principle is shown in Fig. 3.5. 
 
 
Fig. 3.5 A scheme of solid phase peptide synthesis as introduced by Merrifield. The protection 
group (green) is usually Fmoc or Boc. The linker (red) is broken at the end of the synthesis 
to yield the crude product.  
 
Resins, generally consisting of cross-linked polystyrene, are offered with a variety of 
linkers and often with the first Nα-protected amino acid already attached.131 The choice 
of the linker depends on the desired cleaving conditions which have to be coordinated 
with the protection strategy. Very common linkers are listed in Tab. 3.1, all of which 
have been used during the syntheses presented in this thesis. 
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Tab 3.1 Resins with linkers and the corresponding cleavage conditions 
 
resin linker cleavage product 
4-benzyloxybenzyl  
alcohol 
(Wang resin) 
O
HO  
95 % TFA, 
2.5 % TIS 
O
OHpeptide  
peptide acid 
hydroxymethylbenzoic 
acid 
(HMBA resin) 
N
H
O
HO
 
NH3(sat.) in 
MeOH peptide NH2
O
 
peptide amide 
o-chlorotritylchloride 
resin 
(Barlos resin) 
Cl
Cl
 
0.5 % TFA, 
2.5% TIS 
O
OHpeptide  
peptide acid 
 
 
Side chain protection groups should be chosen according to the linker cleavage, to ide-
ally deprotect all side chain functions within the process of cleaving. The addition of 
scavengers may be necessary to quench meta-stable cations generated from the leaving 
groups to avoid electrophilic addition to the product. Trisisopropylsilane (TIS) and ani-
sole derivatives are often used as scavengers. 
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3.4 Neuropeptides – Introduction 
Neuro-active peptides are capable of exerting multiple effects in the CNS and else-
where. The important effects in the CNS have been underlined by increasing numbers 
of publications that have been reviewed for the years 1980-1985,132 1986-1993,133 and 
1994-1999.134, 135 Among these are regulation of aggression, pain, anxiety, feeding and 
stress. Some neuropeptides are stored in intracellular vesicles and act as neurohormones 
upon release in the blood stream. Neuropeptides released into the synaptic cleft are neu-
romodulators that inhibit the action of excitatory neurotransmitters, or neuromediators 
which prolong the action of neurotransmitters.   
Opioid δ-, µ- and κ-receptors, as well as receptors for bradykinin, tachykinins, angio-
tensin, neuropeptide Y, vasointestinal peptide and somatostatin have been cloned and 
characterized. These G-protein-coupled receptors (GPCR) share as a common feature 
seven transmembrane helices. An extracellular signal is transmitted into the cell and 
amplified by coupling to G proteins.136  
 
 
Fig. 3.6 Schematic representation of the three main sequences of opioid peptide precursors. EK = 
enkephalin. 
  
3.5  Biological properties of [Leu5]-Enkephalin 23 
Neuropeptides are synthesized in the form of large protein precursors (Fig. 3.6) that 
undergo protolytic processing to yield the bioactive peptides.  
The signal peptide sequence is required for vectorial transport across the membranes of 
the ER. The conformation of the signal peptide, usually a β-turn, is important for the 
recognition of the exact cleavage site. The cleavage at pairs of basic amino acids (Lys, 
Arg) is catalyzed by trypsin-like endopeptidases (prohormone converting enzyme). 
Post-translational processing can generate a number of active peptides from a single 
precursor protein137 which has for example been demonstrated for POMC, this being the 
common precursor for ACTH, β-endorphin, MSH, corticotropin-like intermediate lobe 
peptide (CLIP), and related peptides.138  
 
3.5 Biological properties of [Leu5]-Enkephalin 
Opiates such as morphine have been widely used by clinicians both for blockade of se-
vere pain and for anesthesia. For more than thousand years has opium been the natural 
source for morphine, and it was surprising to find that nature provided morphine not 
only as a plant product (from papaver somniferum) but also (as structurally related opi-
ates) in mammals, albeit in very small amounts.139  
Collier first postulated the existence of  “endogenous morphine” in 1972 and the bind-
ing of endogenous opioid receptor ligands was independently demonstrated one year 
later by three groups.140-142 In 1975 Hughes and co-workers reported the discovery of 
the first endogenous peptide ligands143 followed by the characterization of four major 
types of morphine receptors (µ, δ, κ and σ) a few years later.144 
The opioid peptides first isolated from porcine brain were named Met-enkephalins and 
Leu-enkephalins, respectively, according to their C-terminal amino acid (Fig. 3.7).  
 
H-Tyr1-Gly-Gly-Phe-Met5-OH H-Tyr1-Gly-Gly-Phe-Leu5-OH
Met-Enk Leu-Enk  
Fig. 3.7 Sequences of methionine enkephalin (left) and leucine enkephalin (right). The latter has 
been exclusively used for the research presented in this thesis. 
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These enkephalins (from enkephalos = brain) were found to occur naturally and bind as 
physiological agonists to the opioid receptors mainly found in the brain, but also being 
expressed in the spinal region145 and colon.146 The structure of [Leu5]-Enkephalin in 
solid state could be elucidated by x-ray diffraction, revealing 4 different conformations 
in the asymmetric unit.147 These findings indicated the high flexibility of the pentapep-
tide. 
The similarities between enkephalin, morphine and naloxone, which is a morphine an-
tagonist, can be seen in Fig. 3.8. The tyrosine- and N-terminal amino-functions are es-
sential for the receptor affinity.148 
 
 
Fig. 3.8 Comparison of structural motifs between different opioid receptor binding substances.  
 
Besides the enkephalins, endorphins and dynorphins are the most important of these 
neuropeptides. They all originate from three large precursor proteins, shown in Fig. 3.6. 
These typical opioid peptides share the N-terminal sequence H-Tyr-Gly-Gly-Phe-, and 
most of the members bind to more than one type of opioid receptor, though certain se-
lectivity is clear. The so-called “atypical” opioid peptides originate from a variety of 
precursor proteins, with different N-terminal amino acid sequence and a conserved N-
terminal tyrosine residue, which is indispensable for binding to opioid receptors.149 
 
4 Selective labelling of [Leu]-Enkephalin with 
Ferrocene / Cobaltocinium 
4.1 Synthesis of metal markers 
As shown in the introduction chapters some attempts to label biomolecules with metal-
locenes, mostly ferrocene,100 have been made so far. Tartar and co-workers presented an 
artificial amino acid ferrocenylalanin as a substitute for phenylalanine (Fig. 1.7).94 
However, the bioconjugates showed heavily reduced activity and the isolation of enan-
tiomerically pure compounds was tedious. Metzler-Nolte et al. reported the stepwise 
synthesis of ferrocenyl amines in solution,150, 151 which could be successfully coupled to 
the C-terminus of amino acids and peptides. Since the synthetic direction in solid phase 
synthesis is mostly from C-terminus to the N-terminus, a marker containing a carboxy 
group would be ideal for N-terminal labelling. 
The simplest metal markers, which fulfil this demand, seem to be the carboxylic acid 
derivatives of ferrocene and cobaltocenium. These compounds are known to be sta-
ble,152 can be easily prepared153 and can be activated using standard amino acid cou-
pling reagents (chapter 3).154  
 
The synthesis of ferrocenecarboxylic acid 1 is a two step reaction as reported by 
Reeves.153  The two synthetic steps comprise a Friedel-Crafts mono acylation followed 
by hydrolysis (Fig. 4.1) 
 
Fe +
O Cl
Cl
AlCl3
CH2Cl2
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O Cl
H2O, t-BuOK
dimethoxyethan
Fe
O
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1  
Fig. 4.1 Synthetic pathway for ferrocene carboxylic acid as suggested by Reeves et al. 
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This synthesis is very convenient and offers high yields of 80% referred to starting 
amount of ferrocene. The product is a brown, air-stable solid with a melting point of 
220 °C. The crude compound can be recrystallized from toluene to improve purity, 
which is not necessary for most synthetic tasks, though. The EI mass-spectrum shows a 
signal at m/z = 230 with the typical isotopic pattern of iron (56Fe, 100%; 54Fe, 6.4%; 
57Fe, 2.3%). This pattern should be kept in mind, since it can be used in mass spectra of 
bioconjugates for fragment identification. 1H NMR signals are clearly resolved and cor-
respond to the literature. Two pseudo-triplets representing each 2 protons of the substi-
tuted Cp-ring and one singlet of 5 protons for the unsubstituted Cp-ring can be observed 
between 4.2 and 4.8 ppm.  
 
Cobaltocenium carboxylic acid was synthesized as the hexafluorophosphate salt 2 ac-
cording to Sheats and Rausch,118 who also presented elaborate works on cobaltocenium 
salts in general.117  
In the first step methylcyclopentadiene and cyclopentadiene are reacted with anhydrous 
CoBr2 under argon atmosphere to yield methyl-, dimethyl- and unsubstituted cobaltoce-
nium. The reaction is carried out in dried pyrrolidine and takes 12 h of stirring. After 
removal of the organic solvent in vacuo, dissolution in water and extraction with di-
ethylether, precipitation of the cationic compounds is performed with the addition of 
sodium hexafluorophosphate in aqueous solution. 
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CH3
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Fig. 4.2 synthetic scheme of methylcobaltocenium 
 
To the mixture of methylcobaltocenium (max. 50% of starting material) and the two by-
products sodium permanganate and NaOH are added, and the aqueous solution is heated 
at reflux for a prolonged time of 8 h, which slightly improved the yield compared to 
literature (2 h). The obtained mono- and dicarboxy compounds can be separated from 
unsubstituted cobaltocene by the addition of sodium hexafluorophosphate followed by 
filtration. The two carboxy cobaltocenium salts are then precipitated by the dropwise 
addition of 6N HCl. Contrary to the mono acid which shows good solubility in acetone, 
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is cobaltocenium dicarboxylic acid virtually insoluble. The isolation of the desired 
monocarboxylic acid by soxhlet extraction using acetone seems to be superior to the 
simple washing process presented in literature.  
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Fig. 4.3 Synthesis of cobaltocenium carboxy compounds from corresponding methyl derivatives by 
means of oxidation in an aqueous solution 
 
Cobaltocinium ions can be electrochemically reduced to the corresponding cobaltocenes 
at negative potentials between -0.8 and -1.5 V, which is strongly influenced by the sub-
stituents at the Cp-rings. The electron withdrawing nature of the carboxy group lowers 
the potential drastically, thus enabling distinction between the desired product and po-
tential by-products, which is useful for purity estimation (Fig. 4.4).   
 
Fig. 4.4 Square Wave voltammogram of a mixture of cobaltocinium compounds obtained as a crude 
product, recorded in acetonitrile using TBABF as supporting electrolyte. Detailed condi-
tions for all electrochemical experiments are given in chapter 8. 
 
The EI mass-spectrum of the purified compound 2 shows a signal of 40 % intensity at 
m/z = 233, representing the cation. Because cobalt only occurs in its single isotope 59Co, 
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no metal related isotopic pattern can be observed. Infrared and NMR spectra show the 
reported signals. The 1H NMR looks similar to that of ferrocenecarboxylic acid but 
shifted about 1 ppm lower field. Signals appear between 5.2 and 6.0 ppm. Compared to 
1, the four signals in 13C NMR are shifted approximately 20 ppm to the lower field, as 
well. These shifts originate from the de-shielding effect of the cationic charge. 
 
 
4.2 Synthesis of [Leu]-Enkephalin  
4.2.1 Synthesis of H-Enk-OH 3 
[Leu5]-Enkephalin, in the following simply referred to as “Enk”, is a neuropeptide con-
sisting of 5 amino acids of the sequence H-Tyr-Gly-Gly-Phe-Leu-OH. The solid phase 
synthesis of this relatively small molecule was carried out on Wang resin, following 
Fmoc protection strategy. The Wang or p-hydroxybenzyl alcohol linker can be cleaved 
by 95% TFA, releasing the product with a carboxylic acid at the C-terminus. The only 
function to be protected in Enk is the hydroxy group in the tyrosine residue that can be 
protected by a t-butyl group, which is removed within the cleavage procedure. 
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Fig. 4.5 H-Enk-OH is released from Wang resin by cleavage with 95% of TFA. The Tyr protection 
group is simultaneously removed under the same conditions.  
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Nα-protected amino acids have been reacted with TBTU/HOBt prior to coupling to yield 
the activated OBt-esters, as shown in Figure 4.6. To facilitate the deprotonation of the 
acid and thus the formation of the carboxy activated form, ten equivalents of DIPEA 
were added.   
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Fig. 4.6 Conversion of Fmoc-protected amino acids into their activated benzotriazole esters 
 
After the final step of Fmoc deprotection and excessive washing with DMF and DCM, 
the resin was dried in vacuo and treated with a cleavage mixture of 95% TFA, 2.5% 
H2O and 2.5% of TIS, acting as a scavenger, for 3 hours. After removal of the cleavage 
cocktail under reduced pressure, the crude product was precipitated from cold ether. All 
following solid phase peptide syntheses correspond to this roughly explained standard 
procedure if not mentioned explicitly. A more detailed description of SPPS can be 
found in chapter 8 (experimental section).  
Preparative RP-HPLC purification and subsequent lyophilization of H-Enk-OH 3 re-
sulted in an off-white powder. Negative electron spray ionisation mass spectrometry 
(ESI-MS, neg.) shows a strong signal at 1109.18 m/z representing the dimeric, nega-
tively single charged 2M-1 Species. The base peak at 554.27 m/z corresponds to M-1.  
The 1H NMR spectrum in DMSO-d6 shows all expected signals except for the N-
terminal amine protons (Fig. 4.7). The same spectrum measured in MeOH reveals only 
slight changes in shifts but lacks all five amide and the carboxyl proton signals, caused 
by proton/deuteron exchange with the solvent. Assignment of signals was supported by 
HH-COSY 2D NMR.  
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Fig. 4.7 Proton NMR spectrum of H-Enk-OH 3, measured in DMSO-D6 at 300.16 MHz. 
 
 
Fig. 4.8 13C NMR spectrum of H-Enk-OH 3, measured in DMSO-D6 at 75.47 MHz. 
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13C NMR shows all expected signals, although Cα(Gly) and Cβ(Phe, Tyr) signals are 
close to the downfield and upfield sides of the solvent signal (Fig. 4.8). 
 
The white substance shows slightly hygroscopic behaviour and is to be stored under 
argon. Freeze-drying improves the substances stability, because traces of trifluoro acetic 
acid, dimethylformamide, diethylether and other impurities, originating from synthesis, 
cleavage or workup procedures, are removed. It was also observed that freeze-dried 
samples still showed high purity in HPLC even after prolonged storage, whereas crude 
products seemed to be more sensitive to decomposition. This is even more true for met-
allocene labelled peptides.  
 
4.2.2 Synthesis of Ac-Enk-OH 4 
The preparation of acetyl enkephalin, Ac-Enk-OH 4, was carried out similar to that of 3. 
After the final Fmoc deprotection step, the resin was treated with a mixture of Ac2O, 
2,6-Lutidine, N-methylimidazol and THF (1:1:1:7) for 60 min.131  
 
 
Fig. 4.9 HPLC chromatogram of crude Ac-Enk-OH 4, detected at a wavelength of 220 nm.  
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After cleavage a slightly yellow powder of 95% purity was obtained, and no further 
work-up was required, as demonstrated by the HPLC spectrum in Fig. 4.9. All analyti-
cal HPLC spectra were run using a gradient from 5% CH3CN in H2O to 100% CH3CN 
in 20 min, with both eluents containing 0.1% of TFA for improved solubility of pep-
tides. Like in the case of 3, ESI mass spectra indicate that a dimer is formed during 
mass spectrometry, as well. This could only be observed with the simple peptides 3 and 
4, while metallocene marked peptides only showed monomeric peaks in MS, but tend to 
be multiply charged (Fig. 4.10). 
 
 
 
Fig. 4.10 ESI mass spectrum of Ac-Enk-OH 4 
 
 
All signals in 1H NMR are almost identical to those in H-Enk-OH 3 except for the ace-
tyl peak at 1.75 ppm with a correct integral of 3 protons. One additional 13C signal at 
22.4 ppm appears for this acetyl group. UV spectra for both 3 and 4 show strong ab-
sorbance at 220 nm related to peptide bond absorption and at 260 nm from the aromatic 
systems of phenylalanine and tyrosine. As expected, neither compound underwent a 
redox reaction in electrochemical studies between the potentials of +/- 1000 mV. These 
experiments were necessary to prove that the peptide itself is stable under the conditions 
of electrochemical detection of the metallocene markers. 
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4.3 N-terminal labelling of [Leu]-Enkephalin 
4.3.1 Synthesis of Ferrocenoyl-Enkephalin (Fc-CO-Enk-OH) 6 
 
In order to bind ferrocenecarboxylic acid as a sixth amino acid to the N-terminus of 
enkephalin, it has to be carboxy activated in the same way as a regular amino acid. The 
most practical approach uses the standard activation protocols for solid phase peptide 
synthesis, since the aim is to establish a facile method for the labelling of peptides on 
the resin. However, after activation of ferrocenecarboxylic acid with HOBt and DCC, 
the activated ester could be isolated and purified by column chromatography, and al-
though the compound is highly reactive towards amino groups it showed prolonged 
stability under inert atmosphere for weeks. 
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Fig. 4.11 Benzotriazole ester of ferrocenecarboxylic acid 5 as the reactive form for building peptide 
bonds 
 
 
NMR spectra show all desired signals and EI mass spectrometry reveals a peak at 347 
m/z which corresponds to the M+-peak of 5. All data were similar to that reported by 
Kraatz et al. who have studied and characterized 5 before.154, 155  
 
After some successful attempts to couple Fc-OBt to amino acids the system was found 
to be suitable for the labelling of a peptide on the solid support. As a consequence, en-
kephalin was synthesized on Wang resin and ferrocene carboxylic acid, this time treated 
with TBTU/HOBt in DMF to form 5, was attached as the last amino acid. As an indica-
tion of a successful reaction the resin changed color from slightly yellow to dark brown. 
After the cleavage from the resin had been carried out with standard Wang cleavage 
solution (95% TFA, 2.5% H2O and 2.5% TIS) the color changed from red to green 
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pointing to a possible oxidation of ferrocene. As a fact 6 could only be isolated by 
HPLC-purification in very low yield of 10%.  
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Fig. 4.12 Synthetic scheme of the reaction between Enk and Fc-OBt to form Fc-CO-Enk-OH 6 on the 
resin. Cleavage under standard conditions leads to very small yields.  
 
 
To prevent the ferrocene from being oxidized during the cleavage procedure an anti 
oxidizing agent had to be used. First ascorbic acid had been added to the cleavage mix-
ture which resulted in a better yield of approximately 50%, with no good reproducibil-
ity, though. The addition of phenol gave yields of 90% and a very smooth workup        
(chapter 8) and was therefore used in all following preparations which contain the ferro-
cene moiety.  
 
Ferrocenoyl-Enkephalin 6 is a light red solid and stable to air and water. ESI (pos.) 
mass spectrometry shows clear single charged product peaks at m/z 768.4 (M+H)+, 
790.5 (M+Na)+, 806.4 (M+K)+, whereas ESI (neg.) only contains one single peak at m/z 
766.4 (M-H)-. No dimers could be observed in any mass spectra. Proton NMR reveals 
most signals to be identical to those of 4 except for the metallocene Cp-signals between 
4 and 5 ppm, which significantly indicate the presence of the ferrocene group in the 
peptide. The amide proton of the ferrocene peptide bond is the one most up-field at 7.78 
ppm, which could be confirmed by HH-COSY NMR.  
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Fig. 4.13 The 1H NMR of Fc-CO-Enk-OH 6 shows four signals for the ferrocene group (green). C 
and C’ are magnetically different, thus resulting in the formation of two singlet signals 
 
 
The cyclopentadiene protons show an interesting pattern, because the nuclei on C2 and 
C5 seem to be different (c and c’ in Fig. 4.13). This is confirmed by 13C NMR, where C2 
and C5 result in two signals, as well. The reason for this is the proximity to the closest 
chirality center, like indicated in Fig. 4.14. The distance between the chiral tyrosine Cα 
and the cyclopentadiene carbons C2 and C5 is only 4 carbon bonds, leading to a slightly 
different chemical environment for both atoms. Carbons C3 and C4 are equivalent, be-
cause they are too far away from the chiral center to be influenced anymore. The elec-
tronic properties of cobaltocenium are much different from ferrocene so that this effect 
cannot be observed here. When a chiral center is present but too far away from the 
ferrocene group, equivalency of C2 and C5 of the substituted cyclopentadiene results in 
a singlet for both 1H and 13C NMR spectra, which will be shown by the example of side 
chain derivatives. 
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Fig. 4.14 Chirality of the tyrosine Cα carbon leads to a different chemical environment at the 
cyclopentadiene ring of ferrocene. 
 
 
Electrochemical measurements revealed a one-electron, fully reversible behaviour for 
the ferrocenyl group with a half-wave potential of E½ = 214 mV and a peak separation 
of 74 mV. 
 
Fig. 4.15 Overlay of a square wave and cyclovoltammogram of 6, measured in acetonitrile with 
TBABF as the supporting electrolyte. 
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UV spectra showed a weak absorbance for ferrocene at 444 nm with a molar extinction 
coefficient of ε = 210 l/mol·cm, and two stronger maxima at 266 and 215 nm with ε266 = 
5550 and ε215 = 27920 l/mol·cm, respectively. The aromatic π-systems of phenylalanine 
and tyrosine are responsible for the absorbance at 266 while peptide bonds absorb best 
at 210-220 nm. For this reason all HPLC measurements are recorded at both 220 and 
254 nm. 
 
4.3.2 Synthesis of Fc-CO-Enk-NH2 7 and Fc-CO-Enk-NHNH2 8 
To circumvent the issue of ferrocene oxidation in strong acidic cleavage media, a dif-
ferent resin with a base labile linker was employed. The hydroxymethylbenzoic acid 
linker (HMBA) releases the product through basic treatment with a variety of functional 
groups at the C-terminus as shown in Tab. 4.1. 
Tab 4.1 Common cleavage conditions for HMBA resin and the corresponding peptide products 
 
Cleavage reagent Product 
1. NH3 / MeOH Peptide carboxamide 
2. NH2NH2 Peptide hydrazide 
3. Aq. NaOH Peptide acid 
4. MeOH / DIPEA Peptide methylester 
5. NaBH4 / EtOH Peptide alcohol 
 
Before cleaving the peptide from HMBA derivatized resins, it is important that the side-
chain protection groups are removed. This is generally achieved by treating the peptidyl 
resin with 95% TFA, which had to be avoided in this case as the strong acidic media 
seemed to accelerate ferrocene decomposition. Therefore 2-chlorotrityl as a tyrosine 
protection group had been chosen, since it can be removed by dilute acid solutions con-
taining 1% TFA.   
After synthesis of enkephalin on the resin and the following coupling of ferrocene car-
boxylic acid, the side-chain protection group was removed by repetitive treatment with 
a mixture of 1% TFA and 5% TIS in DCM. The peptide cleavage itself was performed 
using ammonia saturated methanol at 0 °C (Tab. 4.1, option 1, product 7) and 5% hy-
drazine in DMF (Tab. 4.1, option 2, product 8) for 24 h  and 3 h, respectively. Both 
methods had lower yields of approximately 50%, though, and had to be purified by 
HPLC, since the crude products contained reasonable amounts of by-products either 
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originating from the synthesis or more likely from side-chain deprotection and cleavage. 
Non-labelled [Leu5]-enkephalin could be identified in major HPLC peaks of both reac-
tions.  
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Fig. 4.16 Reaction scheme of HMBA based Fc-CO-Enk synthesis. Cleavage with different reagents 
leads to different C-terminal functions. 
 
Both 7 and 8 show almost the same spectroscopic properties as Fc-CO-Enk-OH 6, like 
expected. ESI (neg.) mass spectra show the correct mass with peaks at 765.3 for 7 and 
780.3 for 8, and C-terminal amino and hydrazide amide protons can be observed in 1H 
NMR at 8.01 ppm and 8.21 ppm. No signal was found for the hydrazine NH2 group, 
though. 13C NMR reveal all expected peaks, very similar to 6 and electrochemical be-
haviour was identical, as well, for both compounds showed reversible oxidation proc-
esses at ca. 220 mV. The ferrocene center is obviously unaffected by the C-terminus 
and the type of functional group attached to it. While these basic cleavage methods 
evade the problematic decomposition of ferrocene groups they have major drawbacks 
concerning yield and reproducibility. That is why most of the compounds presented in 
this thesis were preferably synthesized on Wang resin and cleaved by standard acidic 
cleavage solutions containing a reducing additive like phenol or ascorbic acid. These 
additives could be easily removed from the precipitated peptide by repetitive washing 
with cold ether. Details on selected procedures are given in the experimental section for 
each compound. 
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4.3.3 Synthesis of Cobaltocenium-Enkephalin (Cc-CO-Enk-OH) 9 
Cobaltocenium carboxylic acid is expected to react in the same way like its isoelec-
tronic congener ferrocene. In addition, no oxidation during synthesis or cleavage is ex-
pected, as can be deduced from the electrochemical studies, which only show a reduc-
tive event at very high negative potentials between -1200 and -1500 mV (Fig. 2.4 and 
4.4). The positive charge carried by cobaltocenium ions will change the bioconjugates 
biological properties drastically, compared to a ferrocene marked species, making this 
marker an interesting alternative. 
The synthetic procedure carried out was similar to that of Fc-CO-Enk-OH 6. Because 
cobaltoceniumcarboxylic acid, available as the hexafluorophosphate salt, showed re-
duced solubility in DMF, an extra addition of DIPEA was necessary, which accelerated 
the deprotonation of the acid group and thus the formation of the activated benzotriazole 
ester. Early experiments clearly indicated that the reactivity of activated cobaltocenium 
carboxylic acid (Cc-CO-OBt) was somewhat lower than that of ferrocene, since HPLC 
analysis of the freshly cleaved crude product showed major peaks, which could be iden-
tified as unlabelled peptide. Therefore prolonged coupling time was granted to the label-
ling reaction (3 h instead of 60 min), resulting in a total conversion to Cc-CO-Enk-OH. 
Because the reaction was carried out on Wang resin, again t-butyl protection was cho-
sen for the tyrosine residue as it had been cleanly removed during cleavage procedure 
before. The counter-ion of PF6- was completely exchanged by TFA- from the cleavage 
mixture.  
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Fig. 4.17 Reaction scheme of Cc-CO-Enk-OH 9. Almost full coupling efficiency is reached after 3 h 
of reaction time. The resulting product is the TFA salt of the cationic bioconjugate.  
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ESI (pos.) mass spectrometry of the slightly yellow powder shows a single peak at    
m/z = 770.5 in accordance with the calculated mass for the cationic species Cc+-Enk-
OH of 770.26 g/mol. 1H NMR spectra display all amide protons clearly resolved, as 
well as the significant Cp-signals of cobaltocenium between 6.5 and 5.5 ppm. Com-
pared to ferrocene, these peaks are shifted down-field due to the positive charge at the 
metal center and the related de-shielding effect (Fig. 4.18). Another noteworthy obser-
vation is the fact that the C2 and C5 atoms of the unsubstituted Cp-ring show almost the 
same resonance and do not split clearly into two signals like those of the corresponding 
ferrocene compound.  
 
 
Fig. 4.18 Positive charge at the cobalt center has a de-shielding effect on the ring current of the Cp-
rings, causing a down-field shift. C2 and C5 carbon atoms (c+c’) seem to be more equiva-
lent than those in ferrocene. 
 
However, the signal caused by c and c’ is always broader than the one of b, indicating 
that the chiral center of tyrosine does have an effect on the ring atoms, even if it is much 
smaller, compared to ferrocene. 13Carbon signals for the Cp-system underline this, as 
only four peaks between 83 and 93 ppm are visible. Here, too, a down-field shift is ob-
served. The electrochemical behaviour of the cobaltocenium labelled enkephalin was 
expected to be only of partly reversible nature. The reduced cobaltocene species is itself 
a very good reducing agent and tends to transfer the electron to any nearby intra- or in-
termolecular electron acceptor, thereby undergoing oxidation again. This non-reversible 
behaviour can be observed in cyclovoltammetry as shown in Fig. 4.19.  
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Fig. 4.19 A cyclovoltammogram of 9, recorded in acetonitrile, demonstrates an irreversible one-
electron reduction of cobaltocenium-enkephalin. The Half-wave potential is E½ = 1439 
mV.  
 
 
4.4 Side-chain labelling of [Leu]-Enkephalin 
While the N-terminal labelling of peptides is an easy way to introduce a metal marker 
into the desired biomolecule it might be desirable to attach the organometallic probe to 
a side-chain function and leave the N-terminus untouched. The precise positioning of 
the metal center inside a possible secondary structure or the decrease in receptor binding 
activity might be possible reasons. An alkylated or free N-terminal amino group are 
known to be essential for the receptor binding of enkephalin, for example.156 This is 
also true for most of all drugs that bind to opiate receptors (compare Fig. 3.8). Enkepha-
lin offers 4 easily accessible labelling sites which are shown in the figure below. 
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Fig. 4.20 The four indicated modification sites of Leu-enkephalin are accessible by organic synthesis. 
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In the case of enkephalin the N-terminus as well as the tyrosine hydroxy function are 
essential for the binding properties to the opiate receptor and cannot be labelled if activ-
ity is to be retained. Labelling of the C-terminus would mean to reverse the direction of 
synthesis or to modify the peptide post cleavage, which is both to be avoided. Therefore 
phenylalanine was chosen as the location of side-chain modification. Another advantage 
of phenylalanine is the huge number of known substitution reactions, which have al-
ready been carried out on the phenyl ring and are thoroughly tested for convenience.  
The introduction of a p-nitro group would allow an easy handling without the employ-
ment of a protection group, because the nitro function is inert under SPPS conditions. In 
addition, it could be reduced on the resin157-159 to yield p-amino phenylalanine which 
might be reactive towards carboxy activated metallocene derivatives and undergo a pep-
tide bond formation. Thus, the following reaction pathway had been elaborated to syn-
thesize the modified building block, which is also commercially available but expen-
sive. 
 
H2N COOH
HNO3 / H2SO4
H2N COOH
NO2
Fmoc-ONSu
Dioxan / H2O
N
H
COOH
NO2
O
O
10 11  
Fig. 4.21 Reaction pathway to obtain Fmoc-p-nitro-phenylalanine 11 as a building block for SPPS. 
  
 
Commercially available and inexpensive L-phenylalanine was nitrated in 4-position 
according to literature160 to yield p-nitro-phenylalanine 10, which was then Fmoc pro-
tected by standard methods131 to give 11, an Nα-Fmoc protected amino acid ready for 
solid phase peptide synthesis.  
The preparation of 10 was carried out by addition of L-phenylalanine to a mixture of 
HNO3 and H2SO4 at 0 °C and the following neutralisation with sodium hydroxide solu-
tion until precipitation of the product occurred. The EI mass spectrum shows the M+ 
peak at correct 210 m/z and all expected signals in both 1H and 13C NMR spectroscopy 
can be observed. Solubility of 10 is poor in most solvents, though.  
Fmoc protected p-nitro-phenylalanine 11 was synthesized from 10 using standard Fmoc 
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introduction procedures. Both Fmoc-chloride and N-(9-Fluorenylmethoxycarbonyl)-
succinimide (Fmoc-OSu) were successfully used for the conversion. For the Fmoc-
chloride procedure a faster reaction could be observed, although at the cost of reduced 
yield of only 45%. Thin layer chromatography revealed higher purity for this product 
than for the one obtained through the Fmoc-OSu reaction, which had to be recrystal-
lized from EtOAc. FAB mass spectrometry of 11 confirms the correct molecular mass 
of 432.12 g/mol with a [M+H]+-peak at m/z = 433.0. The aromatic Fmoc-signals of 
product 11 can be clearly observed in the 1H NMR spectrum between 7.8 and 7.3 ppm, 
while the Fmoc methylene group gives rise to a signal at 4.23 ppm. The single ipso ring 
proton produces a peak at 4.15 ppm. The 13C NMR spectrum shows all expected reso-
nances, one significant being the methylene carbon of the Fmoc group at 65.6 ppm.  
 
4.4.1 Synthesis of Ac-Enk[Phe4(4-NH2)]-OH 12 
Before the preparation of side-chain labelled bioconjugates could be performed, a veri-
fication of the concept was carried out by the synthesis of an N-terminal acetylated Leu-
enkephalin containing a p-nitro-phenylalanine residue. Before cleavage the efficiency of 
on-resin reduction using tin(II)chloride in DMF was checked. The obtained product, 
Ac-Enk[Phe4(4-NH2)]-OH 12, was purified by HPLC and fully characterized. 
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Fig. 4.22 A p-nitro functionalized phenylalanine was incorporated into enkephalin and reduced to 
the p-amino derivative using 1 M tin(II)chloride in DMF for 12 hours. Standard cleavage 
was applied. 
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The ESI (pos.) mass spectrum of 12, confirmed the successful formation of the product, 
as it showed the calculated molecular mass of 612.29 g/mol with three main peaks at 
m/z 613.4 (M+H+), 635.4 (M+Na+) and 651.4 (M+K+). Also very weak signals of 
dimers could be observed at 1225.7 (2M + H+), 1247.6 (2M+Na+) and 1263.8 (2M + 
K+), like those in the plain peptides H-Enk-OH 3 and Ac-Enk-OH 4. 
1H NMR shows the characteristic AA’BB’ pattern of 1,4-disubstituted phenyl-rings for 
both tyrosine and newly introduced p-amino-phenylalanine between 7.3 and 6.6 ppm. 
 
 
Fig. 4.23 Proton NMR Ac-Enk[Phe4(4-NH2])-OH 12. Para-substituted phenylalanine shows signifi-
cant doublets with a distance of 0.2 ppm, while the tyrosine signals a 0.38 ppm apart. 
 
The p-amino modified phenylalanine residue shows two doublets, which are separated 
0.2 ppm, while the tyrosine doublets always show a distance of 0.38 ppm (Fig. 4.23). 
The formation of an amide bond at the amino-phenylalanine will drag the two signals 
apart from each other to a value of 0.38 ppm, which will be shown in the following. 
This change in spectroscopic properties is useful for monitoring the reaction’s progres-
sion. All expected carbon signals are visible in 13C NMR, except for the quaternary car-
bon atoms of the aromatic 4-amino-phenyl system. This is also the case for all deriva-
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tives, which contain this function. The relaxation time of these nuclei seems to be too 
long to gain proper signal strength.  
 
4.4.2 Synthesis of Ac-Enk[Phe4(NH-CO-Fc)]-OH 13 
After the successful integration of the artificial amino acid 10 via SPPS into the pep-
tide’s sequence and the succeeding on-resin reduction with tin(II) chloride in DMF have 
been demonstrated, the labelling with metallocene derivatives 1 and 2 was carried out 
according to the following scheme. 
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Fig. 4.24 Reaction strategy for the preparation of side-chain labelled enkephalin. The N-terminal 
acetylation was chosen to prevent the amino group from undergoing possible side reactions 
 
The aromatic amino group is expected to show less reactivity towards the formation of a 
peptide bond due to interaction with the phenyl π-system, so that a prolonged coupling 
time of 3 h was chosen. Since early HPLC analyses indicated that incomplete coupling 
had occurred, the excess of the metallocene carboxylic acid was raised from 3-fold to 5-
fold. This improved the yield significantly, and no more 12 was observed in HPLC. As 
well as in N-terminal labelling did the color of the resin change from beige to brown for 
ferrocene and to intense yellow for cobaltocenium, respectively. Based on the positive 
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experiences made with the addition of phenol to the cleavage cocktail, the same mixture 
was used with 13 to avoid oxidative decomposition of ferrocene (see chapter 4.3.1).  
 
The ESI (pos.) mass spectrum reports m/z 825.5 (M+H)+, 847.4 (M+Na)+ and 863.4 
(M+K)+ for the product 13, which has a molecular weight of 824.24 g/mol. ESI (neg.) 
mass spectrometry shows only a single peak at 823.5 for (M-H)-. The proton NMR ex-
periment confirms all expected peaks and shows a shift of the aromatic hydrogen atoms 
of the substituted phenylalanine ring, caused by the withdrawal of electron density from 
the ring towards the peptide bond. The doublets also have a distance of 0.38 ppm, which 
has nearly doubled from the earlier reported 0.2 ppm for the amino-derivative 12. The 
Cp-signals can be found between 5.0 and 4.0 ppm, but interestingly do not split into a 1-
1-2-5 pattern but show two pseudo-triplets for each 2 protons of the substituted 
cyclopentadiene and a singlet with an integral of 5 protons. The above discussed influ-
ence of nearby chiral centers is too weak, because the nearest location of chirality is too 
far away. 
 
 
Fig. 4.25 1H NMR spectrum of Ac-Enk[Phe4(NH-CO-Fc])-OH 13. The signal j is caused by the pro-
tons on C2 and C5, which are isochronic in this case.  
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The Cp-signals are also slightly shifted down-field in comparison with Fc-CO-Enk-OH 
7, with the unsubstituted ring having moved from 3.95 to 4.20 ppm. The other Cp-
signals experience the same shift of 0.25 ppm. This will be shown in the double func-
tionalized compounds presented in the upcoming chapter, where bioconjugates with two 
simultaneously attached metallocenes will be presented.  
The amide proton i (Fig. 4.25) is observed as a very broad singlet of relative down-field 
position of 9.03 ppm. HH-COSY NMR spectroscopy was used to identify the amide 
protons by their coupling with Cα-protons of the related amino acids. It can also be 
nicely seen, that no coupling event for the OHTyr at 9.36 ppm occurs, which is correct.  
 
Fig. 4.26 HH-COSY 2D NMR spectrum of 13, measured in DMSO-d6 at 300.16 MHz. The bottom left 
signal corresponds to the p-amido proton of phenylalanine. No coupling is expected due to 
the lacking of an adjacent Cα-proton. 
 
The CαH of leucine is hidden under the signal of Cp’ but can be identified from the 
above HH correlated spectrum, as well. The 13C NMR spectrum shows all necessary 
resonances, with the Fc-attached carbonyl carbon giving a signal at 168 ppm which 
makes it the most up-field shifted carbonyl. The quaternary phenylalanine signals, 
which were not observable in the p-amino derivative 12 are clearly visible at 137.5 and 
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132.5 ppm. The cyclopentadienyl rings result in only 4 signals, which is in accordance 
to the observation of proton isochronicity of H2 and H5.  
Electrochemical measurements reveal a one-electron reversible oxidation, very similar 
to that of Fc-CO-Enk-OH 7. The half-wave potential of this redox reaction is               
E½ = 220 mV vs. Fc/Fc+ with a peak separation of 75 mV.  
 
4.4.3 Synthesis of Ac-Enk[Phe4(NH-CO-Cc)]-OH 14 
The cobaltocenium compound Ac-Enk[Phe4(NH-CO-Cc)]-OH 14 was synthesized in 
analogy to the ferrocene derivative 13. The only difference being the application of the 
standard cleavage mixture without any anti-oxidant agent. The crude product in form of 
a yellow powder contained over 25% impurities according to HPLC UV detection.  
 
 
Fig. 4.27 Analytical HPLC chromatograms of 14 showing the crude product (left) and the purified 
substance (right). Details on chromatograms and gradients are given in chapter 8.  
 
After purification by preparative HPLC the pure compound was characterized by ESI 
(pos.) mass spectrometry, which showed the correct mass of the bioconjugate cation at 
m/z = 827.3 (M-TFA)+, 433.3 (M-TFA+K)2+ and 425.3 (M-TFA+Na)2+. The signals 
observed in proton NMR were identical to those of 13 except for the Cp-signals which 
are placed between 6.50 and 5.90 ppm. Another interesting change is the position of the 
CONH of the connected cobaltocenium moiety, which can be observed at 10.35 ppm, 
exactly 1 ppm to the lower field than the corresponding signal in its ferrocene labelled 
congener. The position of the phenylalanine aromatic signals in 1H NMR is with 7.61 
and 7.28 ppm almost identical to those in 13, only the distance is somewhat smaller at 
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only 0.33 ppm compared to 0.38 ppm. All Cp-carbon resonance signals in the 13C NMR 
spectrum appear at the exact same position as in the N-terminal labelled compound. The 
position of the cobaltocenium amide carbon signal is with 159.7 ppm remarkably shift-
ed to the higher field.  
The electrochemical studies showed indeed something different from the N-terminal 
labelled cobaltocenium compound 8. The reduction process seemed to be irreversible at 
lower scan rates of 100 mV but changed to quasi-reversible behaviour with increasing 
scan rates up to 600 mV/s. The peak separation changes proportional to the scan rate, 
identifying the redox reaction as a quasireversible process (Fig. 4.27), which means that 
the reduced cobaltocene decomposes relatively slowly. The half-wave potential is with       
1131 mV significantly shifted compared to N-terminal bound Cc (E½ = 1439 mV). 
 
 
Fig. 4.28 Cyclovoltammograms from 100 mV (red) to 600 mV (dark blue) show a quasireversible 
behaviour for 14, indicated by the decreasing peak separation with increasing scan rate. 
 
The N-terminal cobaltocenium group appears to be of electrochemically irreversible 
nature, while the side chain labelled species at least shows (quasi)reversible properties. 
These preliminary results have to be investigated in a more detailed approach, though.  
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4.5 Multiple labelling of [Leu5]-Enkephalin 
 
Two different techniques to introduce a metal marker either at the N-terminus or at the 
side-chain of a modified amino-acid have been presented so far. As a consequence, the 
possible combination of these techniques was studied, hoping to gain access to biocon-
jugates which carry multiple organometallic labels. This could either help to increase 
the peptide/metal ratio in order to improve the detection of low concentrations and also 
modify the biomolecules chemical properties with regard to solubility, hydrophilicity, 
transport across membranes, etc. (see chapter 6). 
 
4.5.1 Synthesis of Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH 15 
The synthesis was planned as shown in the following reaction scheme (Fig. 4.29). The 
introduction of the metallocene carboxylic acid was performed at both N-terminus and 
side-chain simultaneously. Post-cleavage analytical HPLC showed an improved reac-
tion progress for double-coupling with each 5 equivalents of metallocene (2.5 equiv. per 
function) over a single-coupling strategy with double the amount of metallocene. 
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Fig. 4.29 Synthetic strategy for the preparation of a di-labelled enkephalin derivative. 
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That is why the double-coupling strategy has been favoured and used for compounds 15 
and 16. The N-terminal amino group is stable towards treatment with tin(II) chloride 
and was therefore left unprotected. The color of the resin was significantly darker com-
pared to the single labelled compounds. This more intense color could also be observed 
after cleavage and purification (Fig. 4.30). The absorbance maximum does only slightly 
shift from 442 (7) to 448 nm (15), confirming the addition of chromophore absorbance 
instead of a bathochromic shift.  
 
 
Fig. 4.30 The color of the ferrocene di-labelled enkephalin 15 (top) is more intense compared to that 
of the single substituted compound 7 (bottom) 
 
The HPLC-purified substance 15 (Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH) was subjected to 
ESI (neg.) mass spectrometry, yielding the base-peak at m/z = 993.5 for the anion (M-
H+)-. The 1H NMR spectrum showed both sets of Cp-signals from each metallocene 
(Fig. 4.31) between 3.8 and 5.0 ppm. The presence of one signal group with intensities 
2-2-5 and of another one with 1-1-2-5 confirms the above postulation that the tyrosine 
chirality center influences the CH groups 2 and 5 on the substituted Cp-ring, while the 
side-chain bound ferrocene is not affected in such a way. These corresponding reso-
nances could be identified with the help of 2D NMR spectroscopy. The amide proton 
signals for the two ferrocenes resonate at 9.05 ppm as a very broad and weak singlet 
(side-chain Fc) and at 7.78 as a doublet (N-terminal Fc), respectively. The 13C NMR 
experiment also shows that two sets of Cp-signals can be observed, one from each 
ferrocene moiety. The peak patterns are simply a superposition of the two 13C NMR 
spectra of ferrocene side-chain and N-terminal labelled compounds 7 and 13 as is 
shown in Fig. 4.32. The spectrum shows all 8 expected aromatic signals from tyrosine 
and phenylalanine residues, as well. 
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Fig. 4.31 Selected region from the 1H NMR spectrum of 15 displaying the mixed Cp-signals, related 
to each of the ferrocene groups.  
 
 
 
Fig. 4.32 Cp-carbon resonances from three ferrocene containing enkephalin derivatives.  
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The electrochemical experiments show only one reversible event at 199 mV but no sec-
ond signal for the two metallocene groups. The peak separation is 76 mV, which is 
close to the 59 mV for the full reversibility of perfect Nernstian system. The difference 
at the metal centers concerning their oxidation potentials seems therefore to be very 
small. The half-wave potentials of N-terminal labelled enkephalin 7 and of the phenyla-
lanine side-chain labelled species 13 are very similar with E½ = 214 mV and 220 mV, 
which explains the presence of only one peak in 15. The potential seems to be shifted   
15-20 mV, though. Coulometric experiments have to be carried out, to confirm the si-
multaneous oxidation of two ferrocene groups by measuring the amount of electrical 
charge.   
 
4.5.2 Synthesis of (Cc-CO-Enk[Phe4(NH-CO-Cc)]-OH) TFA2 16 
The preparation of Bis-cobaltocinium-enkephalin 16 was carried out according to that 
of the corresponding ferrocene derivative. Again, the only difference was the constitu-
tion of the cleavage mixture, which did not contain any anti-oxidizing reagent like 
ascorbic acid or phenol. The bright yellow color of the resin indicated successful cou-
pling after the SPPS was finished. The crude product was purified by preparative HPLC 
to remove minor amounts of mono- and unlabelled peptide.  
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Fig. 4.33 Chemical structure of Cc-CO-Enk[Phe4(NH-CO-Cc)]-OH + 2TFA 
 
 
As each cationic cobaltocenium group is accompanied by a trifluoroacetic acid anion, 
which originates from the cleavage process, the double marked peptide is expected to be 
a di-cation. This is confirmed by the ESI (pos.) mass spectrum which shows a di-
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cationic peak at m/z = 500.29 for (M - 2 TFA-)2+, which is correct since the molecular 
mass of the di-cation is 1000.5 g/mol. Interestingly a second peak at m/z = 999.31 is 
observed, which represents the deprotonated mono-cation (M - 2 TFA- - H+)+. The re-
corded 1H NMR spectrum does not reveal any unusual signals and all peptide related 
resonances known from other enkephalin derivatives can be found. The Cp-signals, 
however, are similar to that of the ferrocene congener, since one cyclopentadienyl group 
gives signals of intensities 2-2-5, while the other resonates in a pattern of 1-1-2-5. 
Anyway, the chiral influence is much weaker on the cobaltocenium than on the ferro-
cene, as the peak distance is less than 0.02 ppm in 16, while it is more than 0.1 ppm in 
the ferrocene case. Both groups of Cc-signals are displaced by 0.35 ppm. This matches 
exactly the distance in Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH 15 measured between the Cp’ 
resonances in both cases. 13C NMR spectroscopy shows both cobaltocenium-bound car-
bonyl carbon atoms with 161.3 and 159.8 ppm shifted relatively to high field. All other 
carbonyl signals appear approximately 10 ppm more downfield. Also the Cp-carbons 
resonate at roughly 10 ppm downfield of the ferrocene signals, caused by the de-
shielding effect of the positively charged cobalt ion, as already mentioned above (chap-
ter 4.3.3). The electrochemical behaviour of Bis-cobaltocenium-enkephalin was poor 
and only badly shaped cyclovoltammograms could be recorded. The reduction took 
place at -1.435 V but was of irreversible character. The electrode had to be polished 
after each measurement due to a plating effect on the electrode surface and the meas-
urements were often not reproducible. This contributes to the picture of cobaltocenium 
being a stable and easy to handle metal marker but at the cost of insufficient and inap-
plicable electrochemical properties.  
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4.5.3 Synthesis of (Fc-CO-Enk[Phe4(NH2)]-OH) 17 
While the simultaneous coupling of two identical metal markers is a simple enterprise 
concerning protection group strategies, the introduction of two different organometallic 
labels into a biomolecule is a more challenging task. The first attached metallocene has 
to be stable under the coupling conditions of the second one and has also to survive de-
protection steps, which are necessary to avoid double coupling of the first marker. As a 
first experiment, ferrocene was coupled to the N-terminus of enkephalin, which con-
tained the p-nitro-phenylalanine residue. This nitro-function was afterwards reduced to 
yield the p-amino group where a potential second metal marker like cobaltocenium 
could be attached. This compound 17 was synthesized and isolated to verify the ferro-
cene’s stability under reducing conditions. The preparation was carried out according to 
the scheme in Fig. 4.34. 
 
H2N N
H
H
N
N
H
H
N
O
O
O
O
O
O
NO2
H
N
N
H
H
N
N
H
H
N
O
O
O
O
O
O
NO2
H
N
N
H
H
N
N
H
H
N
O
O
O
O
O
O
Fc-COOH 
TBTU  / HOBt / DIPEA
3 h coupling
1M SnCl2 . 2 H2O / DMF
2 x 12 h
3:) 92.5% TFA
3.) 5% phenol
3.) 2.5% TIS
17
Fe
O
H
N
N
H
H
N
N
H
H
N
O
O
O
O
O
Fe
O
OH
OH
Fe
O
NH2NH2
 
Fig. 4.34 The Synthesis of 17 was carried out to test for the stability of ferrocene under reducing 
conditions, enabling a follow-up introduction of a different organometallic marker like Cc.  
 
 
The crude compound 17 was obtained in high yields of more than 85%, indicating ma-
jor stability towards tin(II) chloride reduction. The reduction strength of tin chloride 
turns out to be high enough to convert the nitro group to an amino function but still low 
enough not to harm the iron metal center.  
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The isolated crude product 17 was purified by HPLC to remove any unlabelled or non-
reduced fragments and afterwards subjected to ESI (pos.) mass spectrometry. The   
product shows peaks at m/z = 783.3 (M+H)+, 805.4 (M+Na)+ and 821.3 (M+K)+ for 
mono-cations and peaks at m/z = 403.3 (M+H+Na)2+ and 411.4 (M+H+K)2+ represent-
ing di-cationic species, confirmed by their isotopic patterns. The 1H NMR spectra show 
all expected signals and the reduced 1,4-disubstituted phenyl group appears at 7.24 and 
7.15 ppm, which is similar to the positions of their related compound 12 , where the 
doublets resonated at 7.27 and 7.07. The ferrocene signals show in the typical pattern 
for N-terminal attached ferrocene with intensities of 1-1-2-5. The CH-groups 2 and 5 
have shifts of 4.82 and 4.72 ppm, while the other CH-groups resonate at 4.39 (2H) and 
3.94 (5H) ppm. Interestingly, again no quaternary carbon atoms can be observed in 13C 
spectroscopy. The spectrum shows only 6 signals between 155.7 ppm (CTyr, OH) and 
114.1 ppm (m-CH, Tyr), confirming the same observation in the compound Ac-
Enk[Phe4(NH2)]-OH 12. These signals are only visible after a peptide bond has been 
established on the amino function.  
 
 
Fig. 4.35 Comparison between 13C-signals of p-amino phenylalanine before and after a peptide bond 
has been established. The quaternary signals a and d are not visible in 17 and 12. 
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The relaxation time for carbons a and d (see Fig. 4.35) is too long in the p-amino case 
to yield a good signal to noise ratio but seems to be faster after a peptide bond has been 
formed.  
 
4.5.4 Synthesis of Fc-CO-Enk[Phe4(NH-CO-Cc)]-OH 18 
After the successful on-resin reduction of a p-nitro-phenylalanine residue in a ferrocene 
derivatized peptide, the next synthetic step could be carried out, namely the introduction 
of two different metal markers into one peptide. Besides the reduction with the first 
metallocene already attached, a second more general Fmoc approach could be used.  
Fig. 4.36 shows the two exercised reaction pathways in a schematic way. 
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Fig. 4.36 Two different reaction pathways lead to the bi-functionalized bioconjugate 18  
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Both strategies lead to the desired product 18 in high yields of over 75%. The purifica-
tion by means of preparative HPLC is necessary, though, to remove the possible mono 
functionalized by-products. The purified substance is an orange powder, which is stable 
in air and aqueous solutions, but decomposes slowly in organic solvents like DMF, 
MeOH and DMSO. The decomposition can be related to ferrocene oxidation, supported 
by the observation of broadened NMR signals in DMSO-d6 solution, caused by dia-
magnetic Fe3+. The positive ESI mass spectrum shows a peak at m/z 997.3 confirming 
the successful synthesis of the di-labelled enkephalin, which has a molecular weight of 
1110.25 g/mol as the TFA salt, while the detected cation has a calculated molecular 
mass of 997.26 g/mol. All expected resonances are visible in the 1H NMR spectrum and 
the identification of all signals is supported by the HH-COSY experiment. The amide 
proton of the side-chain bound cobaltocenium group gives the characteristic singlet at 
10.42 ppm, which is identical to the other side-chain functionalized Cc-species 14 and 
16. The Cp signals of both cobaltocenium and ferrocene are clearly visible and show as 
expected in the typical patterns 2-2-5 (side-chain bound Cobaltocenium) and 1-1-2-5 
(N-terminal bound ferrocene) between 6.70 and 5.80 ppm and 4.80 and 3.90 ppm, re-
spectively. The AA’BB’ signals of the substituted phenylalanine ring appear at the usual 
chemical shifts of 7.60 and 7.32 ppm with a slightly reduced distance of 0.28 ppm com-
pared to 0.32 ppm in former compound 16. All peaks are slightly broadened, most 
probably due to oxidized Fe3+, why the addition of a non-detectable reducing agent (Tin 
(II)salts or similar) is advised for future experiments. The 13C NMR spectrum, instead, 
shows all peaks in a sharp and clear way, as can bee seen in Fig. 4.37. The presence of 
both Cp-signal groups, which are roughly 10 ppm apart, confirms that both different 
metallocenes are bound. The carbonyl carbon atom of the side-chain connected cobalto-
cenium resonates at 159.7 ppm, which is again the most up-field shifted carbonyl signal 
in the 13C NMR spectrum. All eight aromatic signals from the two phenyl rings in tyro-
sine and phenylalanine can be observed between 155.6 and 114.8 ppm. The quaternary 
carbon atoms of the phenylalanine residue appear at 136.2 and 134.0 ppm.  
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Fig. 4.37 Selected region from the 13C NMR spectrum of Fc-CO-Enk[Phe4(NH-CO-Cc)]-OH 18, 
showing all cyclopentadienyl carbon signals 
 
 
Electrochemical studies of a peptide containing both ferrocene and cobaltocenium 
groups were expected to be more difficult than such experiments with the single substi-
tuted peptides, mainly because of the wide scan-range from positive to negative values. 
However, the cyclovoltammogram shows two single-electron processes, one oxidation 
event for ferrocene and a reduction of the cobaltocenium (Fig. 4.38). Latter was ex-
pected to be irreversible, which could be confirmed. The square-wave experiment 
clearly shows that both electron transfers occur but also reveals an unidentified electro-
chemical process at -600 mV, which can also bee seen in the CV and is probably related 
to a side-reaction of the reduced cobaltocene, since it occurs at the back-slope of the 
cycle. Even the increase in scan-rate did not change the shape of the cyclic voltammo-
gram so that the cobaltocenium reduction has to be regarded as truly irreversible.  
 
60 4  Selective labelling of [Leu]-Enkephalin with Ferrocene / Cobaltocinium 
 
 
Fig. 4.38 Cyclovoltammogram (blue) and square-wave voltammogram (red) of 18 (1 mM), measured 
in pure acetonitrile using Bu4NBF4 (0.1 M) as a supporting electrolyte.  
 
The half-wave potential of the reversible ferrocene oxidation is with 172 mV signifi-
cantly shifted compared to E½ = 214 mV vs. Fc/Fc+ in Fc-CO-Enk-OH 6. The half-
wave potential of the cobaltocenium reduction peak is 1133 mV in Fc-CO-
Enk[Phe4(NH-CO-Cc)]-OH 18 and thus identical to that in Cc side-chain bound deriva-
tive Ac-Enk[Phe4(NH-CO-Cc)]-OH 14, where  a value of 1131 mV for E½ could be 
observed. The remarkable shift of the ferrocene oxidation to lower potentials may be 
explained by a stabilization of the corresponding oxidized ferrocinium group. Whether 
the cobaltocenium plays a role in this stabilization process is unclear and has to be 
eluded by detailed electrochemical experiments. 
 
All results presented in this chapter conclude that a facile introduction of metal markers 
like ferrocene or cobaltocenium is possible at various positions in the studied peptide. 
Also the combination of these methods has been practiced, yielding multiple labelled 
peptides, either as homo- or hetero-metallic compounds. All reactions were performed 
on solid phase and crude products of high purity were obtained. Since these tools may 
be still insufficient in certain situations a supplementary approach for the labelling of 
peptides with metallocenes will be presented in the following chapter 5.
5 Selective labelling of peptides using Pd-catalyzed 
cross-coupling 
5.1 Introduction 
 
The direct coupling of a metallocene via its carboxy function to a free amino group 
through the formation of a peptide bond has been presented in the previous chapter. 
These methods work flawlessly under the described conditions but can not be applied 
when there is no amino group available, rendering them less universal than desired. A 
method which allows the introduction of the organometallic marker at a determined 
position in the biomolecule has to utilize special chemical reactivity, which has to be 
orthogonal to the reactivity of all other functional groups in the target molecule. Bind-
ing the metal label to the side-chain of a modified amino acid like the above presented 
p-amino-phenylalanine turned out to be a practical method. However, the amino-
function had to be generated from the p-nitro group by reduction, which is another con-
version step to be avoided.  
A very promising reaction is the Sonogashira coupling161, a palladium catalyzed cross-
coupling between alkynes and iodoarenes, which was presented by K. Sonogashira in 
1975. A variety of functional groups can be submitted to this reaction,83, 162, 163 which 
uses mild conditions and can also be run in aqueous solution, the latter being an impor-
tant demand for many bio-molecular reactions.  
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Fig. 5.1 Simplified reaction scheme of the Sonogashira coupling, first presented in 1975 
 
 
Since the Sonogashira coupling demands two different functional groups, an alkyne and 
a iodo-arene, it is possible to plan the coupling reaction in two ways. The alkyne group 
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could be attached to the biomolecule and the metal marker therefore modified with a 
iodo-phenyl group or vice versa. Two strong arguments favour the latter strategy, one of 
it being the easy and well known synthesis of a p-iodo-phenylalanine group which of-
fers a useful location for the binding of a metal marker molecule, as already shown in 
chapter 4. Secondly, very recent results from Schultz et al. offer innovative recombi-
nant methods for the introduction of artificial amino acids like p-iodo-phenylalanine164 
or p-azido-phenylalanine165 into a vast number of biomolecules. Therefore an alkyne 
modified metallocene marker is a versatile molecule which can bind in aqueous solution 
to the iodo-phenylalanine residue via Sonogashira coupling and also to the azido group 
to form a triazole ring. Thus, the development of a practical coupling strategy, where an 
alkyne modified metallocene is bound to either group in the target molecule, would in-
stantly provide access to the labelling of a huge number of biomolecules.  
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5.2 Synthesis of dipeptides containing p-iodo-phenylalanine 
 
To study the conditions and properties of the Sonogashira coupling, dipeptides were 
synthesized as model compounds, consisting of a Boc-protected amino acid and the 
methyl ester protected p-iodo-phenylalanine. All reactions were carried out in solution.  
5.2.1 Synthesis of p-iodo-phenylalanine 19 
The preparation of p-iodo-phenylalanine 19 was carried out according to the litera-
ture,166 where commercially available and inexpensive phenylalanine was iodized in 
strongly acidic solution by the addition of iodine.  
 
 
H2N COOH
I
H2N COOH
I2 / NaIO3 / NaIO4
HOAc / H2SO4
19  
Fig. 5.2 Preparation of p-iodo-phenylalanine 19 as described by Schwabacher et al. 
 
L-phenylalanine was dissolved in a mixture of HOAc and H2SO4 and iodine, sodium 
iodate and sodium periodate were added. After fading of the dark brown color to a clear 
orange solution and the following removal of the solvents under reduced pressure, the 
residual viscous oil was diluted with water and the product 19 was precipitated through 
neutralization with sodium hydroxide solution. The off-white powder was dried in 
vacuo and submitted to standard characterization procedures including EI mass spec-
trometry and NMR, which confirmed the correct formation of 19.   
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5.2.2 Synthesis of p-iodo-phenylalanine methyl ester hydrochloride 20 
To enable the formation of dipeptides either the N- or the C-terminus has to be pro-
tected to avoid side-reactions, as explained in chapter 3. It was chosen to protect the C-
terminus with a methyl ester and to couple the free amino-function to the activated car-
boxy group of a Nα-Boc-protected amino acid.  
To form this methyl ester, 19 was dissolved in dry methanol and thionylchloride was 
added dropwise at ice bath temperature. After 60 min. of stirring the solvent was re-
moved on a rotary evaporator and the remaining oil was dissolved in methanol and 
poured into diethylether to yield the pure product 20 as a white precipitate.  
 
 
 
H2N COOH
I
ClH3N COOMe
I
19 20
SOCl2
MeOH / 0 °C / 1 h
 
Fig. 5.3  Treatment of p-iodo-phenylalanine with thionylchloride in methanol leads to p-iodo-
phenylalanine methyl ester hydrochloride 20 
 
 
EI mass spectrometry, as well as NMR spectroscopy and elemental analysis confirm the 
expected formation of 4-iodo-phenylalanine methyl ester as the hydrochloride salt 20, 
which was straightforwardly prepared through 19 using only standard procedures. The 
simplicity of modifying the phenylalanine side-chain as shown above with the 4-nitro or 
the 4-iodo derivatives should be emphasized again, as it makes the whole synthetic 
strategy practical and affordable.  
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5.2.3 Synthesis of dipeptides 
The dipeptides 21(a-d) were synthesized from Nα-Boc-protected amino acids alanine, 
leucine, phenylalanine and tyrosine with 20. The Boc-amino acids were carboxy acti-
vated using the mixed anhydride method. The reaction scheme is shown in Fig. 5.4. 
 
H
N COOMe
I
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H
R
Boc OH
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21a : R = CH3 (Ala)
21b : R = CH2-CH(CH3)2 (Leu)
21c : R = CH2-C6H5 (Phe)
21d : R = CH2-C6H4-OH (Tyr)
21
+
20
 
Fig. 5.4 General reaction scheme for the synthesis of dipeptides using the mixed anhydride method. 
 
The activation using alkyl chloroformiates like IBCF was preferred to other common 
techniques such as the carbodiimide activation, which was introduced by Sheehan and 
Hess in 1955.167 This was mainly due to the easy removal of by-products like CO2 and 
i-butanol, whereas the carbodiimide procedure generates derivatives of urea, which are 
much more difficult to remove. Both methods imply the danger of a possible racemiza-
tion, which was not observed, though. A number of strategies have been developed to 
prevent racemization and rearrangement reactions. Among the most widely spread are 
those that employ 1-hydroxybenzotriazole (HOBt) to yield activated esters, which form 
the peptide bond under stereochemical retention. These HOBt esters are the basis for 
modern solid phase peptide chemistry and can be generated by the use of coupling re-
agents like TBTU, HBTU etc. (see previous chapter 4) 
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The spectroscopic data of the dipeptides 21a-d did not reveal any unexpected signals 
and the reactions occurred straightforward. The elemental analyses confirm the correct 
chemical compositions, as well as the FAB mass spectra always show the calculated 
(M+1)+ peaks and also molecular fragments of the type (M-C4H9)+ and (M-Boc)+. The 
1H NMR spectrum shows the Boc amide proton between 6.76 and 6.87 ppm and the NH 
proton of 4-iodo-phenylalanine between 8.13 and 8.33 ppm. While the position of the 
Boc amide proton seems to be the same in all 4 compounds, it is obvious that the dipep-
tides with two aromatic amino acids show a small shift down-field compared to 21a and 
21b, which contain alanine and leucine as aliphatic residues (Tab. 5.1). 
 
 
Fig. 5.5 Proton NMR spectrum of Boc-Tyr-Phe(I)-OMe 21d. The amide resonances b and h show 
only slight differences between compounds 21a-d 
 
 
The aromatic protons of the 4-iodo-substituted phenyl ring resonate at 7.60 and 7.00 
ppm, leaving a distance of 0.60 ppm between both signal groups. Since the 4-iodo-
phenylalanine is the location where the alkyne is being coupled to, the shift and distance 
of these signals will be of interest for the monitoring of a successful reaction. All dipep-
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tides have been recrystallized from ethyl acetate (EA) and as a consequence traces of 
EA may be observed in some 1H NMR spectra of compounds a-d.  
 
Tab 5.1 Selected shifts of amide protons from 1H NMR. All spectra measured at 360.14 MHz in 
DMSO-d6. 
 
Compound NHBoc [ppm] 3J (NHBoc) [Hz] NHPhe [ppm] 3J (NHPhe) [Hz]
21a 6.85 7.2 8.13  7.5  
21b 6.80 8.4 8.12 7.8 
21c 6.87 8.6 8.33 7.6 
21d 6.76 8.6 8.26 7.7 
 
 
The iodine atom has a strong shielding effect on the C4 carbon of the phenyl ring, which 
is shifted to 92.3 ppm in the 13C NMR spectrum. This carbon atom will be shifted over 
30 ppm down-field after the Sonogashira coupling of the alkyne. This shift is therefore a 
useful indicator for a successful binding to the target metal complex. 
 
 
Fig. 5.6 13C NMR spin-echo spectrum of 21. Secondary and quaternary signals point upwards. 
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The carbonyl carbon atoms of the tyrosine and phenylalanine residues resonate at 172.0 
and 171.8 ppm, respectively, whereas the Boc carbonyl carbon atom is shifted up-field 
to 154.9 ppm due to the positive induction effect of the butoxy group. Infrared spectra 
(KBr) of all dipeptides show bands of medium intensity below 3400 cm-1, which indi-
cates the existence of hydrogen bonds in the solid state. 
 
 
 
5.3 Sonogashira coupling of ferrocene derivatives to dipeptides 
 
5.3.1 Synthesis of ferrocenoyl-diethylpropargylamide 22 (H-DEPA-CO-Fc) 
For the introduction of the ferrocene group into a iodo-phenyl derivatized biomolecule 
through Sonogashira coupling, an alkyne group has to be bound to the ferrocene marker. 
This can be provided by modification of ferrocenecarboxylic acid 1. The carboxyl func-
tion of 1 readily undergoes peptide bond formation as presented in literature and con-
firmed in experiments (chapter 4). As a consequence, the reaction with an amino alkyne 
has to result in the formation of the desired ferrocene alkyne derivative. This reaction 
has already been presented168, 169 and was well reproducible, according to the following 
scheme. The structure of 22 has also been reported168 as obtained from x-ray crystal 
diffraction. 
 
1) thionyl chloride
2) NEt3
DCM / 6h / RT
Fe
OH
O
Fe
H
N
O
H
H2N
H
+
1 22  
Fig. 5.7 Simplified reaction scheme for the preparation of an alkyne derivatized ferrocene 
 
 
After the treatment of 1 with thionylchloride in dry DCM for 2 hours and the following 
removal of all volatile reagents on a vacuum pump, diethylpropargylamine and triethyl-
amine was added in DCM and the mixture was stirred for 6 hours. After filtration and 
extraction with CHCl3/H2O an orange solution was obtained, which yielded after evapo-
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ration the crude product in a yield of 89%. The orange powder was recrystallized from 
methanol and analytically pure, as could be confirmed by elemental analysis, HPLC and 
FAB mass spectrometry. The alkyne hydrogen atom shows at 3.19 ppm in the 1H NMR 
spectrum, while the alkyne carbon atoms resonate at 85.9 and 72.8 ppm in 13C NMR. 
Since no chirality center is present the Cp-signals give the expected 2-2-5 pattern in the 
proton NMR spectrum. The UV spectrum reveals 2 characteristic absorbance maxima at 
259 nm (Cp, aromatic) and 444 nm (FeCp2). Especially the 444 nm absorbance peak is 
observable in all Fc-labelled bioconjugates, as will be shown later. The electrochemical 
experiments show a perfect reversible one-electron redox event at E½ = 223 mV, which 
is confirmed by a Randles-Sevcik plot (Fig. 5.8). 
 
 
Fig. 5.8 Cyclic and square wave voltammograms of H-DEPA-CO-Fc 22. The Randles-Sevcik plot 
shows good reversibility.  
 
 
 
Randles and Sevcik suggested plotting the square root of the scan rate versus the ca-
thodic peak current of the corresponding voltammogram.170 A linear behaviour indicates 
a reversible redox process, while a curve would hint to quasi- or non-reversibility. The 
outstanding electrochemical properties of this ferrocene compound 22 make it a valu-
able probe for bio-labelling and redox detection.  
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5.3.2 Sonogashira coupling 
All dipeptides 21a-d have been labelled with H-DEPA-CO-Fc 22 and also with com-
mercially available ethynylferrocene, to prove the universal character of the reaction. 
The procedure was the same for both ferrocene derivatives as can be seen in Fig. 5.9. 
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Fig. 5.9 General reaction Scheme for the labelling of 4-iodo-phenylalanine containing dipeptides 
with H-DEPA-CO-FC 22 and ethinyl ferrocene 
 
 
The reactions were carried out under argon and in degassed and thoroughly dried sol-
vents. After various attempts with different solvents and bases, a mixture of THF and 
NEt3 in a ratio of 1:1 turned out to be the most successful. Shortly after all reagents had 
been added, the clear solutions became cloudy and greenish ammonium salts precipi-
tated, which indicated the proceeding reaction. Directly after filtration the solutions 
were purified by silica column chromatography, using mixtures of ethyl acetate and 
hexane. All pure products were orange powders, which readily dissolved in organic sol-
5.3  Sonogashira coupling of ferrocene derivatives to dipeptides 71 
vents like CH3CN, THF, DMF, DCM, EtOH and MeOH but showed only moderate 
solubility in water.  
 
 
H
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Boc
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Fe
23a : R = CH3 (Ala)
21b : R = CH2-CH(CH3)2 (Leu)
21c : R = CH2-C6H5 (Phe)
21d : R = CH2-C6H4-OH (Tyr)
 
Fig. 5.10 Constitution of H-DEPA-CO-Fc labelled dipeptides 23a-d. All substances are orange sol-
ids, thus enabling easy purification on a silica column. 
 
The purified DEPA-CO-Fc labelled dipeptides 23 were submitted to elemental analysis, 
HPLC and mass spectrometry, confirming the successful reaction. The FAB mass spec-
tra show in addition to the M+-peaks signals for [M-Boc]+, [M-Boc-Cp]+ and also frag-
ments of m/z = 213 and 185, which can be assigned to [Fc-CO]+ and [Fc]+, respectively. 
Proton NMR signals for the Cp rings can be observed at 4.64, 4.30 and 4.21 ppm     
according to the usual 2-2-5 intensity pattern. The 1H NMR spectrum also shows a 
singlet for the DEPA-CO-Fc NH amide proton at 5.74 ppm, which is the same for all 4 
compounds. The phenyl ring of the former 4-iodo-phenylalanine residue still resonates 
in form of the two pseudo-doublets of a typical AA’BB’ system but the signals have 
changed positions and distances compared to the dipeptide starting material. Significant 
changes in these shifts are given in Table 5.2 (measured in DMSO-d6).  
 
Tab 5.2 Comparison of selected 1H NMR signals before and after labelling with DEPA-CO-Fc.  
 
Compound Nr. δ Phe3,4  [ppm] 
δ Phe2,5 
[ppm] 
∆ 
[ppm] 
Boc-Ala-Phe(I)-OMe 21a 7.61 7.03 0.58 
Boc-Ala-Phe(DEPA-CO-Fc)-OMe 23a 7.38 7.20 0.18 
Boc-Leu-Phe(I)-OMe 21b 7.61 7.04 0.57 
Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b 7.39 7.21 0.18 
Boc-Phe-Phe(I)-OMe 21c 7.62 7.05 0.57 
Boc-Phe-Phe(DEPA-CO-Fc)-OMe 23c 7.35 7.16 0.19 
Boc-Tyr-Phe(I)-OMe 21d 7.60 7.03 0.57 
Boc-Tyr-Phe(DEPA-CO-Fc)-OMe 23d 7.34 7.14 0.20 
H
N COOMe
R
R = I, alkyne
O 2
5
3
4
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The distance between the two pseudo-doublets changes significantly from average 0.57 
to 0.19 ppm. This is due to a difference in electron density of the phenyl ring before and 
after coupling. The methyl protons of both DEPA ethyl groups resonate in form of one 
triplet signal with the correct intensity of 6 protons at 1.08 ppm (Fig. 5.11, signal f), 
while the methylene groups split into two multiplets at 2.38 and 1.91 ppm (signals m 
and m’). The singlet signal of the alkyne proton, which was observed in 22 at 3.10 ppm, 
is not anymore present. As a consequence no free alkyne is left and the coupling has 
fully taken place.  
 
 
Fig. 5.11 1H NMR spectrum of Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b.  
 
The carbon NMR spectrum shows apart from the dipeptide related signals the additional 
resonances from the added metal marker. An indication for a successful formation of 
the alkyne-phenyl bond is the down-field shift of the alkyne carbon atoms in the 13C 
NMR spectrum from 85.9 and 72.8 ppm in H-DEPA-CO-Fc 22 to 91.2 and 83.4 ppm in 
dipeptide bound DEPA-CO-Fc. Absorbance maxima in the UV-Vis spectrum, measured 
in chloroform, can be observed at 246 and 255 nm for all compounds 23a-d (Fig. 5.12). 
These absorbances are π→π* excitations of aromatic systems with molar extinction            
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coefficients ε of 25000 and 23000 l/mol·cm, respectively. The significant but weaker 
ferrocene signal can be observed at 444 nm (ε = 250 l/mol·cm). 
 
 
Fig. 5.12 UV-Vis spectrum of Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b. The absorbance peak at 444 
nm indicates the presence of a ferrocene group. 
 
The electrochemical properties of all compounds are very similar, showing that the pep-
tide’s influence on the redox behaviour of the marker is small to none. The half-wave 
potentials are between 209 and 213 mV with peak separations of 80 to 87 mV.         
Table 5.3 lists all electrochemical values of compounds 23a-d. 
 
 
Tab 5.3 Electrochemical properties of compounds 23. All oxidations show full reversibility. 
 
Compound E½ [mV] Peak Sep. [mV] 
Boc-Ala-Phe(DEPA-CO-Fc)-OMe 23a 213.0 82 
Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b 212.0 80 
Boc-Phe-Phe(DEPA-CO-Fc)-OMe 23c 211.5 87 
Boc-Tyr-Phe(DEPA-CO-Fc)-OMe 23d 209.5 85 
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The half-wave potential of DEPA-CO-Fc 22 does not change through binding to the 
target molecule. The pure compound shows the redox event at 223 mV, which is only 
10 mV different from the average dipeptide bound DEPA-CO-Fc group.  
 
 
 
Fig. 5.13 Voltammograms and Randles-Sevcik plot of 23b are representative for all compounds 23  
 
 
The redox-reaction is still perfectly reversible, confirmed by the strongly linear behav-
iour of the according Randles-Sevcik plot, which shows a correlation higher than   
99.99 %. As a conclusion, the binding of the ferrocene marker to a dipeptide does not 
worsen the electrochemical properties required for sensitive detection as shown above 
in Figure 5.13. This is promising information for the labelling of bigger molecules like 
peptides and proteins. Cobaltocenium has not been used as a marker here, since ferro-
cene better fulfils the electrochemical requirements for detection of bioconjugates even 
in small amounts.  
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To verify the universal applicability of the Sonogashira cross coupling method for the 
introduction of metal markers, all dipeptides have as well been labelled with another 
ferrocene derivative, the commercially available ethynylferrocene, as already shown in 
Figure 5.9. 
 
24a : R = CH3 (Ala)
21b : R = CH2-CH(CH3)2 (Leu)
21c : R = CH2-C6H5 (Phe)
21d : R = CH2-C6H4-OH (Tyr)
H
N COOMe
O
N
H
R
Boc
24
Fe
 
Fig. 5.14 Ethynylferrocene labelled dipeptides 24a-d. The synthesis was identical to that of com-
pounds 23a-d. 
 
For the synthesis of ethynylferrocene labelled dipeptides the ferrocene marker has been 
treated under protective atmosphere with the aim to avoid oxidation in air as recom-
mended by the manufacturer. Prolonged contact to air oxygen did not harm the product 
quality or the yield in any way, though. The Sonogashira reaction went even faster than 
that of H-DEPA-CO-Fc 22, as could be observed by TLC. After 3 hours all dipeptide 
reactant was converted into the labelled product. 
All products 24a-d are orange solids like their DEPA-CO-Fc congeners and also their 
ability to dissolve in water is very similar, although the additional peptide bond in com-
pounds 23 improves their water dissolution. The purification on silica gel columns is 
most practical due to the orange color of the compounds. Such purely obtained sub-
stances have been characterized by elemental analysis, HPLC and FAB mass spec-
trometry, with the latter showing [M]+ as the base peak and additional fragments related 
to [M-C4H9]+ and [M-Boc]+. All compounds show a strong peak in their mass spectra at 
m/z = 299, which can be assigned to the cationic species [Fc-alkynyl-Ph-CH2]+. 1H 
NMR spectra display the expected Cp resonances at 4.53, 4.31 and 4.24 ppm, the 
methyl ester singlet at 3.59 ppm and the Boc-protons at 1.37 ppm, possessing the highs 
intensity of 9 protons. Figure 5.15 shows a selected region of the 1H NMR spectra of 
Boc-Leu-Phe(I)-OMe 21b and Boc-Leu-Phe(ethinyl-Fc)-OMe 24b to demonstrate the 
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signal shift of the phenyl protons before and after the coupling process. The values are 
very similar to those stated in Table 5.2, where compounds 21a-d are compared to the 
DEPA-CO-Fc derivatized substances 23a-d. 
 
 
Fig. 5.15 Aromatic region of the proton NMR spectra of 21b and 24b, which shows the shift of the 
phenyl-ring signals after the iodine has been replaced by an alkyne group. 
 
 
The 13C NMR spin-echo spectrum shows both alkyne signals at 88.4 and 85.3 ppm. The 
binding to the phenyl ring causes a slight down-field shift compared to the free alkyne. 
The ester and dipeptide carbonyl carbon atoms are the most down-field shifted signals 
in the spectrum, resonating at 172.2 and 171.1 ppm, respectively. The Boc carbonyl 
resonance can be found at 155.4 ppm, showing reduced intensity. All four aromatic sig-
nals can be observed at 135.4/122.6 ppm (quaternary) and 131.4/129.2 ppm (tertiary). 
The Cp-signals are slightly different from those observed in the corresponding DEPA-
CO-Fc derivative, which is self-explanatory due to electron pushing effect of the alkyne 
group. This mostly affects the ipso-carbon of the substituted Cp ring, shifting it to be the 
most up-field resonance of all Cp-signals (see Figure 5.16). The ipso-carbon is hidden 
under the solvent signal in 23b. 
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Fig. 5.16 Selected region from the 13C NMR spectra of Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b and 
Boc-Leu-Phe(alkynyl-Fc)-OMe 24b. Comparison of alkyne and Cp signals. 
 
 
UV-Vis spectroscopy shows an interesting absorbance maximum at 304 nm, which ap-
pears next to the already observed maxima at 256 nm (aromatic) and 444 nm (Fc). It can 
probably be assigned to the conjugated π-system, which extends from the phenyl ring 
over the alkyne group to the substituted Cp-ring. Another interesting observation is the 
higher molar extinction coefficient for the ferrocene related absorbance compared to the 
DEPA derivatives. UV spectroscopic properties of all dipeptides are compared in Table 
5.4.  
Tab 5.4 Absorbance maxima of all labelled dipeptides from UV-Vis spectra, measured in MeOH. 
 
Compound Nr. λ1max 
ε (λ1) 
[l/mol·cm] λ2max 
ε (λ2) 
[l/mol·cm] λ3max 
ε (λ3) 
[l/mol·cm] 
Boc-Ala-Phe(DEPA-CO-Fc)-OMe 23a 246 24825 256 22150 442 236 
Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b 246 28330 255 24240 444 249 
Boc-Phe-Phe(DEPA-CO-Fc)-OMe 23c 246 27985 256 24510 442 276 
Boc-Tyr-Phe(DEPA-CO-Fc)-OMe 23d 246 26010 256 22840 442 231 
Boc-Ala-Phe(Fc)-OMe 24a 256 18335 300 16305 445 563 
Boc-Leu-Phe(Fc)-OMe 24b 256 17930 301 16030 445 582 
Boc-Phe-Phe(Fc)-OMe 24c 256 18340 301 16235 446 586 
Boc-Tyr-Phe(Fc)-OMe 24d 256 18740 301 16360 444 537 
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Hydrogen bonding in the solid state may be concluded from the IR spectra, where NH-
stretch bands appear below 3400 cm-1. The characteristic alkyne stretch band is visible 
at 2207 cm-1, comparable to that in 23a-d. The electrochemical experiments deliver the 
usual one-electron reversible redox reaction from all 4 compounds. The electronic situa-
tion for the iron atom is different, though, since the alkyne group is an electron pushing 
function, opposite to the electron density withdrawing carbonyl group of DEPA-CO-Fc 
22 and Fc-COOH 1. Therefore the half-wave potentials of compounds 24a-d are shifted 
to lower values between 152.5 to 169.0 mV. Peak separations lie in the range of 73 to      
98 mV. Only 24a shows a higher peak separation of 142 mV. The redox-processes, 
checked by measurements at increasing scan rates of 100, 200, 300...600 mV and the 
following constructions of Randles-Sevcik plots, are of highly reversible nature. Corre-
lation values are 99.942 to 99.999 % for a linear behaviour, as calculated from the re-
gression.  
 
 
Fig. 5.17 An Overlay of six cyclovoltammograms of Boc-Phe-Phe(alkynyl-Fc)-OMe 24c is shown. 
The scan rate was increased from standard 100 mV/s (red cycle) to 600 mV/s (blue cycle)  
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Figure 5.17 shows constant peak positions of all cyclovoltammograms under variation 
of the scan rate. The electrochemical properties of the ethynylferrocene marker do not 
rank behind the above presented DEPA-CO-Fc 22 group. Both substances have advan-
tages and while DEPA-CO-Fc is easy to prepare in gram scales from Fc-COOH 1 and 
less sensitive, the smaller size and even better electrochemical behaviour of 
ethynylferrocene may recommend the latter. The choice of the marker has to be made 
according to the proposed synthetic strategy and the demands concerning label size and 
ease of handling. The fact that two different markers have been tested in this thesis may 
help to facilitate the planning of a synthetic pathway to a better access of organometallic 
labelled bioconjugates. 
Because the H-DEPA-CO-Fc 22 marker was synthesized in the lab and therefore well 
characterized, it was chosen to be the candidate for the labelling of a larger peptide like 
[Leu5]-Enkephalin via the Sonogashira route, as shown in the following. The results 
obtained from this dipeptide project suggest that ethynylferrocene would perform ac-
cording to the DEPA-CO-Fc marker, synthetically and in terms of characterization and 
detection.  
 
 
 
5.4 Synthesis of enkephalin containing p-iodo-phenylalanine 
5.4.1 Synthesis of Fmoc-Phe(I)-OH 25 
The previous chapter 5.3 has introduced the palladium catalyzed Sonogashira coupling, 
where an alkyne is bound to a iodo-phenyl group. The dipeptide model approach 
showed that alkyne derivatized ferrocenes could be coupled to iodo-phenylalanine in a 
convenient and practical way. Since this method was to be extended, aiming at the la-
belling of bigger molecules like peptides and proteins, the acquired results were applied 
to the model peptide [Leu5]-Enkephalin. As a consequence, the p-iodo-phenylalanine 
moiety had to be inserted into the peptide using solid phase peptide synthesis tech-
niques. Since enkephalin contains a Phe in position 4 it was the ideal location for the 
introduction of an artificial phenylalanine, without altering the original biomolecule too 
severely. For the use of p-iodo-phenylalanine 19 in SPPS it had to be Nα-protected, 
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preferable using Fmoc as protection group, integrating it seamlessly into the whole   
synthetic workflow. The introduction of Fmoc into H-Phe(I)-OH was carried out fol-
lowing standard procedures, which most often employ Fmoc-OSu or Fmoc-Cl as re-
agents. 
 
 
H2N COOH
H
N COOH
I
FmocOSu / ACN
I
O
O
H2O, NEt3, 2h
19 25  
Fig. 5.18 Simplified reaction scheme for the introduction of the 9-fluorenylmethoxycarbonyl (Fmoc) 
protection group 
 
 
 
After 2 hours of stirring the reaction mixture was poured into a beaker containing 1.5 M 
HCl solution whereby a white solid precipitated, which was filtered and repeatedly 
washed with water. The product 25 was dried overnight in vacuo resulting in a yield of 
63% of pure substance. Using Fmoc-Cl for the protection process gave better yields 
(78-85%) but also worse purity. The Fmoc-OSu method was preferred, because the 
starting material for both methods is not pricey and readily available.  
The white powder was characterized by elemental analysis, HPLC and FAB mass spec-
trometry. The [M+H]+ peak at m/z = 504 and the fragments at m/z = 388 [M-I+H]+, 203 
[M-C6H4I+H]+ and 165 [fluorenyl]+ found in the mass spectrum confirmed the success-
ful introduction of the Fmoc group. 1H and 13C NMR spectra showed the typical signals 
for 19 and additionally all required resonances for the fluorenyl group in the aromatic 
region and the Fmoc-methylene group at 4.17 and 65.5 ppm, respectively. The solubil-
ity in DMF was sufficient as 500 mg clearly dissolved in 2 ml solvent.  
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5.4.2 Synthesis of Ac-Enk[Phe4(I)]-OH 26 
With the Nα-Fmoc-protected p-iodo-phenylalanine 25 in hand, Ac-Enk[Phe4(I)]-OH 26 
was synthesized by standard solid phase peptide synthesis, where Fmoc-Phe-OH was 
simply replaced by the modified amino acid. The synthesis was carried out on Wang 
resin and the cleavage conditions comprised a mixture of 95% TFA, 2.5% H2O and 
2.5% of TIS and a duration of 3h.  
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Fig. 5.19 Chemical constitution of the p-iodo-phenylalanine modified and N-acetylated enkephalin 
 
 
The crude product (yield: 79%) was purified by preparative HPLC to give a white pow-
der, which shows good solubility in both organic solvents and water. The FAB mass 
spectrum displays two product peaks for m/z = 746 [M+Na]+ and m/z = 724 [M+H]+ 
and a number of fragment signals which could be assigned to [M-(Leu-OH)]+, [M-
(Phe(I)-Leu-OH]+ and [M-(Gly-Phe(I)-Leu-OH]+, observable at m/z =593, 320 and 263, 
respectively. The typical signals for [Leu5]-enkephalin can be found in the proton NMR 
spectrum but also the unambiguous resonances for the p-iodo-phenylalanine residue, 
forming pseudo-doublets at 7.99 and 7.60 ppm, are visible. The distance is with          
0.39 ppm smaller than the value of 0.57 ppm that was observed in the dipeptides. The 
CH3 acetyl group resonates in form of a singlet at 1.77 ppm, as shown in Fig. 5.20. The 
assignment of all signals was supported by HH-COSY 2D NMR spectroscopy.  
82 5  Selective labelling of peptides using Pd-catalyzed cross-coupling 
 
 
Fig. 5.20 1H NMR spectrum of Ac-Enk[Phe4(I)]-OH 26 in DMSO-d6. Signals p and o correspond to 
the 1,4-disubstituted phenyl-ring of the modified amino acid 25. 
 
 
All expected carbon signals are observable in the 13C NMR spectrum. Most interesting 
is the chemical shift of the ipso-carbon atom, which is directly connected to the iodine 
atom. This quaternary carbon signal resonates at 92.1 ppm but is expected to move ap-
proximately 30 ppm to the lower field after the iodine has been substituted by the al-
kyne group of the ferrocene marker. UV-Vis spectroscopy reveals two major absorb-
ance maxima at 225 nm and 259 nm which can be assigned to peptide bond and aro-
matic π→π* excitations.  
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5.4.3 Synthesis of I-Ph-Enk-OH 27 
Among the main demands for a versatile labelling methodology is a high grade of vari-
ability which allows not only to choose between different types of marking agents and 
reaction conditions but also to select a certain coupling site inside the biomolecule. 
Metal markers have been successfully attached to the N-terminus and the side-chain of 
enkephalin as presented in chapter 4. To provide the same flexibility for the Sonoga-
shira coupling strategy, the introduction of a p-iodo-phenyl function at the N-terminus 
was carried out using p-iodo-benzoic acid (PIBA) as a ‘sixth’ amino acid in SPPS. 
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Fig. 5.21 [Leu]-enkephalin was derivatized at the N-terminus using p-iodo-benzoic acid, thus intro-
ducing a Sonogashira compatible function. 
 
 
The reaction was carried out according to the synthesis of 26. The cleavage of the 
Wang-attached product was performed under standard conditions and after removal of 
90% of the solvents and the subsequent precipitation in diethylether, nearly pure com-
pound 27 was obtained in a yield of 86%. The white powder was submitted to FAB 
mass spectrometry showing the correct peaks at m/z = 808 [M+Na]+ and 786 [M+H]+. 
Additional fragments are observable in analogy to 26. The successful introduction of the 
p-iodo-phenyl residue at the N-terminal side of the peptide is confirmed by the corre-
sponding aromatic signals at 7.82 and 7.57 ppm, which each possess coupling constants 
of 8.4 Hz. These values are similar to those found in all previously presented 
1,4-disubstituted phenyl groups, which range from 7.8 to 8.6 Hz. A selected part of the 
aromatic region of the measured 1H NMR spectrum is shown in Figure 5.22.  
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Fig. 5.22 Aromatic region of the 1H NMR spectrum of I-Ph-Enk-OH 27. Glycine amide protons can 
be identified by their triplet shape (f and g).  
 
 
 
The 13C NMR spectrum shows 6 carbonyl carbon resonances between 173.7 (COOH) 
and 165.6 ppm (PIBA). In addition, all 12 aromatic carbon signals can be observed, 
being positioned between the highly down-field shifted signal of tyrosine (155.6 ppm) 
and the iodine bound carbon atom resonance at 98.7 ppm. As well as in the case of 
compound 26, the shielding effect of the iodine atom is responsible for the shift to 
higher field and the cross coupling reaction is expected to make the signal move down-
field by more than 30 ppm. Therefore the signal can be consulted as an indicator for the 
monitoring of a successful Sonogashira coupling.  
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5.5 Sonogashira coupling of H-DEPA-CO-Fc to [Leu5]-Enkephalin 
5.5.1 Synthesis of Ac-Enk[Phe4(DEPA-CO-Fc)]-OH 28  
Differently from the synthesis of the ferrocene coupled dipeptides 23a-d and 24a-d, the 
side-chain modified enkephalin derivative 26 was reacted in a mixture of DMF/NEt3 
(1:1) out of solubility reasons. Apart from the change of solvents the synthesis of 28 
was carried out in analogy to the dipeptide Sonogashira reactions, as given in Fig. 5.23. 
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Fig. 5.23 An alkyne derivatized ferrocene is bound to the p-iodo-phenylalanine side-chain of modi-
fied enkephalin 26 to yield the labelled biomolecule 28  
 
 
 
The reaction progress was monitored by HPLC and the synthesis was finished after 12 
hours, when no more peptide starting material was detected. The solvents were removed 
on the vacuum pump and the residual oil was re-dissolved in acetonitrile and purified by 
preparative HPLC. The light yellow powder was characterized by ESI (neg.) mass spec-
trometry where the spectrum shows a peak for [M-H]- at m/z = 917.4, while the ESI 
(pos.) spectrum confirms this observation showing three molecular peaks at m/z 919.4 
[M+H]+, 941.4 [M+Na]+ and 957.5 [M+K]+. The successful introduction of the ferro-
cene label had occurred as can be deduced from the typical 2-2-5 Cp signal pattern in 
the 1H NMR spectrum. The Cp-protons resonate at 4.92, 4.33 and 4.19 ppm. Table 5.5 
shows the comparison between the Cp signal positions of all DEPA-CO-Fc 22 labelled 
compounds. The influence of the biomolecule on the chemical shifts of the Cp-protons 
seems to be small, which is explainable by the long distance of the peptide to the ferro-
cene moiety. 
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Tab 5.5 Overview of the chemical shifts in DEPA-CO-Fc compounds as observed in 1H NMR spec-
troscopy (all spectra measured in DMSO-d6). 
 
Compound Nr. 
δ 
Cp2,5 
[ppm] 
δ 
Cp3,4 
[ppm] 
δ Cp’ 
 
[ppm] 
H-DEPA-CO-Fc 22 4.89 4.33 4.18 
Boc-Ala-Phe(DEPA-CO-Fc)-OMe 23a 4.89 4.31 4.17 
Boc-Leu-Phe(DEPA-CO-Fc)-OMe 23b 4.90 4.32 4.19 
Boc-Phe-Phe(DEPA-CO-Fc)-OMe 23c 4.90 4.33 4.20 
Boc-Tyr-Phe(DEPA-CO-Fc)-OMe 23d 4.95 4.35 4.27 
Ac-Enk[Phe4(DEPA-CO-Fc)]-OH 28 4.92 4.33 4.19 
Fc-DEPA-Ph-Enk-OH 29 4.95 4.37 4.21 
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Except for the phenylalanine ring protons all other peptide related proton NMR signals 
stay unchanged before and after the coupling reaction. The amide protons produce sig-
nals above 7.5 ppm, because hydrogen bonds are formed with the solvent DMSO. The 
dipeptide compounds 21, 23 and 24 have additionally been measured in chloroform, 
where the amide signals occur below 7.5 ppm, suggesting that no intermolecular hydro-
gen bonds are present, whereas infrared spectroscopy (KBr) shows the formation of 
hydrogen bonds both in dipeptides and enkephalin in the solid state. Beyond these ob-
servations no other conclusions concerning molecular conformations can be drawn. The 
carbon atom to which the iodine atom was connected has shifted from 92.1 ppm in 26 to 
120.5 ppm in 28. The Cp-carbon signals of the tethered ferrocene compound resonate 
between 76.5 and 68.2 ppm and underlining the successful reaction. The DEPA ethyl 
groups show signals at 8.4 for CH3 and at 29.9 ppm for CH2, while the alkyne carbon 
atoms resonate at 91.7 and 82.0 ppm. A comparison of the carbon NMR spectra before 
and after the coupling process is shown in Fig 5.24.  
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Fig. 5.24 Selected regions from 13C NMR spectra of Ac-Enk[Phe4(I)]-OH 26 (red) and Ac-
Enk[Phe4(DEPA-CO-Fc)]-OH 28 (blue). Signals b (blue) and a (red) are coincidentally 
almost isochronic.    
 
 
The ferrocene characteristic absorbance maximum at 444 nm is visible in the UV-Vis 
spectrum, which was measured in methanol. The experimentally determined extinction 
coefficient ε is 272 l/mol·cm and therefore congruent with all other DEPA-CO-Fc de-
rivatives. Only the ethynylferrocene dipeptides 24a-d have higher extinction coeffi-
cients between 535 and 585 l/mol·cm, albeit with the same absorbance maximum at 445 
nm (see Table 5.4). By the tethering of a ferrocene group new electrochemical proper-
ties are introduced. Those have been studied by the recording of cyclovoltammograms 
and square wave voltammograms, which are shown in Fig. 5.25. The half-wave poten-
tial value E½ was determined to be 210 mV, which is comparable to other DEPA-CO-
Fc compounds. The one-electron redox process is reversible as can be read from the 
Randles-Sevcik calculations and a peak separation of 80 mV.  
 
88 5  Selective labelling of peptides using Pd-catalyzed cross-coupling 
 
 
Fig. 5.25 Electrochemical measurements prove the presence of a ferrocene group in the biomolecule 
revealing the typical one-electron reversible redox process. 
 
 
 
5.5.2 Synthesis of Fc-CO-DEPA-Ph-Enk-OH 29  
DEPA-CO-Fc 22 was coupled to the N-terminal PIBA-derivatized enkephalin 27 under 
the same reaction conditions like those employed for the synthesis of 28. Again, the 
reaction progress was followed by analytical HPLC and the conversion was finished 
after 10 hours. The solvents were removed and the crude product was purified by prepa-
rative HPLC. However, the yield was significantly lower in comparison to 28, and only 
a few mg of pure substance were obtained. A reaction scheme for the formation of Fc-
CO-DEPA-Ph-Enk-OH 29 can be regarded in Fig. 5.26.  
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Fig. 5.26 Synthesis of Fc-CO-DEPA-Ph-Enk-OH 29 by Sonogashira coupling in solution 
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The mass peak at m/z = 979.5 (ESI, neg.) can be assigned to the single deprotonated 
molecular mass [M-H]- anion. The signals found in the proton NMR spectrum tell that 
the bond formation has occurred indicated by the disappearance of the alkyne resonance 
of 22. In addition, the Cp-signals are visible at 4.92, 4.34 and 4.19 ppm. These chemical 
shifts are identical to those of all other measured DEPA-CO-Fc compounds (see Tab. 
5.5). 
 
 
Fig. 5.27 1H NMR spectrum of Fc-CO-DEPA-Ph-Enk-OH 29 recorded at 300.16 MHz in DMSO-d6  
 
Not enough substance was obtained to measure a qualitative satisfying 13C NMR spec-
trum but still the required signals in the carbonyl area between 175 and 160 ppm and all 
four Cp-carbon resonances around 75 ppm can be identified. The signal to noise ratio is 
not good enough to identify the alkyne carbon atom, which have small intensities by 
nature, anyway. The UV-Vis experiment shows one huge absorbance peak at 269 nm 
and the demanded Fc-absorbance maximum at 442 nm, which is responsible for the 
yellow-orange color of all ferrocene containing bioconjugates presented so far.  
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Fig. 5.28 UV-Vis absorbance spectrum for Fc-CO-DEPA-Ph-Enk-OH 29. Spectrum recorded in 
MeOH 
 
 
The concluding electrochemical studies show the same reversible behaviour as all other 
ferrocene derivatives. Similar to the side-chain derivative 28 the working electrode had 
to be polished after each run, because the recorded cyclovoltammograms became mis-
shaped after repetitive use. The same effect was observed with the peptide bound Fc/Cc 
derivatives (chapter 4) and can be interpreted as a passivation of the electrode surface 
by a plating process of oxidized peptide material. Table 5.7 contains comparison of 
electrochemical data of all Sonogashira labelled compounds.   
 
Tab 5.6 Half-wave potentials and peak separation values of Fc-labelled biomolecules 
 
Compound Nr. mol. mass [g/mol] E½ [mV] Peak Sep. [mV] 
H-DEPA-CO-Fc 22 323.10 223.0 86 
Boc-Ala-Phe(DEPA-CO-Fc)-OMe  23a 671.27 213.0 82 
Boc-Leu-Phe(DEPA-CO-Fc)-OMe  23b 713.31 212.0 80 
Boc-Phe-Phe(DEPA-CO-Fc)-OMe  23c 747.30 211.5 87 
Boc-Tyr-Phe(DEPA-CO-Fc)-OMe  23d 763.29 209.5 85 
Boc-Ala-Phe(CC-Fc)-OMe  24a 558.18 163.0 142 
Boc-Leu-Phe(CC-Fc)-OMe  24b 600.23 169.0 98 
Boc-Phe-Phe(CC-Fc)-OMe  24c 634.21 152.0 73 
Boc-Tyr-Phe(CC-Fc)-OMe  24d 650.21 161.0 82 
Ac-Enk[Phe4(DEPA-CO-Fc)]-OH 28 918.36 210.0 80 
Fc-CO-DEPA-Ph-Enk-OH 29 980.38 216.0 80 
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The successful introduction of alkynylated Fc derivatives into dipeptides and different 
positions of a pentapeptide has been presented in chapter 5. These results prove the 
Sonogashira coupling method to be of high value for the easy tethering of metal com-
pounds to modified biomolecules. Together with the experimental results of chapter 4 
two strategies for the selective labelling of biomolecules are provided to the chemist 
who is interested in structural elucidation of large biomolecules, electronic modifica-
tions or the wide area of diagnostic agents. Especially for the latter it is important not 
only to chemically bind the metal marker to the desired biomolecule but also to monitor 
the change in biological properties like hydrophilicity, bio-availability and pharmaco-
kinetics/dynamics. To gain insight into the metal marker’s impact on such key attrib-
utes, biological studies have been carried out with selected substances from chapters 4 
and 5. These interesting results will be explained in the following chapter. 

6 Biological properties of metallocene labelled Leu-
Enkephalins 
6.1 Introduction 
The detection of biomolecules like hormones, enzymes, nucleic acids and peptides in-
side a biological system is among the main interests in modern diagnostic medicine. 
This requires in most cases the introduction of a chemical probe, which provides unique 
spectroscopic properties. However, this may lead to altered biological characteristics, 
which can affect uptake, activity, metabolism and toxicity of the original target mole-
cule. It is therefore essential to gather information about the marker’s influence on these 
biological and pharmacological attributes.  
An important factor for cell uptake is the lipophilicity of a substance, which has to be 
high enough to enable passage through the phospholipid cell membrane. The 
n-octanol/water partition coefficient Po/w is commonly used to describe the lipophilicity 
of a compound and is usually given in the logarithmized form, logP. The labelling of 
enkephalin with metallocene derivatives is expected to have a huge influence on the 
logP values of the peptide, because lipophilic metallocenes are bound to the rather hy-
drophilic biomolecule. Partition coefficients are either determined by the shake-flask 
method171 or more conveniently by RP-HPLC methods.172, 173  
Lipophilicity is also a reliable physicochemical parameter for the prediction of blood-
brain-barrier (BBB) permeation,174-176 which is given in form of apparent permeability 
coefficients (Papp). These Papp values are measured in transport experiments, where the 
time dependent permeation of a substance through a cell monolayer is studied. These in 
vitro blood-brain-barrier models make use of bovine, rat or porcine brain endothelial 
cells, which are extracted, purified and cultured. 
In this thesis, logP values have been determined for various enkephalin derivatives, 
which were presented in chapter 4. In addition, blood-brain-barrier permeation experi-
ments through pig brain endothelial cells have been conducted with selected enkephalin 
compounds. These results will be compared and presented in the following chapter. 
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6.2 LogP measurements of Enkephalin derivatives 
6.2.1 Theoretical background 
Since the introduction of the Hansch approach177 to drug design, the lipophilicity of 
drug molecules, agrochemicals and general chemicals gained great importance. Fujita et 
al. first proposed the octanol water coefficient (Po/w) as a good model for biological par-
tition.178 Since then, the logarithm of the octanol-water partition coefficient (logP) has 
become the most widely used lipophilicity parameter. The logP property value is taken 
from the ratio of the respective concentrations of a compound in the octanol and water 
partitions of a two-phase system at equilibrium. The concentration measurements are 
made at a constant temperature, normally 25° C.  
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The calculation of logP values: [X]= concentrations, oct = octanol, aq = water 
 
 
The shake flask method171 is the oldest and most tedious way of measuring logP values. 
The UV absorbance (fluorescence, radioactive decay, etc.) of an aqueous solution is 
measured before and after being shaken with a known volume of octanol. The method is 
messy and smelly but is still the best procedure that can be used in cases of very low 
logP values. One advantage is that the appearance of compound in the octanol phase 
may be checked against the disappearance from the aqueous phase to see if any surface 
effects have occurred. Some molecules may form effective surfactants and by that fal-
sify the observed results.  
High performance liquid chromatography (HPLC) provides an easy, reliable and accu-
rate way to measure the concentrations of dissolved compounds, thus it can be used as a 
method to obtain octanol-water partition coefficients. However, the technique has 
greater potential to determine the partition properties of compounds based on their 
chromatographic retention times.179  
Considering retention in a chromatographic partition system as a dynamic equilibrium 
process with an equilibrium constant KR, the retention process can be described by 
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where ∆GR, R and T are the Gibbs free energy change of retention, gas constant and 
absolute temperature, respectively. The chromatographic retention time directly relates 
to the compound’s distribution between the mobile and the stationary phase. The capac-
ity factor k’, determined from the retention time (tR) and dead time (t0), is equal to the 
ratio of the average number of analyte molecules in the stationary phase to the average 
number of molecules in the mobile phase (Eqn. 3) during the elution process. 
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Ns, Nm = number of molecules in the stationary/mobile phase, tR = retention time, t0 = dead time 
 
The calculation of the capacity factor requires knowledge of the system’s dead time, t0. 
In theory, t0 is equal to the retention time of a solute “identical” to the mobile phase,180 a 
value which is experimentally impossible to determine. In practice, several approaches 
have been applied to solve this problem. The most frequently applied procedures in-
clude (a) the use of labelled mobile phase components, (b) the use of non-retained polar 
solutes and (c) the use of organic or inorganic salts.180-183  
The capacity factor is related to the thermodynamic equilibrium constant KR via 
 
 Φ= RKk '  (4)
 
where Ф is the phase ratio of the stationary to the mobile phase. Combination of equa-
tions (2) and (4) yields 
 
 Φ+∆−= ln'ln RT
Gk R    or   Φ+∆−= log
3.2
'log
RT
Gk R  (5a,b)
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Equations 3 and 5 show that the capacity factor k’ (3) is directly connected to retention 
times via the system’s free energy.  
The addition of an organic solvent like MeOH to the water phase reduces the surface 
tension and enables the analytes to dissolve easier in the mobile phase, thereby decreas-
ing the energy demand of the system and with that the retention time. As a result, a dif-
ferent capacity factor is obtained for each water-organic solvent ratio. This behaviour is 
found to be linear under certain conditions184 and follows the expression 
 
 ϕSkk W += log'log  (6)
 
where ϕ  is the volume fraction of the organic solvent (MeOH) in the water-organic 
solvent mixture, kW represents the capacity factor of the analyte at 100% water as mo-
bile phase (obtained by extrapolation to the intercept of the ordinate) and S the slope of 
the regression curve.   
 
 
Fig. 6.1 Retention times of a substance have been measured at different MeOH/H2O mixtures (55-
85% MeOH) and the resulting capacity factors, calculated according to (3), have been 
plotted versus the MeOH fraction. Extrapolation to 0% MeOH gives logkW.  
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Such obtained logkW values have been much more successfully correlated to logP than 
the simple capacity factors.185, 186 The best results were obtained for neutral and lipo-
philic compounds, whereas ionic substances show a more complex behaviour than that 
of simple partitioning. No universal system has been found so far and it can be observed 
that experimentally determined logP values of more complex molecules show high de-
viations when measured by different methods.179 On the other hand, HPLC methods are 
besides computational approaches still the most feasible tools to determine logP values.  
 
6.2.2 Quantitative structure-activity relation (QSAR) 
Lipophilicity expressed in form of logP appears in almost every analysis of physico-
chemical properties related to absorption and permeation.187 In modern drug design it is 
one of four key properties that are taken in account to predict the drug’s solubility and 
permeation behaviour. These four properties are (a) molecular weight, (b) logP, (c) the 
number of H-bond donors and (d) the number of H-bond acceptors. After analysis of 
more than 6000 potent drugs Lipinski188 found that poor absorption and permeation are 
more likely when: 
 
  (a) The molecular weight is over 500 
 (b) The logP is over 5 
 (c) There are more than 5 H-bond donors (the sum of OH and NH groups) 
 (d) There are more than 10 H-bond acceptors (the sum of O and N atoms) 
 
Because the cut-off values for these four parameters are all close to 5 or multiples of 5, 
the system was named the ‘rule of 5’.189 The predictive power of this rule lead to the 
development of a great number of techniques to measure or calculate the logP of a de-
sired lead structure. A major drawback of computational methods is their weakness 
concerning metal complexes or organometallic groups. These are either not supported190 
or only added in form of an incremental approach191, both leading to unsatisfying re-
sults. Therefore, lipophilicity of the metallocene labelled enkephalin derivatives could 
only be determined experimentally (chapter 6.2.3).  
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Typical logP values range from -3 to +6 with the higher numbers representing higher 
lipophilicity. Functional groups that can establish hydrogen bonds with water decrease 
the lipophilicity drastically. The same is valid for functional groups which can yield 
ions through dissociation. Alkyl and aryl groups, on the other hand, increase the logP of 
a substance. Table 6.1 gives a few examples of logP values of some small peptides, 
drugs and general chemicals.188, 192-197 
Tab 6.1 A selection of various types of substances and their corresponding logP values 
 
Compound logP Ref Compound logP Ref 
phenol 1.46 185 Aspirin 1.70 181 
3-hydroxyphenol 0.80 185 Captopril 0.64 181 
anisole 2.11 185 Diclofenac 3.99 181 
4-methoxyanilin 0.95 185 Ibuprofen 3.23 181 
thymol 3.30 185 Naloxone 1.53 181 
AcTyrNH2 -0.79 186 Omeprazol -4.34 181 
AcGlyNH2 -1.76 186 Diazepam 3.36 181 
AcPheNH2 0.04 186 Erythromycin -0.14 181 
AcLeuNH2 -0.04 186 Mannitol -2.50 181 
AcTyrLeuNH2 0.32 187 Glycine -3.44 181 
AcGlyPheNH2 -0.56 187 Met-Enkephalin -1.15 188 
AcPheValNH2 0.43 187 Morphine  -0.55 189 
AcLeuIleNH2 0.68 187 Leu-Enkephalin -1.55 190 
 
From a survey of the literature, it is possible to obtain some general guidelines about the 
optimum logP values for certain classes of drugs.198 The meaning of logP for passive 
absorption and dosing is given in Table 6.2.  
Tab 6.2 Ideal ranges of lipophilicity (logP) for passive absorption and dosing forms 
 
Type of absorption ideal logP Type of formulation ideal logP 
oral  1.80 injectable below 0 
intestinal  1.35 oral 0-3 
colonic 1.32 transdermal 3-4 
sublingual 5.50 toxic build-up in fatty tissues 5-7 
percutaneous 2.60   
 
A rough guideline as shown above enables better estimation of how the target molecule 
is going to behave in a biological environment. However, it should be kept in mind that 
logP values cannot easily be compared when measured by different systems. Albeit, for 
an internal comparison or correlation to results from biological experiments these meth-
ods are of great value and may help to better describe the substance’s properties in vivo. 
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6.2.3 logP values of selected Enkephalin derivatives 
Minick et al. have presented a simple procedure for the calculation of logP by determi-
nation of logkW values.192 Since this method has been experimentally confirmed by 
other groups,199 it was chosen to be suitable for investigating partition coefficients of 
the synthesized metallocene-enkephalin derivatives.  
The eluents were prepared according to literature. The water phase was saturated with 
1-octanol using a separatory funnel and was subsequently filtered before use. Then the 
buffering agent (MOPS, 0.02 M) and the amino modifier (n-decylamine, 0.15% v/v) 
were added. Because not all silanol groups of the stationary phase are substituted by 
C18 chains, RP-columns show partly hydrophilic behaviour, which hinders a correct 
emulation of a water/octanol system. Therefore an amino modifier is used to mask the 
majority of free silanol groups. The pH of the water phase was afterwards adjusted to 
7.4. The methanol phase was simply mixed with n-octanol (0.25%, v/v). 
Four different standards with known logPs (4-methoxyanilin, 4-bromoanilin, naphtha-
lene and tert-butylbenzene) were chosen for calibrating the system and to establish a 
correlation between logkW and logP. These substances were dissolved in methanol (0.1 
mM) and uracil was added (0.01 mM) to indicate the system’s dead time. In first ex-
periments, dead time was also measured by urea but the results compared to uracil were 
found to be nearly identical. For the final logP experiments uracil was preferred due to 
its additional 254 nm chromophore, while urea only absorbed at 220 nm in UV. The 
standard mixture was run with 7 isocratic gradients containing between 55 and 85% of 
MeOH. The retention times, together with the dead times obtained from uracil, were 
used to calculate the corresponding capacity factors k’ according to eqn (3) for every 
water/methanol ratio. Table 6.3 shows the results for 4-methoxyanilin as an example. 
Tab 6.3 The retention times of 4-methoxyanilin measured in different isocratic mixtures of wa-
ter/methanol were used together with the dead times to calculate the capacity factors k’. 
  
MeOH t (uracil) dead time t (4-Methoxyanilin) k’ (4-Methoxyanilin) logk’ (4-Methoxyanilin)
55 3,439 4,057 0,180 -0,745 
60 3,446 3,927 0,140 -0,855 
65 3,457 3,824 0,106 -0,974 
70 3,395 3,681 0,084 -1,074 
75 3,377 3,606 0,068 -1,169 
80 3,303 3,470 0,051 -1,296 
85 3,313 3,445 0,040 -1,400 
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In the same way, capacity factors k’ were obtained for all four standards, logarithmized 
and plotted against the related methanol fraction, resulting in linear functions by regres-
sion (Fig. 6.2). The extrapolation to 100% water (0% MeOH) gave the desired logkW 
value for each standard. 
 
 
Fig. 6.2 Plot of calculated logk’ versus the methanol fraction of all 4 standards. The extrapolation 
to 0% of methanol gives logkW 
 
 
The calibration showed high confidence levels of > 99.9%. The linear equations and the 
resulting capacity factors for a 100% water phase (logkW) of each standard substance are 
shown in Table 6.4.   
 
Tab 6.4 The linear equations obtained for the calibration system and the determined logkW values 
 
Compound logP (from ref. 185) linear equation correlation (R
2) logkW 
tert-butylbenzene 4.11 y = -0.0428x + 3.5652 0.9996 3.5652 
naphthalene 3.30 y = -0.0363x + 2.7824 0.9991 2.7824 
4-bromoanilin 2.26 y = -0.0312x + 1.6330 0.9985 1.6330 
4-methoxyanilin 0.95 y = -0.0217x + 0.4463 0.9991 0.4463 
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Calibration was concluded in a last step, where all 4 logkW values were plotted against 
the literature logP values of the standard compounds to obtain a linear function which 
correlates both parameters (Fig. 6.3). This function was then used to determine all other 
logPs from their logkW values, measured in the same way like those of the standard sub-
stances.   
 
 
Fig. 6.3 The correlation of logkW of the four standards with their logP values shows a linear func-
tion, which can be used to calculate logP out of any logkW value measured on that system 
 
 
The linear function, derived from the plot shown in Fig. 6.3 was repeatedly determined 
and was found to vary only marginally. Thus it can be noted that equation (7) is tempo-
rally valid for the system but must be re-checked every time to compensate for column 
degradation and other effects. 
 
 
 5441.0log0019.1log +×= WkP (7)
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Every sample was measure at 55, 60, 65, 70, 75, 80 and 85% of methanol but the 
logk’/V(MeOH) plot was not linear over the whole range in all cases (Fig. 6.4). If 
nonlinearity occurred, only those values were taken in account that showed a linear be-
haviour. The same method has been suggested by literature.192 
 
  
Fig. 6.4 The majority of all measured samples showed linear relation between logk’ and V(MeOH), 
following eqn. (6), (left, Fc-CO-Enk-NH2 7). Especially the cobaltocenium compounds di-
verged from linearity (right, Cc-CO-Enk-OH 9).  
 
 
When non-linearity was found, only those points were used for linear regression, which 
gave a correlation of R2 > 0.98. For a more exact analysis, a quadric function has to be 
applied.200 This was abandoned, because the linear approach seemed to be exact 
enough. The following table shows an overview of all measured samples. 
Tab 6.5 Summary of all measured samples. Regression range gives the range of points (% MeOH) 
used for each regression. LogP is calculated from logkW by the use of eqn. (7) 
 
Compound Nr. regression range logkW logP 
H-Enk-OH 3 60-80 -1.741 -1.20 
Ac-Enk-OH 4 50-70 4.348 4.90 
Fc-CO-Enk-OH 6 50-70 5.231 5.79 
Fc-CO-Enk-NH2 7 55-85 3.444 4.00 
Fc-CO-Enk-NHNH2 8 55-85 3.443 3.99 
Cc-CO-Enk-OH 9 55-70 1.626 2.18 
H-Enk[Phe4(NH-CO-Cc)]-OH -- 65-85 -1.265 -0.72 
Ac-Enk[Phe4(NH-CO-Cc)]-OH 14 55-70 1.004 1.55 
Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH 15 55-75 5.936 6.49 
Cc-CO-Enk[Phe4(NH-CO-Cc)]-OH 16 non-linear -- -- 
Fc-CO-Enk[Phe4(NH2)]-OH 17 55-75 4.498 5.05 
Fc-CO-Enk[Phe4(NH-CO-Cc)]-OH 18 55-75 1.993 2.54 
Ac-Enk[Phe4(I)]-OH 26 55-80 5.876 6.43 
I-Ph-Enk-OH 27 55-80 6.548 7.11 
Cc-CO-Enk[Phe4(I)]-OH -- 55-85 3.884 4.44 
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6.3 Blood-brain-barrier permeation experiments 
6.3.1 Theoretical background 
The concept of a barrier between the blood and the brain arose in the late l9th century 
when bacteriologist Paul Ehrlich observed that certain dyes, which had been adminis-
tered intravenously to small animals, stained most tissues except for the brain.201 One of 
Ehrlich’s students, Edwin Goldmann, reported later202 that subarachnoidally injected 
dyes had exclusively stained the brain but no other organ had been effected, and by that 
confirmed the existence of a barrier between the brain and the circulating blood. More 
than half a century later the hypothesis that brain capillaries provide the anatomical ba-
sis of the blood-brain barrier (BBB) was confirmed by Reese and Karnovsky203 using 
electron microscopy. Today it is known that the endothelial cells which form these 
cerebral capillaries possess several unique features that serve the purpose to protect the 
brain from xenobiotic substances. Most importantly they have been shown to be joined 
by tight junctions, leaving no intercellular clefts like those found in most other systemic 
microvessels (Fig. 6.5).  
 
Fig. 6.5 Brain capillaries consist of endothelial cells connected by tight junctions, which hinder 
solute flow into the brain, whereas general capillaries show intercellular clefts and pores.  
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Apart from such physical barrier functions also carrier mediated mechanisms have been 
identified (Fig. 6.6). There are specific transporters on the endothelial cells of the brain 
for small and large hydrophilic molecules and essential nutrients. Transmembrane pro-
teins also exist on brain capillaries for transporting a number of lipophilic molecules 
that enter the endothelial cells back to the capillary lumen. P-glycoprotein (P-gp) is one 
such transporter present in high concentration on brain capillaries,204, 205 and is an im-
portant component of the BBB.206 The barrier also has an additional enzymatic aspect: 
solutes crossing the cell membrane are subsequently exposed to a variety of degrading 
enzymes that are present inside the endothelial cells, which contain large densities of 
mitochondria, metabolically highly active organelles.  
 
 
Fig. 6.6 A Schematic of transport mechanisms through brain capillary endothelial cells. Only lipo-
philic substances may passively diffuse through the membrane, while hydrophilic sub-
stances are either actively transported by specific carriers or blocked 
 
 
Despite the total length of 650 km and the estimated surface area of 12 m2 of capillaries 
in human brain, this barrier is highly efficient and makes the brain practically inaccessi-
ble for lipid-insoluble compounds, such as polar molecules and small ions. As a conse-
quence, not only undesired substances are withheld from the brain but also most thera-
peutic drugs are hindered from reaching their target, which is why cerebral diseases 
generally prove to be most refractory to therapeutic interventions. For a better under-
standing of transport mechanisms and the development of manipulative tools, in vitro 
models of the blood-brain-barrier have been developed, which find a wide area of appli-
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cation in basic research and pharmaceutical drug development.207-209 Microvessel endo-
thelial cells have mainly been isolated from human, bovine, rat and porcine brains210 
and although there is de-differentiation of the brain capillary endothelial cells when 
grown in culture, primary and established cultures of the cerebral microvessel endothe-
lium have maintained several functional characteristics of the BBB. The access to hu-
man brains is due to ethical and technical constraints strongly limited and the use of 
cattle brain has become problematic because of the spread of bovine spongiform en-
cephalopathy. Because rat brains only yield small amounts of endothelial cells (1-2 mil-
lion cells per brain)209, porcine brain has become a favourable source for the construc-
tion of in vitro BBB models. The use of primary cultures of porcine brain capillary en-
dothelial cells (PBCEC) has been pioneered by Galla and co-workers211 with detailed 
description of the technique published.212 The isolation process essentially involves en-
zymatic digestion of brain tissue homogenate by dispase followed by isolation of capil-
lary microvessels through density centrifugation within a dextran solution. Capillary 
endothelial cells are then obtained following collagenase/dispase incubation and har-
vested by density centrifugation upon a Percoll gradient. From each porcine brain (4 to 
6 month old pig), approximately 50 million endothelial cells can be isolated. Primary or 
low passage cell cultures represent the most frequently used cell population type for in 
vitro models. These are cultures of endothelial cells, directly taken from the brain tissue, 
which retain many blood-brain-barrier characteristics. 
 
Two principal types of cultures are known, monocultures and co-cultures, which are 
used to conduct either cell uptake or cell permeation experiments. Monocultures build 
the most common basis of BBB in vitro experiments.  
 
Fig. 6.7 Monoculture of cerebral capillary endothelial cells grown on a Transwell© filter 
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The cells grow on the culture surface to form a confluent monolayer and are, as in vivo, 
functionally polarized. Cell surfaces are being described as apical (luminal) and baso-
lateral (abluminal) sides (Fig. 6.7). In addition to monocultures, also co-cultures are 
used for BBB in vitro models. For a better retention of brain capillary endothelial spe-
cific properties, monocultures can be treated with an astrocyte conditioned medium. 
Astrocytes, which belong to the family of glial cells that provide physical and nutri-
tional support for neurons, are attached to the brain capillaries’ abluminal side in vivo. 
By adding them to the monoculture, a better simulation of the capillary cell neighbour-
hood is achieved. Astrocytes are either grown on the bottom of the filter insert or on the 
floor of the receiving vessel. These setups are known as direct-co-culture or transfilter-
co-culture, respectively.  
 
Fig. 6.8 Astrocytes are co-cultured with brain capillary endothelial cells.  
 
For the analysis of test substances two types of experiments have been described, cell-
uptake and permeation experiments.213, 214 To determine the uptake of a substance into 
the cells, sowing and cultivation was carried out on the bottom of the culture plate. Af-
terwards the confluent cell monolayer was incubated with the test substance. In analogy 
to nature, the uptake happens on the apical (luminal) membrane side (Fig. 6.9, left). To 
determine the permeation of a substance through the blood-brain-barrier in vitro, brain 
capillary endothelial cells are grown on a permeable membrane filter. This variable 
setup allows for the measuring of permeation in two directions, namely apical to baso-
lateral (blood to brain) and from basolateral to apical (brain to blood). The comparison 
of permeation in both directions is especially important for the elucidation of carrier 
mediated transport mechanisms, since passive diffusion is independent from the direc-
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tion. Carriers like P-glycoprotein (P-gp) transport their substrates back to the lumen of 
the microvessel, meaning they catalyze the transport from brain to blood.  
 
Fig. 6.9 Setups of cell-uptake (left) and cell permeation (right) experiments.  
 
While the results of uptake experiments are generally given as amount of substance per 
time and per 106 cells, the permeation of a substance through the cell monolayer is de-
scribed by the apparent permeation coefficient Papp in cm/s. This Papp value is connected 
to a number of parameters as shown in eqn 8. 
 
 
xCA
V
dt
dAP acceptorapp
11
0
×××= (8)
 
Papp  apparent permeation coefficient [cm/s] 
dt
dA   permeation rate [%/s] 
Vacceptor acceptor volume [ml] 
A  area of the filter insert [cm2] 
Co  initial concentration of donor [100%] 
x  volume correction factor (ratio acceptor volume : donor volume) 
 
The detailed description of the calculation can be found in the experimental section in 
chapter 8.1.  
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6.3.2 Blood-brain-barrier permeation of selected [Leu5]-Enkephalins  
Enkephalin, as a neuropeptide, can be transported through the blood-brain-barrier as 
shown in various experiments.215-218 However, the transport from the capillary blood 
into the brain is limited due to active efflux by P-gp219 and to degradation caused by 
membrane attached peptidases.220 Whether chemical modification of the natural occur-
ring pentapeptide [Leu5]-Enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) by organometallic 
markers can improve BBB permeation was studied in transport experiments using por-
cine brain capillary endothelial cell monolayers.196 
 
PBCECs were cultured on 12-mm polyester filter inserts of a 12-well Transwell Clear© 
plate (0.4 µm pore size), previously treated with rat tail collagen (5µg/cm2). Each well 
was seeded with 250000 cells and cultivated for 7 days before the experiments were 
carried out. Cell monolayer growth and confluence were monitored by light micros-
copy. In addition, the integrity of cell monolayers was confirmed by carboxyfluorescein 
as a paracellular marker. Cells were grown in ‘medium 199’ containing PenStrep, 
HEPES and glutamine, as well as 9 % of defined equine serum (see chapter 8). The 
medium was replaced on days 1, 2 and 4. At the 6th day it was exchanged by 
DMEM/Ham’s F12 (1:1) medium, which was free of serum. After one week of cell cul-
tivation the medium was removed and the filters containing the cell monolayers were 
washed twice with Krebs-Ringer buffer (KRB) and subsequently inserted into a freshly 
prepared 12-well plate, containing 1500 µl of KRB in the acceptor wells. Each of the 4 
selected Enk derivatives, H-Enk-OH 3, Ac-Enk-OH 4, Fc-CO-Enk-OH 6 and Cc-CO-
Enk-OH 9, was prepared as a 50 µM solution in KRB of which 500 µl were used for 
incubation of the PBCEC layer in the donor vial. Samples of 200 µl were taken from the 
acceptor vial after 30, 60 and 90 minutes and immediately replaced by the same volume 
of Krebs-Ringer buffer.  
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Fig. 6.10 Setup of BBB transport experiments for apical to basolateral direction (blood→brain) 
 
All samples, taken in triplicate, were directly frozen at -70° C to avoid decomposition or 
enzymatic degradation and only defrosted prior to HPLC injection. The test substance 
stock solutions (50µM) were used to generate calibration curves by injection of 1, 2, 5, 
10, 25, 50, 75 and 100 µl of each solution into HPLC. These calibration curves were of 
high significance, as shown by the example of H-Enk-OH 3 in Fig. 6.11. 
 
injected volume 
[µl] 
amount of 
substance [nmol]
peak area
1 0,05 13,56
2 0,10 27,72
5 0,25 63,76
10 0,50 128,53
25 1,25 333,64
50 2,50 662,96
75 3,75 999,16
100 5,00 1322,90
H-Enk-OH 3 
 
   
Fig. 6.11 For the generation of calibration curves, the peak area, obtained by integration, was plot-
ted against amount of substance in nmol. 
 
 
100 µl of each 200 µl sample was injected into HPLC running a gradient from 5% 
CH3CN in H20 (t = 0 min.) to 100% CH3CN (t = 20 min.), which then returned to initial 
conditions at 25 min. and equilibrated for another 5 min. Both eluents contained 0.1 % 
of TFA for improved solubility. The signals, recorded at 220 nm, were manually inte-
grated and the amount of substance was calculated from the linear regression function 
110 6  Biological properties of metallocene labelled Leu-Enkephalins 
of the corresponding calibration curve. Despite the very small amount of substance 
which was in the range of 60 to 200 pmol per injection, all peaks could be identified 
clearly by means of retention time, which was taken from the calibration experiments. 
Figure 6.12 shows the HPLC spectrum of H-Enk-OH 3 after 90 minutes of incubation.  
 
 
Fig. 6.12 HPLC of H-Enk-OH 3 after 90 minutes of incubation. 100 µl of a 200 µl sample taken from 
the acceptor vial have been injected onto a C-18 RP-HPLC column. Peaks were manually 
integrated. 
 
 
For the calculation of transported amounts of substance all three measurements have 
been used to create mean values. No mavericks were omitted. Although 3 measure-
ments are in principle insufficient to perform correct error estimation, the consistency of 
most values leads to the assumption that the results are quite significant. The amount of 
transported material for each compound is shown in table 6.6. 
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Tab 6.6 The mean values of transported material during the three half-hour periods of incubation 
and the final amount of substance, which was permeated through the PBCEC monolayer. 
 
mean amount of substance [nmol] substance Nr. ret. time[min] 30’ 60’ 90’ 
final amount 
[nmol] 
H-Enk-OH 3 9.317 0.5151 0.2879 0.3942 1.1972 
Ac-Enk-OH 4 10.490 0.6776 0.5299 0.5398 1.7473 
Fc-CO-Enk-OH 6 13.264 0.8800 0.6584 0.6859 2.0699 
Cc-CO-Enk-OH 9 9.591 0.7207 0.3789 0.5423 1.6239 
 
 
 
All 4 substances showed slight saturation behaviour when incubation time was plotted 
versus permeated amount of substance (Fig. 6.13).   
 
 
Fig. 6.13 Plot of incubation time against the permeated amount of substance 
 
 
It can be noted that all three N-terminal modified [Leu5]-Enkephalin derivatives show 
increased permeation through the PBCEC monolayer. The apparent permeation coeffi-
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cients of all 4 compounds have been calculated according to equation (8) and are pre-
sented together with selected results from literature221-224 in table 6.7.  
 
Tab 6.7 Apparent permeation coefficients Papp of selected enkephalin derivatives, determined by an 
in vitro blood-brain-barrier model based on porcine capillary endothelial cells. 
 
substance Nr. type mean Papp [10-5 cm/s] error Papp [10-5 cm/s] Ref. 
H-Enk-OH 3 porcine 0.38 ± 0.04 this work 
Ac-Enk-OH 4 porcine 0.57 ± 0.17 this work 
Fc-CO-Enk-OH 6 porcine 0.68 ± 0.13 this work 
Cc-CO-Enk-OH 9 porcine 0.52 ± 0.12 this work 
Met-Enkephalin -- bovine  7.74a ± 0.71 214 
Cisplatin -- bovine 3.80 -- 215 
Morphine -- porcine 3.33 ± 0.25 216 
Dopamine -- bovine  0.93a -- 217 
Nicotine -- bovine  1.94a -- 217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
a these values were determined in a slightly different way and cannot be directly compared 
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6.4  Discussion 
6.4.1 Lipophilicity by partition coefficient logP 
The different enkephalin derivatives show logP values between -1.20 for H-Enk-OH 3 
and 7.11 for I-Ph-Enk-OH 27. The lipophilicity determined for H-Enk-OH is consistent 
with experimental data reported for [Leu5]-Enk in literature197 (-0.88 to -1.55) and even 
more with calculated results presented by Fujita and co-workers225 (-1.20 to -1.22). It is 
also close to the logP of -1.15, which was determined for [Met5]-Enk-OH by Lang et 
al.195 The logP values of 7.11 for I-Ph-Enk-OH 27 and 6.43 for Ac-Enk[Phe4(I)]-OH 
26, respectively,  seem to be extraordinarily high for molecules belonging to the class of 
peptides. The iodine atom has obviously a huge impact on the lipophilic properties, 
even more so, in a small molecule like a pentapeptide. The relatively high values of all 
Enk compounds appear to be reasonable, when the lipophilic side chains of H-Tyr-Gly-
Gly-Phe-Leu-OH are taken into consideration. A variety of hydrophobicity scales for 
the natural amino acids have been presented,226, 227 in which Phe and Leu are generally 
among the top four hydrophobic amino acids, whereas Tyr and Gly are to be found in 
the medium area.   
  
Fig. 6.14 The structure of [Leu5]-enkephalin, mapped with a molecular lipophilic potential (MLP). 
The lipophilic areas (red) dominate the solvent accessibility surface, whereas hydrophilic-
ity (blue) can be assigned to the peptide backbone and the free amino group.  
 
Figure 6.14 shows one of the 4 X-ray structures of [Leu5]-Enkephalin observed so 
far,147 mapped with a calculated molecular lipophilic potential (MLP) using the pro-
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gram.228 The red color represents areas of high lipophilicity, while the blue color shows 
hydrophilic behaviour. Even though solvent influences and charge aspects have been 
left aside, the calculation gives at least an idea of the ratio of hydrophilic and hydropho-
bic residues in the peptide. As expected, the N-terminal amino group and the peptide 
back-bone can be identified as locations of elevated hydrophilicity, whereas the non-
ionizable side-chains show high lipophilicity. This observation supports the finding that 
the lowest logP values of -1.20 and -0.72 belong to those Enk derivatives which possess 
free N-terminal amino groups. These are not only functional groups of very high polar-
ity but their basic nature, even at physiological pH of 7.4, leads to the formation of posi-
tively charged ammonium cations and by that to a drastic decrease in lipophilicity. The 
free amino group is needed for the typical zwitterionic structure of amino acids, which 
explains the isolated positions of H-Enk-OH and H-Enk[Phe4(NH-CO-Cc)]-OH with 
being the only derivatives of  negative logP values. With the formation of a peptide 
bond, the basic character of the amino group is lost and as a consequence the lipophilic-
ity is increased. The addition of a ferrocene group results in a strong increase in lipo-
philicity. Cobaltocenium has lower lipophilic properties, which is self-explanatory from 
the presence of the positive charge. Table 6.8 provides a brief overview of logP change 
correlated to functional group introduction. 
 
Tab 6.8 Differences in logP, derived from correlation of the most important Enk-derivatives 
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H-Enk-OH -- 6.10 6.99 3.38 7.63 5.64 6.25 7.69 
Ac-Enk-OH -6.10 -- 0.89 -2.72 1.53 -0.46 0.15 1.59 
Fc-CO-Enk-OH -6.99 -0.89 -- -3.61 0.64 -1.35 -0.74 0.70 
Cc-CO-Enk-OH -3.38 2.72 3.61 -- 4.25 2.26 2.87 4.31 
Ac-Enk[Phe4(I)]-OH -7.63 -1.53 -0.64 -4.25 -- 1.99 -1.38 0.06 
Cc-CO-Enk[Phe4(I)]-OH -5.64 0.46 1.35 -2.26 -1.99 -- 0.61 2.05 
Fc-CO-Enk[Phe4(NH2)]-OH -6.25 -0.15 0.74 -2.87 1.38 -0.61 -- 1.44 
Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH -7.69 -1.59 -0.70 -4.31 -0.06 -2.05 -1.44 -- 
 
 
LogP values have been compared among the most important enkephalin derivatives, 
enabling a rough estimation of the expected logP change by introduction of a certain 
functional group. As stated above, cobaltocenium compounds are remarkably more hy-
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drophilic than their ferrocene congeners, expressed by a logP difference of over 3. The 
introduction of an iodine atom, on the other hand, adds more than 1.5 to the logP. This 
could already be observed during the synthesis of p-iodo-phenylalanine, which turned 
out to be nearly insoluble in water after the iodine atom had been introduced. The com-
parison between Fc-CO-Enk-OH 6 and Fc-CO-Enk[Phe4(NH2)]-OH 15 indicates that 
hydrogen bonding is an important parameter to lipophilicity, lowering it by 0.76 units. 
Another interesting observation is the logP increase of 0.89 for the exchange of the ace-
tyl group in Ac-Enk-OH with ferrocene, since a similar increase can be found for the 
introduction of the second ferrocene in Fc-CO-Enk[Phe4(NH-CO-Fc)]-OH (1.44).  
It can be concluded that the determined water/octanol partition coefficients have to be 
regarded as no absolute values but a fairly precise description of the lipophilic nature of 
[Leu5]-Enkephalin. The results seem to be consistent and can be of predictive use as 
will be shown in chapter 6.4.3. The determination of lipophilicity by RP-HPLC meth-
ods has shown to be a time-saving approach without the loss of exactness, as confirmed 
by the compliance to literature values. The system’s weakness lies in the description of 
ionic compounds, which often do not correlate due to their more complicated partition-
ing behaviour. Computational approaches have recently been made to overcome this 
problem.179, 229   
 
6.4.2 Blood-brain-barrier permeation by apparent permeation coefficient Papp 
The BBB permeation experiments resulted in Papp values between 3.3·10-6 and 5.9·10-6 
cm·s-1 for H-Enk-OH 3 and Fc-CO-Enk-OH 6, respectively. These results seem to be of 
correct dimension, when compared to other values presented in literature. However, it 
might be difficult to correlate permeation coefficients obtained from experiments which 
have been conducted under different conditions. Reproducibility is affected by choice of 
cell type (bovine, porcine, caco-2, etc.), filter inserts (polycarbonate, polyethylene), 
media, buffers and cultivation procedures. The reported value for [Met5]-Enkephalin, 
for example, seems to be very high, compared to other compounds like morphine and 
nicotine, which are taken up fairly well. It should be noted that apart from cell type also 
the calculation of Papp has been carried out differently. But despite of various possible 
setups, apparent permeation coefficients Papp can still give valuable information on the 
blood-brain-barrier permeation behaviour of corresponding test substances. In case of 
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the above presented [Leu5]-Enkephalin derivatives, the results clearly show that N-
terminal modification, be it by acetylation or binding of a metallocene group, improves 
the BBB permeation. One explanation for this effect is the increase in lipophilicity, 
caused by blockage of the amino group as a potential proton acceptor. Since the trans-
port experiments have been carried out only from apical to basolateral sides 
(blood→brain) no conclusion can be drawn on the permeation mechanism or the in-
volvement of carriers. Comparison of both transport directions or the addition of carrier 
inhibitors would yield such information. Nonetheless, the relatively low Papp values of 
the 4 Enk compounds are most probably due to carrier promoted efflux and enzymatic 
degradation. It has been shown, for instance, that [Leu5]-Enkephalin is a substrate to 
P-gp219 and therefore shows reduced permeation, like many other small lipophilic com-
pounds. Membrane bound peptidases like dipeptidyl dipeptidase,230 enkephalinase231 
and aminopeptidase M232 have been reported to hydrolyse small peptides like enkepha-
lin. Such degradation effects could be observed during this work, when samples taken 
from the donor vials were subjected to HPLC. Multiple signals, originating from degra-
dation, could be recorded for H-Enk-OH and Fc-CO-Enk-OH but not for Ac-Enk-OH 
and Cc-CO-Enk-OH. 
  
 
Fig. 6.15 HPLCs of residual sample solutions, taken from donor vials after 90 minutes. Ac-Enk-OH 4 
(left) appears to be in the same pure condition as applied but Fc-Enk-OH 6 shows reason-
able concentrations of breakdown products (right).  
 
The decomposition products could also be observed in samples taken from the acceptor 
vials, but only in small concentrations. The degradation process seems to occur on the 
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apical side and inside of the epithelium, rather than basolaterally. Why only two Enk 
derivatives show these effects is still unclear and has to be eluded in future experiments. 
6.4.3 Correlation of lipophilicity and permeation behaviour 
It is known that relatively lipophilic drugs can cross the BBB by passive diffusion, 
whereas polar molecules normally do not enter the brain easily, although sometimes a 
process of active transport facilitates their penetration. The use of a lipophilicity de-
scriptor like logP for predicting BBB permeation has been successfully demonstrated 
before (see also ‘rule of 5’, chapter 6.2.2). In many cases lipophilicity, expressed by 
logP, was shown to correlate with permeation coefficients, which had been measured 
using BBB in vitro models.233-235 Only some lipophilic compounds, however, showed 
an unexpectedly low apparent transfer rate. These cases have been interpreted in terms 
of high binding to plasma proteins207 or active efflux by P-glycoprotein.236  
 
Lipophilicity and permeation behaviour have been measured for various compounds 
presented in this thesis and Table 6.9 shows logP and apparent permeation coefficients 
Papp values of 4 selected Enk compounds. 
 
Tab 6.9 Selection of 4 [Leu5]-Enkephalin derivatives with their corresponding logP and Papp values. 
 
substance Nr. logP Papp [10-5 cm/s] 
H-Enk-OH 3 -1.20 0.38 ± 0.04 
Ac-Enk-OH 4 4.90 0.57 ± 0.15 
Fc-CO-Enk-OH 6 5.79 0.68 ± 0.13 
Cc-CO-Enk-OH 9 2.18 0.52 ± 0.12 
 
 
It is obvious that H-Enk-OH, the most hydrophilic compound, also shows the worst 
permeation. Fc-CO-Enk-OH, on the other hand, as the most lipophilic substance in the 
test field, also shows the highest Papp value. LogP values have been plotted against the 
apparent permeation coefficients Papp. The result can be viewed in Fig. 6.16. It should 
be noted that the errors appear to be large, which is caused by the significant deviations 
between samples A, B and C from triplicate meaurements. Mean values have been used 
for all calculations, but a higher number of experiments would improve the significance, 
which is suggested for future experiments. 
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Fig. 6.16 Correlation of logP versus apparent permeation coefficient Papp. LogP values have been 
determined using a RP-HPLC method, Papp values have been determined using an in vitro 
BBB model. 
 
 
Figure 6.16 shows a relatively good correlation between the lipophilicity descriptor 
logP and the apparent permeation coefficient Papp. This linear behaviour is in good con-
sistency with reported data from literature. If exclusively passive diffusion is suggested 
for the observed transport mode, both lipophilicity and blood-brain-barrier permeation 
measurements seem to be of some significance, as they show the expected linear behav-
iour. Thus, it can be concluded that the presented experimental procedures can be of 
value for the biological characterization of peptides like [Leu5]-Enkephalin and or-
ganometallic derivatives thereof.   
 
7 Conclusion 
7.1 Summary 
The tethering of organometallic markers to biomolecules can provide unique spectro-
scopic properties, thus enabling the sensitive detection of the target molecule even in-
side biological systems.60, 70 As a consequence, versatile synthetic methods for the se-
lective labelling of biomolecules are needed.  
The aim of this thesis was the development of techniques for the facile introduction of 
metal markers into peptides. The pentapeptide [Leu]-Enkephalin with the sequence of 
H-Tyr-Gly-Gly-Phe-Leu-OH was used as a model peptide, while ferrocene and cobalto-
cenium derivatives have been chosen as organometallic labels. The first class of com-
pounds, presented in chapter 4, comprised N-terminal and side-chain bound metallo-
cene derivatives of enkephalin. These compounds were completely prepared on solid 
phase by the coupling of the metallocene carboxylic acids 1 and 2 to free amino func-
tions in the peptide.  
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Fig. 7.1 [Leu]-enkephalin N-terminally labelled by ferrocene (7) and cobaltocenium bound through 
the side-chain of a modified amino acid (phenylalanine) 
 
In addition to a full characterization by mass spectrometry, 1H and 13C NMR spectros-
copy and UV-Vis techniques, the unique electrochemical attributes of ferrocene and 
cobaltocenium were elucidated. It was found that the bioconjugates still own the elec-
trochemical behaviour of the introduced metal probes. Homo- and heterobimetallic spe-
cies could be synthesized, showing that the techniques for terminal and side-chain in-
troduction can be combined. 
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Fig. 7.2 Structure of a bimetallic enkephalin derivative. The cyclovoltammogram (blue curve) 
shows both redox peaks, confirming the presence of Fc and Cc in the bioconjugate. 
 
It can be necessary to have another synthetic method available, especially if the target 
molecule does not tolerate the reaction conditions of the direct coupling route, presented 
above. The Pd catalyzed Sonogashira coupling161 turned out to be a versatile system for 
the introduction of metal labels into peptides, as explained in chapter 5. An alkyne is 
cross coupled to a iodo-arene function by the help of a Pd catalyst. To evaluate the us-
ability of the Sonogashira method, dipeptides were prepared, containing a p-iodo-
phenylalanine residue. Alkynylated ferrocene derivatives were bound to these non-
natural amino acid side-chains by the use of the above described Sonogashira reaction. 
These products were easily accessible and found to produce high quality electrochemi-
cal spectra.  
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21a : R = CH3 (Ala)
21b : R = CH2-CH(CH3)2 (Leu)
21c : R = CH2-C6H5 (Phe)
21d : R = CH2-C6H4-OH (Tyr)
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Fig. 7.3 Reaction scheme for the synthesis of labelled dipeptides through Sonogashira coupling 
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The dipeptide experiments had successfully shown that alkynyl metal markers can be 
attached to iodo-arene functions in biomolecules by application of the Pd catalyzed 
Sonogashira cross-coupling. To transfer these results onto enkephalin, an Nα-Fmoc pro-
tected p-iodo-phenylalanine building block was synthesized, which could be integrated 
into the standard solid phase peptide synthesis of [Leu5]-Enkephalin, yielding a 4-iodo-
phenylalanine modified peptide. To the newly inserted function, DEPA-Fc was bound 
according to the dipeptide technique (Fig. 7.4).  
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Fig. 7.4 The alkynyl derivatized ferrocene is bound to the p-iodo-phenylalanine side-chain of modi-
fied enkephalin 26 to yield the labelled biomolecule 28 
  
 
Biological properties like receptor affinity, membrane permeation and recognition can 
be severely affected by the introduction of a metal marker group into a relatively small 
biomolecule like [Leu5]-Enkephalin. Lipophilicity, as a physicochemical parameter, is 
connected to such biological properties like those mentioned above.188 Therefore lipo-
philicity, expressed by the water/octanol partition coefficient logP, was determined for a 
selection of Enk derivatives by the use of a modern RP-HPLC method.192 The results 
show the huge influence of the organometallic label on the bioconjugate’s lipophilicity. 
The introduction of such lipid-soluble groups like ferrocene can obviously affect the 
target molecule’s solubility in water, as well as cell uptake and permeation behaviour. 
 
For a deeper insight into this change of biological attributes due to organometallic label-
ling, some compounds were tested for blood-brain-barrier permeation. These transport 
experiments were carried out using a BBB in vitro model, based on porcine brain capil-
lary endothelial cells.208 The test compounds H-Enk-OH 3, Ac-Enk-OH 4, Fc-CO-Enk-
OH 6 and Cc-CO-Enk-OH 9 showed to have better permeation with higher lipophilicity, 
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as expected for a passive diffusion transport mechanism.234 The correlation of both de-
termined values, apparent permeation coefficient Papp and octanol/water partition coef-
ficient logP, show a linear behaviour with a correlation of R2 = 0.95 as can be seen in 
Fig. 7.5.  
 
Fig. 7.5 Plot of apparent permeation coefficients vs. logP values showed a linear behaviour, as 
expected for a passive diffusion transport mechanism.  
 
7.2 Outlook 
The techniques for a regio-selective introduction of organometallic compounds into 
peptides, which were presented in this thesis, are subject to no restrictions in principle. 
It was shown that these methods are applicable to a number of functional groups and 
different organometallic fragments. The binding of the marker molecule is performed 
under mild conditions so that neither biomolecule nor labelling group denature or de-
compose, respectively. This process should therefore be suitable for the labelling of 
more complicated and larger biomolecules. The ‘expansion of the genetic code’ pre-
sented by Schultz and co-workers237 may be an interface for that, since it provides the 
possibility to introduce unnatural amino acids like 4-iodo or 4-azido-phenylalanine into 
a large number of proteins by recombinant methods. Such labelled proteins could be 
purified by HPLC using electrochemical detection. In addition, future biological studies 
might reveal more about the altered physiological properties which the biomolecule 
receives together with the metal marker. 
8 Experimental section  
8.1 Methods and Materials 
Elemental analysis 
Elemental Analysis were performed on a Foss Heraeus Vario EL Elementar Analysator 
in C,H,N mode. 
 
Infrared spectroscopy 
Infrared spectra were recorded on a Brucker Equinox 55 FT-IR spectrometer between 
NaCl windows in distilled CHCl3, or as KBr discs, with a spectral resolution of 2.0 cm-1.         
Wavenumbers, ν, are given in cm-1. 
 
UV-Vis spectroscopy 
UV-Vis spectra were measured in distilled CH3CN or MeOH on a Varian CARY 100 
instrument in 1 cm quarz Suprasil cells thermostated at 25 °C. Absorption maxima, λmax, 
and molar absorption coefficients, ε, are given in nm and l/mol·cm, respectively. 
 
Mass spectrometry 
EI (70eV) and FAB (glycerol or NBA matrix) mass spectra were measured on a Mat 
8200 instrument. Characteristic mass fragments with probable composition are given in 
brackets. For fragments containing metals only the isotopomer with highest intensity 
was described. All ESI (neg./pos.) were recorded on a Finnigan TSQ 700 at 4.5 kV. 
 
NMR Spectroscopy  
NMR spectra were determined either on a Brucker AM 360 spectrometer, 1H operating 
at 360.14 MHz and 13C operating at 90.56 MHz or on a Bruker AM 300 with 
frequencies of 300.16 MHz (1H) and 75.47 MHz (13C). Peak positions in both 1H and 
13C are reported in ppm relative to TMS, the internal standard. Spectra of peptides are 
referenced to the residual DMSO-d6 signal (2.50 ppm in 1H, 39.52 ppm in 13C). All 
other compounds are referenced to the residual CHCl3 signal (7.26 ppm in 1H,         
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77.16 ppm in 13C). Coupling constants, J, are given in Hz. Individual peaks are marked 
as: singlet (s), dublet (d), triplet (t) or multiplet (m) 
 
Electrochemistry 
Cyclic Voltammograms and square wave voltammograms in CH3CN or CH3CN/H2O 
(1:1) solutions were recorded on a Perkin Elmer BES Potentiostat/Galvanostat. 0.1 M 
NBu4PF6 or NaClO4 was added as supporting electrolytes A three-electrodes cell was 
employed with a glassy carbon or platinum working electrode, a platinum-wire as 
auxiliary electrode and a Ag/AgNO3 reference electrode (0.01 M AgNO3 in CH3CN). 
For determination of the redox potentials, ferrocene was added as an internal standard. 
All analyte concentrations were 1.0 mM. 
 
HPLC analysis and purification 
High Performance Liquid Chromatography (HPLC) was performed by using Varian 
Dynastar C-18 reverse phase columns for analytical (250 x 8 mm) and preparative (250 
x 21 mm) runs. Water and CH3CN (Baker, HPLC-grade) were used as eluents, each 
containing 0.1% trifluoroacetic acid. All analytical samples were measured at a flowrate 
of 1 ml/min using the gradient, given in the the following table: 
 
H2O [%] CH3CN [%] time [min]
90 10 0
0 100 18
90 10 20
90 10 25
 
For peptides also H2O/MeOH gradients were used. No TFA was added to the methanol 
phase. The logP studies were carried out on the same system using specials buffers with 
the following composition: 
 
Solvent A Solvent B 
H2O (saturated with n-octanol) MeOH 
0.1% n-decylamine 0.25 % n-octanol
0.1 M MOPS 
pH adjusted to 7.4 
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Chemicals / Material 
All chemicals were used as obtained from commercial sources. THF and NEt3 for the 
Sonogashira reactions were dried over CaH2, thorougly degassed and stored under ar-
gon atmosphere. Isobutyl chloroformiate and oxalylchloride were destilled before use. 
Deuterated NMR solvents were stored in a glove box under inert gas. All standard pep-
tide synthesis chemicals and solvents were analytical reagent grade or better and pur-
chased from Novabiochem (Bad Soden, Germany) or from Iris Biotech (Marktredwitz, 
Germany). Resins were exclusively used in 200 mesh-size, with loadings between 0.59 
and 0.63 mmol/g for Wang resins and 0.19 to 0.23 mmol/g for Tentagel HMBA resins. 
Peptide grade DMF, purchased from Roth (Karlsruhe, Germany), was used for all pep-
tide syntheses. Preparations of buffers and solutions were conducted as follows: 
 
Krebs-Ringer-buffer consisted of: 
NaCl 8.30 g  142 mM 
KCl 0.23 g 3 mM 
K2HPO4 · 3 H2O 0.34 g 1.5 mM 
HEPES 2.40 g 10 mM 
D-glucose 0.72 g 4 mM 
MgCl2 · 6 H2O 0.24 g 1.2 mM 
CaCl2 · 2 H2O 0.21 g 1.4 mM 
H2O ad 1000 ml  
 
Culture medium, with serum (C+) consisted of: 
Medium 199 500 ml  
L-glutamine  2 ml  0.8 mM* 
PenStrep 5 ml 100 IE/ml or 100 µg/ml 
HEPES 5 ml 10 mM 
Equine serum 50 ml 9 % 
* Medium 199 already contains 0.7 mM of L-glutamine, final concentration is therefore 1.5 mM 
 
Culture medium, without serum (C-) consisted of: 
DMEM/Ham’s F12 (1:1) 500 ml  
L-glutamine  5 ml  2 mM* 
PenStrep 5 ml 100 IE/ml or 100 µg/ml 
HEPES 5 ml 10 mM 
* DMEM/Ham’s F12 already contains 2.5 mM of L-glutamine, final concentration is therefore 4.5 mM 
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Solid Phase Peptide Synthesis - general remarks 
If not stated differently, all solid phase syntheses have been carried out according to 
standard procedures, which are described in the following. 
 
Swelling: At the beginning of each synthesis the resin was swollen in DMF twice for 20 
min. When the peptide sythesis had to be interrupted, the peptidyl resin was shrunk us-
ing MeOH and stored in the refridgerator overnight. Before the synthesis was continued 
the resin was again swollen in DMF. 
 
Deprotection: The N-terminal Fmoc protection group was removed by a solution of 
20% piperidine in DMF, which was freshly prepared prior each synthesis. Deprotection 
was carried out 10 plus 5 minutes. 
 
Washing: After each deprotection and coupling step, the resin was excessively washed 
(3 times for 5 minutes) with DMF to remove any residual activation or deprotection 
reagents. 
 
Coupling: Amino acids (3 or 5-fold excess) were mixed with equimolar amounts of 
TBTU and HOBt. Then, 10 equivalents of DIPEA were added and the whole mixture 
was dissolved in 4 ml of DMF. This was shaken until a clear and yellow solution was 
obtained, which took 3 to 5 minutes. Ferrocene and Cobaltocenium activation took 
sometimes longer and afforded an extra addition of DIPEA. The coupling was per-
formed for 45 minutes for all amino acids and 1-2 hours for metallocene compounds. 
 
Acetylation: N-terminal acetylation was carried out by treatment with a mixture of 
Ac2O, NMI, Lutidine and THF (1:1:1:7) for 15 minutes. Before acetylation the 
N-terminally deprotected peptidyl resin was thoroughly washed with DMF and DCM    
 
Cleavage: After the synthesis was finished, the peptidyl resin transferred into a round 
flask and treated with a mixture of 95% TFA, 2.5% H2O and 2.5% TIS (6 ml/g resin) 
for 3 hours. If ferrocene was bound, the cleavage mixture consisted of 92.5% TFA, 5% 
phenol adn 2.5% TIS. After removal of all volatile compounds in vacuo, the crude 
product could be precipitated by addition of cold ether. 
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Calculation of apparent permeation coefficients Papp 
 
The calculation of the apparent permeation coefficient Papp was based on the permeation 
rate of the respective test substance. At first, all samples taken from the acceptor com-
partment were measured quantitatively by HPLC, using a calibration curve. Because the 
removed volume of 200 µl for each sample was replaced by the same amount of fresh 
Krebs-Ringer buffer (KRB), the dilution had to be corrected mathematically, following 
equation (a).  
 
 
acceptor
n
i
sampleiacceptorn
corrn V
VcVc
c
∑−
=
×+×
=
1
1
,
)(
 (for n > 1)             (a)
 
 
cn, corr   → corrected concentration at sample removal n [µmol/ml] 
cn   → concentration at sample removal n [µmol/ml] 
Vacceptor → acceptor volume [ml] 
Vsample → sample volume [ml] 
 
 
From the corrected concentration cn, corr the permeated amount of substance M for the 
particular sample could be calculated by multiplication with the acceptor volume       
Vacceptor (b). The initial amount M0 was determined accordingly (c). 
 
 
 acceptorcorrnn VcM ×= ,  (for n > 1)             (b)
  
 donorVcM ×= 00  (for n > 1)             (c)
 
 
 
Mn   → permeated amount at sample removal n [µmol] 
cn, corr   → corrected concentration at sample removal n [µmol/ml] 
M0   → initial amount of substance in donor [µmol] 
Vacceptor → acceptor volume [ml] 
c0 → initial concentration in donor [µmol/ml] 
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The total amount of test substance, which had permeated from the beginning until the 
particular sample was removed, was determined from equation (d). 
 
 
 100
0
×=
M
MA nn    (for n > 1)             (d)
 
 
An   → percentage of substance at sample removal n [%] 
Mn   → permeated amount at sample removal n [µmol] 
M0   → initial amount of substance in donor [µmol] 
 
 
Permeationcoefficients P are calculated according to Fick’s law as shown in the follow-
ing equation (e). 
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P   → permeation coefficient [cm/s] 
cacceptor → concentration in the acceptor chamber [mg/ml] 
Vacceptor → acceptor volume [ml] 
t   → time [s] 
A   → diffusion area [cm2] 
cdonor → initial concentration in donor [mg/ml] 
 
 
The permeated percentage An was plotted against time and the slope of the linear func-
tion was determined as the permeation rate dA/dt [%/s]. To calculate the apparent pe-
meation coefficient Papp equation (e) was converted to euation (f) 
 
 xcA
V
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dAP acceptorapp
11
0
×××=              (f)
 
 
Papp   → permeation coefficient [cm/s]         dA/dt        → permeation rate [%/s]  
Vacceptor → acceptor volume [ml] 
A   → diffusion area [cm2] 
c0 → initial concentration in donor [mg/ml] 
x → volume correction factor (ratio of Vacceptor : Vdonor) 
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8.2 Syntheses and Characterization 
 
Synthesis of ferrocene carboxylic acid 2 (Fc-COOH) 
 
 
OH
Fe
O
 
 
 
C11H10FeO2 (M = 230.00 g/mol) 
 
Ferrocene carboxylic acid was synthesized as reported by Reeves238. Some minor 
changes have been applied to the preparation. 
 
Fe
O Cl
Cl+
AlCl3
CH2Cl2
0 - 25 °C
Fe
O Cl
 
 
a.) (2-Chlorobenzoyl)ferrocene     A thoroughly dried 1-l three-necked round-bottom 
flask was equipped with a mechanical stirrer, a funnel for adding solids and an adapter 
holding a thermometer and a gas-inlet tube. The system has been maintained under 
positive pressure of argon throughout the synthesis. The flask was charged with 18.6 g 
(100 mmol) of ferrocene, 17.5 g (100 mmol) of 2-chlorobenzoyl chloride and 250 ml of 
dried DCM. The flask was immersed in an ice bath and while stirring 14.0 g (105 
mmol) of anhydrous aluminum chloride was added through the funnel at such a rate that 
the reaction mixture remained below 5 °C. The appearance of a deep blue color indi-
cated that the reaction was occurring. After the addition was complete, stirring was con-
tinued for another 30 min with ice cooling and for 2 hours at room temperature.  
 
The reaction mixture was cooled again in ice, 200 ml of water was added cautiously, 
and the resulting two-phase mixture was stirred vigorously for 30 minutes. After sepa-
rating the layers in a separatory funnel, the aqueous layer was extracted with three 100 
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ml portions of DCM and the combined DCM solutions were washed twice with 100 of 
10% aqueous sodium hydroxide, dried over Na2SO4, filtered and evaporated to dryness 
a reduced pressure yielding 28.1 g (87% from ferrocene) of a red viscous oil. 
 
 
H2O, t-BuOK
DME
Reflux
Fe
O Cl
Fe
O
OH
 
 
b.) Ferrocenecarboxylic acid 2    A dry, 1-l 3-necked round-bottom flask, equipped with 
a mechanical stirrer, a reflux condenser and a gas-inlet was charged with a solution of   
46 g of potassium tert-butoxide (411 mmol) in 300 ml of DME. 2.2 ml of water was 
added with stirring, producing a slurry, to which the crude (2-chlorobenzoyl)ferrocene 
in 80 m of DME was added. The red solution was stirred and refluxed under argon until 
the color faded to tan, indicating completion of the reaction (1 hour). After the reaction 
mixture was allowed to cool it was poured into 1000 ml of water, washed three times 
with 200 ml of Et2O and the combined organic solutions were back-extracted with three 
100 ml portions of 10% aqueous sodium hydroxide. The aqueous phases were then 
combined and acidified with conc. hydrochloric acid. The light brown precipitate was 
collected by filtration and air dried, yielding 14.6 g (64% from ferrocene) of ferrocene-
carboxylic acid as an air-stable orange powder. 
 
 
1: Anal. calc. for C11H10FeO2 (230.00 g/mol): C, 57.43; H, 4.38. Found: C, 55.94; H, 
4.60.   IR (cm-1) in KBr: 2972, 2877 (w) υCH, 1654 (vs) υCOO, 1283 (s) δCO. MS (EI): 
m/z 230 (100, [M]+), 213 (18, [Fc-CO]+). 1H NMR (CD3OD, 360.14 MHz): 4.77 (m, 
2H, CpH2,5), 4.45 (m, 2H, CpH3,4), 4.21 (s, 5H, CpH). 13C NMR (CD3OD, 90.56 MHz): 
175.9 (COO), 72.6 (CCp, 2,5), 72.3 (CCp, 1), 71.4 (CCp’), 70.9 (CCp, 3,4). 
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Synthesis of Cobaltoceniumcarboxylic acid 2 (Cc-COOH) 
 
 
OH
Co
O PF6
 
 
 
C11H10FeO2 (M = 377.97 g/mol) 
 
Cobaltoceniumcarboxylic acid 2 was synthesized as reported by Sheats and Rausch.118 
Some minor changes have been applied to the preparation. 
 
+ CoBr2+ Co
CH3
PF6
pyrrolidine
0-25 °C / 12h
 
 
a.) Methylcobaltocenium     16.5 g (0.25 mol) of cyclopentadiene and 20 g of methyl-
cyclopentadiene (0.25 mol) which had been freshly cracked from their dimers prior to 
the reaction, were dissolved in 200 ml of dried pyrrolidine in a 500 ml 3-necked round-
bottom flask. The mixture was cooled to 0 °C and under positive argon pressure was 
added in little portions 20.75 g (0.1 mol) of anhydrous cobalt(II)bromide. The solution 
was allowed to warm to room temperature and the stirring was continued for another 12 
h. The solvent was evaporated under reduced pressure and the purple residue was dis-
solved in 500 ml of hot water. A green residue containing cobalt(II)oxide remained. 
After the solution was extracted with three 50 ml portions of Et2O to remove unreacted 
cyclopentadiene it was clarified with 10g of Norit. The crude product was precipitated 
as hexafluorophosphate salts by dropwise addition of a solution of 15 g of sodium 
hexafluorophosphate in 75 ml of water. 
Yield: 7.7 g 
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Co
CH3
PF6
KMnO4 / NaOH
Co
COOH
PF6
H2O / 95 °C / 3h
 
 
b.) Cobaltoceniumcarboxylic acid 2     6 g (17 mmol) of the mixture obtained in a.) was 
dissolved in a solution of 8.05 g (51 mmol) of potassium permanganate and 1.36 g (34 
mmol) of sodium hydroxide in 120 ml of water. The mixture was heated to 95 °C for 3 
hours and the occurring manganese(II)oxide was removed by filtration through celite. 
Sodium hexafluorophosphate was added and the solution chilled. The yellow precipi-
tate, identified as cobaltocenium hexafluorophosphate, was removed by filtration and 
dropwise addition of 6 M HCl yielded a mixture of cobaltoceniumcarboxylic acid and 
1,n’-cobaltoceniumdicarboxylic acid. The precipitate washed repeatedly with hot ace-
tone in a soxhlet apparatus. Cobaltoceniumcarboxylic acid dissolved readily, whereas 
the 1,n’di-acid was virtually insoluble. The acetone solution was evaporated to dryness 
on a rotary evaporator yielding 3.82 g (60%) of the product as yellow flakes. 
 
 
2: Anal. calc. for C11H10CoF6O2P (377.97 g/mol): C, 34.94; H, 2.67. Found: C, 32.20; 
H, 3.69. IR (cm-1) in KBr: 3125 (s) υCH, 2914, 2645 (w) υOH, 1709 (vs) υCOO, 1418 (s) 
δCH, Cp’, 1302 (s) δCO. MS (EI): m/z 233 (12, [M-PF6]+), 188 (35, [CoCp2]+). 1H NMR 
(D2SO4, 360.14 MHz): 5.93 (m, 2H, CpH2,5), 5.59 (m, 2H, CpH3,4), 5.50 (s, 5H, CpH). 
13C NMR (D2SO4, 90.56 MHz): 168.9 (COO), 86.9 (CCp, 2,5), 85.9 (CCp’), 85.5 (CCp, 1), 
85.3 (CCp, 3,4). 
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.61 5 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 500 146 mg (86.1 %) 
 
 
3: C28H37N5O7 (555.27 g/mol): MS (ESI, neg): m/z 1109.18 [2M – H+]-, 554.27 [M – 
H+]-. 1H NMR (DMSO-d6, 300.14 MHz): 12.61 (s, br, 1H, COOH), 9.35 (s, br, 1H, OH-
Tyr), 8.74 (t, 1H, J=5.0Hz, NHGly), 8.35 (d, 1H, J=7.8Hz, NHLeu), 8.11 (t, 1H, J=5.4Hz, 
NHGly), 8.04 (d, 1H, J=7.3Hz, NHPhe), 7.26 (m, 5H, HAr, Phe), 7.06 (d, 2H, J=8.2Hz, HAr, 
Tyr), 6.71 (d, 2H, J=8.2Hz, HAr, Tyr), 4.58 (dt, 1H, J=3.6Hz, J=9.2Hz, CαHPhe), 4.22 (m, 
1H, CαHTyr), 3.98 (m, 1H, CαHLeu), 3.74 (m, 4H, CαHGly), 2.90 (m, 4H, CβHPhe, Tyr), 1.64 
(m, 1H, CH(CH3)2), 1.55 (m, 2H, CβHLeu), 0.88 (dd, 6H, J=6.2Hz, J=17.4Hz, 
CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.7 (COO), 171.0, 168.4, 168.0 
(CON), 155.6 (CArOHTyr), 137.6 (CAr, q, Phe), 130.3 (CAr, q, Tyr), 129.1, 127.9, 126.1 (CAr), 
124.7, 115.2 (CAr), 53.6 (Cα, Phe), 53.4 (Cα, Tyr), 50.2 (Cα, Leu), 41.8, 41.5 (Cα, Gly), 37.6 
(Cβ, Phe), 36.1 (Cβ, Tyr), 24.2 (Cβ, Leu), 22.7 (CH3, Leu), 21.2 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.59 3 
95% TFA 
2.5% H2O 
2.5% TIS 
2 h 510 140 mg (77.9 %) 
 
 
4: C30H39N5O8 (597.28 g/mol): MS (ESI, neg): m/z 1193.73 [2M – H+]-, 596.30 [M – 
H+]-. 1H NMR (DMSO-d6, 400.13 MHz): 12.55 (s, br, 1H, COOH), 9.12 (s, br, 1H, OH-
Tyr), 8.22 (d, 1H, J=8.0Hz, NHLeu), 8.19 (t, 1H, J=5.2Hz, NHGly), 8.03 (d, 1H, J=8.1Hz, 
NHTyr), 7.97 (d, 1H, J=8.0Hz, NHPhe), 7.89 (t, 1H, J=5.3Hz, NHGly), 7.23 (m, 5H, HAr, 
Phe), 7.00 (d, 2H, J=8.2Hz, HAr, Tyr), 6.61 (d, 2H, J=8.2Hz, HAr, Tyr), 4.54 (dt, 1H, 
J=3.4Hz, J=8.6Hz, CαHPhe), 4.38 (m, 1H, CαHTyr), 4.21 (m, 1H, CαHLeu), 3.63 (m, 4H, 
CαHGly), 2.89 (m, 4H, CβHPhe, Tyr), 1.75 (s, 3H, CH3, acteyl), 1.62 (m, 1H, CH(CH3)2), 1.53 
(m, 2H, CβHLeu), 0.86 (dd, 6H, J=6.4Hz, J=16.4Hz, CH(CH3)2). 13C NMR (DMSO-d6, 
100.61 MHz): 173.8 (COO), 171.9, 171.0, 169.3, 168.9, 168.2 (CON), 155.7 (CArOH-
Tyr), 137.7 (CAr, q, Phe), 139.9 (CAr, q, Tyr), 129.2, 128.0, 127.9, 126.2, 114.6 (CAr), 54.4 (Cα, 
Phe), 53.5 (Cα, Tyr), 50.3 (Cα, Leu), 42.0, 41.7 (Cα, Gly), 37.6 (Cβ, Phe), 36.6 (Cβ, Tyr), 24.2 (Cβ, 
Leu), 22.7 (CH3, Leu), 22.4 (CH3, acetyl), 21.3 (CH(CH3)2).  
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Ferrocenecarboxylic acid 1 (550 mg, 2.4 mmol) was dissolved in 12 ml of dried DCM. 
To the stirred suspension was added 500 mg (2.4 mmol) dicyclohexylcarbodiimide 
(DCC) and 340 mg (2.4 mmol) of hydroxybenzotriazole (HOBt). After 3 h of continu-
ous stirring the solid was removed and the remaining solvent was purified by column 
chromatography using 100% DCM as an eluent (Rf = 0.35). The remaining reddish 
brown solid had a very characteristic smell of petroleum. 
 
5: Anal. calc. for C17H13FeN3O2 (347.04 g/mol): C, 58.82; H, 3.77; N, 12.10. Found: C, 
60.13; H, 4.37; N, 10.70. IR (cm-1) in KBr: 2930 (w) υCH, 1775 (vs) υCOO, 1261 (s) δCO. 
MS (EI): m/z 347 (40, [M]+), 213 (100, [Fc-CO]+). 1H NMR (CDCl3, 360.14 MHz): 
8.08/7.47 (m, 4H, HOBt, Ar), 5.07 (pseudo-t, 2H, CpH2,5), 4.67 (pseudo-t, 2H, CpH3,4), 
4.43 (s, 5H, CpH). 13C NMR (CDCl3, 90.56 MHz): 168.2 (COO), 143.5 (COBt, 4), 128.5 
(COBt, 9), 124.6 (COBt, 6,7), 120.4 (COBt, 5,8), 77.2 (CCp, 1), 73.4 (CCp, 3,4), 79.9 (CCp, 2,5), 70.7 
(CCp’). 
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
92.5% TFA 
5.0% Phenol 
2.5% TIS 
3 h 200 84 mg (86.9 %) 
 
 
6: C39H45FeN5O8 (767.26 g/mol): MS (ESI, pos): m/z 768.4 [M + H+]+, 790.5 [M + 
Na+]+, 806.4 [M + K+]+, MS (ESI, neg): m/z 766.4 [M – H+]-. 1H NMR (DMSO-d6, 
300.14 MHz): 12.62 (s, br, 1H, COOH), 9.12 (s, br, 1H, OHTyr), 8.28 (d, 1H, J=7.8Hz, 
NHLeu), 8.19 (t, 1H, J=5.2Hz, NHGly), 8.07 (d, 1H, J=8.4Hz, NHPhe), 7.79 (d, 1H, 
J=8.2Hz, NHTyr), 7.25 (m, 5H, HAr, Phe), 7.17 (d, 2H, J=8.1Hz, HAr, Tyr), 6.67 (d, 2H, 
J=8.3Hz, HAr, Tyr), 4.83/4.72 (s, 1H, CpH2,5), 4.59 (m, 2H, CαHPhe, Tyr), 4.30 (m, 2H, 
CpH3,4), 4.22 (m, 1H, CαHLeu), 3.95 (s, 5H, CpH), 3.67 (m, 4H, CαHGly), 2.92 (m, 4H, 
CβHPhe, Tyr), 1.62 (m, 1H, CH(CH3)2), 1.54 (m, 2H, CβHLeu), 0.87 (dd, 6H, J=6.3Hz, 
J=16.4Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.5 (COO), 171.8, 170.7, 
168.8, 168.5, 167.8 (CON), 155.4 (CArOHTyr), 137.4 (CAr, q, Phe), 129.6, 128.8 (CAr), 
128.2 (CAr, q, Tyr), 127.6, 125.8, 114.5 (CAr), 75.5 (CCp,1), 69.5 (CCp, 3,4), 68.9 (CCp’), 
68.2/67.4 (CCp, 2,5), 54.3 (Cα, Phe), 53.1 (Cα, Tyr), 49.9 (Cα, Leu), 41.7, 41.3 (Cα, Gly), 37.2 
(Cβ, Phe), 35.7 (Cβ, Tyr), 23.9 (Cβ, Leu), 22.4 (CH3, Leu), 21.0 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
HMBA 0.23 5 NH3 (sat.) in MeOH, 0 °C 24 h 800 
76 mg 
(53.9 %) 
 
 
7: C39H46FeN6O7 (766.28 g/mol): MS (ESI, neg): m/z 765.3 [M – H+]-. 1H NMR 
(DMSO-d6, 400.13 MHz): 9.07 (s, br, 1H, OHTyr), 8.12 (t, 1H, J=5.5Hz, NHGly), 8.07 (d, 
1H, J=8.0Hz, NHLeu), 8.01 (t, 1H, J=5.5Hz, NHGly), 7.94 (s, 2H, NH2), 7.75 (d, 1H, 
J=8.2Hz, NHPhe), 7.69 (d, 1H, J=7.8 Hz, NHTyr), 7.29 (m, 5H, HAr, Phe), 7.02 (d, 2H, 
J=8.6Hz, HAr, Tyr), 6.57 (d, 2H, J=8.6Hz, HAr, Tyr), 4.85/4.68 (s, 1H, CpH2,5), 4.59 (m, 
1H, CαHTyr), 4.49 (dt, 1H, J=4.7Hz, J=8.8Hz, CαHPhe), 4.31 (pseudo-t, 2H, CpH3,4), 4.19 
(m, 1H, CαHLeu), 3.94 (s, 5H, CpH), 3.67 (m, 4H, CαHGly), 2.89 (m, 4H, CβHPhe, Tyr), 
1.55 (m, 1H, CH(CH3)2), 1.45 (m, 2H, CβHLeu), 0.83 (dd, 6H, J=6.4Hz, J=17.8Hz, 
CH(CH3)2). 13C NMR (DMSO-d6, 100.62 MHz): 173.8 (CONH2), 170.6, 168.8, 168.5, 
168.1, 167.8 (CON), 155.5 (CArOHTyr), 137.7 (CAr, q, Phe), 129.9, 129.1 (CAr), 128.0 (CAr, 
q, Tyr), 127.0, 126.2, 114.6 (CAr), 75.0 (CCp,1), 69.7 (CCp, 3,4), 69.2 (CCp’), 67.2, 66.8 (CCp, 
2,5), 54.0 (Cα, Phe), 53.0 (Cα, Tyr), 50.9 (Cα, Leu), 41.3, 40.9 (Cα, Gly), 37.8 (Cβ, Phe), 35.8 (Cβ, 
Tyr), 24.1 (Cβ, Leu), 23.0 (CH3, Leu), 21.6 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
HMBA 0.24 5 
5% NH2NH2  
in DMF,  
0 °C 
3 h 795 73.5 mg (49.3 %) 
 
 
8: C39H47FeN7O7 (781.29 g/mol): MS (ESI, pos): m/z 782.3 [M + H+]+, 804.4 [M + 
Na+]+, 820.3 [M + K+]+. 1H NMR (DMSO-d6, 300.14 MHz): 9.10 (s, br, 1H, OHTyr), 
8.25 (m, 1H,  NHLeu), 8.16 (m, 1H, NHGly), 8.07 (d, 1H, J=8.4Hz, NHPhe), 8.00 (m, 1H, 
NHGly), 7.78 (d, 1H, J=8.2Hz, NHTyr), 7.21 (m, 5H, HAr, Phe), 7.15 (d, 2H, J=8.1Hz, HAr, 
Tyr), 6.65 (d, 2H, J=8.2Hz, HAr, Tyr), 4.81/4.71 (s, 1H, CpH2,5), 4.59 (m, 2H, CαHPhe, Tyr), 
4.29 (m, 2H, CpH3,4), 4.22 (m, 1H, CαHLeu), 3.94 (s, 5H, CpH), 3.67 (m, 4H, CαHGly), 
2.83 (m, 4H, CβHPhe, Tyr), 1.60 (m, 1H, CH(CH3)2), 1.54 (m, 2H, CβHLeu), 0.86 (m, 6H, 
CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 172.3, 171.0, 169.3, 169.0, 168.5 
(CON), 155.8 (CArOHTyr), 137.7 (CAr, q, Phe), 130.0, 129.1 (CAr), 128.5 (CAr, q, Tyr), 128.0, 
126.3, 115.0 (CAr), 75.8 (CCp,1), 69.9 (CCp, 3,4), 69.3 (CCp’), 68.7, 67.9 (CCp, 2,5), 54.7 (Cα, 
Phe), 53.8 (Cα, Tyr), 49.9 (Cα, Leu), 42.2, 41.9 (Cα, Gly), 37.5 (Cβ, Phe), 36.1 (Cβ, Tyr), 24.3 (Cβ, 
Leu), 22.9 (CH3, Leu), 21.8 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 3 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 500 189 mg (68.0 %) 
 
 
9: C41H44CoF3N5O10 (883.5g/mol): MS (ESI, pos): m/z 770.5 [M + TFA-]+, 404.9 [M – 
TFA- + K+]2+. 1H NMR (DMSO-d6, 500.13 MHz): 12.50 (s, br, 1H, COOH), 9.24 (s, br, 
1H, OHTyr), 8.87 (d, 1H, J=7.8Hz, NHLeu), 8.19 (t, 1H, J=5.2Hz, NHGly), 8.07 (d, 1H, 
J=8.4Hz, NHPhe), 7.79 (d, 1H, J=8.2Hz, NHTyr), 7.25 (m, 5H, HAr, Phe), 7.17 (d, 2H, 
J=8.1Hz, HAr, Tyr), 6.67 (d, 2H, J=8.3Hz, HAr, Tyr), 4.83, 4.72 (s, 1H, CpH2,5), 4.59 (m, 
2H, CαHPhe, Tyr), 4.30 (m, 2H, CpH3,4), 4.22 (dd, 1H, J=8.4Hz, J=13.9Hz, CαHLeu), 3.95 
(s, 5H, CpH), 3.67 (m, 4H, CαHGly), 2.92 (m, 4H, CβHPhe, Tyr), 1.62 (m, 1H, CH(CH3)2), 
1.54 (m, 2H, CβHLeu), 0.87 (dd, 6H, J=6.3Hz, J=16.4Hz, CH(CH3)2). 13C NMR (DMSO-
d6, 75.47 MHz): 173.5 (COO), 171.8, 170.7, 168.8, 168.5, 167.8 (CON), 155.4 (CArOH-
Tyr), 137.4 (CAr, q, Phe), 129.6, 128.8 (CAr), 128.2 (CAr, q, Tyr), 127.6, 125.8, 114.5 (CAr), 
75.5 (CCp,1), 69.5 (CCp, 3,4), 68.9 (CCp’), 68.2, 67.4 (CCp, 2,5), 54.3 (Cα, Phe), 53.1 (Cα, Tyr), 
49.9 (Cα, Leu), 41.7, 41.3 (Cα, Gly), 37.2 (Cβ, Phe), 35.7 (Cβ, Tyr), 23.9 (Cβ, Leu), 22.4 (CH3, 
Leu), 21.0 (CH(CH3)2).  
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At 0°C, conc. H2SO4 (120ml) was slowly added under stirring to 120ml of conc. HNO3.        
H-Phe-OH (100g, 605mmol) was added in portions over a period of 20min., giving a 
yellow, sticky solution. Stirring was continued overnight, the resulting slurry was 
poured over crushed ice and brought to pH = 7 with NaOH. The white precipitate was 
separated by filtration and dried in vacuo. 
Yield: 92.6g (441mmol, 72.8%) 
 
10: Anal. calc. for C9H10N2O4 (210.06 g/mol): C, 51.43; H, 4.80; N, 13.33. Found: C, 
52.61; H, 5.34; N, 13.50. IR (cm-1) in KBr: 3020 (m, br) υCH, 1677 (vs) υCOO, 1200 (m) 
υC-O. MS (EI): m/z 210 [M]+, 165 [M - NO2]+, 137 [CH2-Ph-NO2]+. 1H NMR (D2O, 
360.14 MHz): 8.16 (d, 2H, J=8.4Hz, HAr, Phe), 7.45 (d, 2H, J=8.6Hz, HAr, Phe), 3.98 (m, 
1H, CαHPhe), 3.27 (m, 2H, CβHPhe). 13C NMR (D2O, 90.56 MHz): 173.9 (COO), 144.4, 
144.2 (CAr, q, Phe), 131.4, 125.0 (CAr), 56.2 (Cα, Phe), 37.2 (Cβ) 
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5.45 g (25 mmol) of p-nitro-phenylalanine was dissolved in a mixture of each 50 ml of 
H2O and CH3CN and treated with 1 equivalent of NEt3 (2.5 g, 25 mmol). After 10 min. 
of stirring 8.0 g (23.75 mmol, 95%) of Fmoc-ONSu in 50 ml of CH3CN was added 
dropwise over a period of 20 min, while pH was adjusted to 8.5 - 9.0. After 2 h of con-
tinuous stirring and subsequent filtration the solvents were removed in vacuo and a red 
oil remained. The oily residue was again dissolved in water and afterwards neutralized 
using 1 N HCl until the crude product precipitated. Recrystallization from EtOAc 
yielded 5.9 g (53%) of pure product in form of a white solid.  
 
11: Anal. calc. for C24H20N2O6 (432.12 g/mol): C, 66.66; H, 4.66; N, 6.48. Found: C, 
66.40; H, 4.71; N, 6.41. IR (cm-1) in KBr: 3433 (m) υNH, 3222, 3055 (m, br) υCH, 1694 
(vs) υCOO, 1516 (s) δNH, 1227 (m) υC-O. MS (FAB): m/z 433 [M + H]+, 255 [M – Fluo-
renyl + H]+, 165 [Fluorenyl]+. 1H NMR (DMSO-d6, 360.14 MHz): 8.11 (d, 2H, 
J=8.6Hz, HAr, Phe), 7.84 (d, 2H, J=7.5Hz, HAr, Fluorenyl), 7.78 (d, 1H, J=8.6Hz, NH), 7.60 
(m, 2H, HAr, Fluorenyl), 7.53 (d, 2H, J=8.6Hz, HAr, Phe), 7.38 (pseudo-t, 2H, HAr, Fluorenyl), 
7.27 (dd, 2H, J=6.8Hz, J=13.1Hz, HAr, Fluorenyl), 4.30 (m, 1H, CαHPhe), 4.23 (m, 2H, CH2, 
Fluorenyl), 4.15 (m, 1H, R3CHFluorenyl), 3.25, 3.02 (m, 2H, CβHPhe). 13C NMR (DMSO-d6, 
90.56 MHz): 172.9 (COO) 155.9 (CON), 146.4, 146.2 (CAr, q, Phe), 143.7, 140.7 (CAr, q, 
Fluorenyl), 130.4, 127.6, 127.0, 125.1, 123.2, 120.1 (CAr), 65.6 (CH2, Fluorenyl), 54.8 (Cα, Phe), 
46.6 (R3CHFluorenyl), 36.1 (Cβ) 
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 200 70 mg (90.8 %) 
 
 
12: C30H40N6O8 (612.29 g/mol): MS (ESI, pos): m/z 1263.8 [2M + K+]+, 1247.6 [2M + 
Na+]+, 1225.7 [2M + H+]+, 651.4 [M  + K+]+, 635.5 [M + Na+]+, 613.4 [M + H+]+. 1H 
NMR (DMSO-d6, 300.14 MHz): 9.23 (s, br, 1H, OHTyr), 8.26 (d, 1H, J=8.2Hz, NHLeu), 
8.25 (t, 1H, J=5.7Hz, NHGly), 8.08 (d, 1H, J=7.9Hz, NHTyr), 7.98 (d, 1H, J=8.6Hz, 
NHPhe), 7.93 (t, 1H, J=5.7Hz, NHGly), 7.27 (d, 2H, J=8.3Hz, HAr, Phe), 7.07 (d, 2H, 
J=8.2Hz, HAr, Phe), 7.01 (d, 2H, J=8.4Hz, HAr, Tyr), 6.63 (d, 2H, J=8.4Hz, HAr, Tyr), 4.54 
(dt, 1H, J=3.8Hz, J=9.4Hz, CαHPhe), 4.39 (dt, 1H, J=4.8Hz, J=9.2Hz, CαHPhe), 4.22 (m, 
1H, CαHLeu), 3.67 (m, 4H, CαHGly), 2.82 (m, 4H, CβHPhe, Tyr), 1.77 (s, 3H, CHAcetyl), 1.64 
(m, 1H, CH(CH3)2), 1.55 (m, 2H, CβHLeu), 0.87 (dd, 6H, J=6.3Hz, J=17.0Hz, 
CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.8 (COO), 171.9, 170.9 (CON), 
169.3, 168.9, 168.2 (CON), 155.6 (CArOHTyr), 130.3, 129.9 (CAr), 127.9 (CAr, q, Tyr), 
120.7, 114.8 (CAr), 54.5 (Cα, Phe), 53.4 (Cα, Tyr), 50.3 (Cα, Leu), 42.0, 41.7 (Cα, Gly), 36.9 
(Cβ, Phe), 36.5 (Cβ, Tyr), 24.2 (Cβ, Leu), 22.7 (CH3, Leu), 22.4 (CH3, Acetyl), 21.3 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.61 5 
92.5% TFA 
5% phenol 
2.5% TIS 
3 h 724 mg 281 mg (74.7 %) 
 
 
13: C41H48FeN6O9 (824.28 g/mol): MS (ESI, pos): m/z 825.5 [M + H+]+, 847.4 [M + 
Na+]+, 863.4 [M + K+]+. (ESI, neg): m/z 823.5 [M - H+]-. 1H NMR (DMSO-d6, 300.14 
MHz): 9.36 (s, 1H, NHFc), 9.08 (s, br, 1H, OHTyr), 8.26 (d, 1H, J=7.9Hz, NHLeu), 8.22 (t, 
1H, J=5.8Hz, NHGly), 8.05 (d, 1H, J=7.9Hz, NHTyr), 7.97 (d, 1H, J=8.4Hz, NHPhe), 7.94 
(t, 1H, J=5.7Hz, NHGly), 7.58 (d, 2H, J=8.3Hz, HAr, Phe), 7.20 (d, 2H, J=8.3Hz, HAr, Phe), 
7.00 (d, 2H, J=8.2Hz, HAr, Tyr), 6.62 (d, 2H, J=8.2Hz, HAr, Tyr), 4.89 (pseudo-t, 2H, 
CpH2,5), 4.55 (dt, 1H, J=3.8Hz, J=9.0Hz, CαHPhe), 4.42 (pseudo-t, 2H, CpH3,4), 4.38 (m, 
1H CαHPhe), 4.23 (m, 1H, CαHLeu), 4.20 (s, 5H, CpH), 3.68 (m, 4H, CαHGly), 2.78 (m, 
4H, CβHPhe, Tyr), 1.75 (s, 3H, CHAcetyl), 1.65 (m, 1H, CH(CH3)2), 1.53 (m, 2H, CβHLeu), 
0.87 (dd, 6H, J=6.2Hz, J=16.4Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 
173.8 (COO), 172.0, 171.1, 169.4, 169.0, 168.3 (CON), 168.0 (CONFc), 155.7 (CArOH-
Tyr), 137.5, 132.5 (CAr, q, Phe), 130.1, 129.4, 128.1, 120.1, 114.9 (CAr), 76.6 (CCp,1), 70.4 
(CCp, 3,4), 69.5 (CCp’), 68.6 (CCp, 2,5), 54.6 (Cα, Phe), 53.7 (Cα, Tyr), 50.4 (Cα, Leu), 42.2, 41.8 
(Cα, Gly), 37.2 (Cβ, Phe), 36.7 (Cβ, Tyr), 24.3 (Cβ, Leu), 22.9 (CH3, Leu), 22.5 (CH3, Acetyl), 21.4 
(CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.61 5 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 500 189 mg (65.8 %) 
 
 
14: C43H48CoF3N6O11 (940.27 g/mol): MS (ESI, pos): m/z 827.3 [M - TFA-]+, 433.3 [M 
- TFA- + K+]2+, 425.3 [M - TFA- + Na+]2+. 1H NMR (DMSO-d6, 300.14 MHz): 12.57 
(s, br, 1H, COOH), 10.35 (s, 1H, NHCoCp2), 9.16 (s, br, 1H, OHTyr), 8.29 (d, 1H, 
J=8.5Hz, NHTyr), 8.24 (t, 1H, J=5.5Hz, NHGly), 8.07 (d, 1H, J=7.9Hz, NHLeu), 7.99 (d, 
1H, J=8.2Hz, NHPhe), 7.95 (t, 1H, J=5.7Hz, NHGly), 7.61 (d, 2H, J=8.2Hz, HAr, Phe), 7.28 
(d, 2H, J=8.3Hz, HAr, Phe), 7.01 (d, 2H, J=8.0Hz, HAr, Tyr), 6.62 (d, 2H, J=8.1Hz, HAr, Tyr), 
6.41 (s, 2H, CpH2,5), 5.98 (s, 2H, CpH3,4), 5.90 (s, 5H, CpH), 4.56 (m, 1H, CαHPhe), 4.38 
(m, 1H, CαHTyr), 4.23 (m, 1H, CαHLeu), 3.68 (m, 4H, CαHGly), 2.85 (m, 4H, CβHPhe, Tyr), 
1.76 (s, 3H, CH3, Acetyl), 1.64 (m, 1H, CH(CH3)2), 1.55 (m, 2H, CβHLeu), 0.88 (dd, 6H, 
J=6.1Hz, J=17.2Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.8 (COO), 
171.9, 170.9, 169.3, 168.9, 168.2 (CON), 159.7 (CONCoCp2), 155.6 (CArOHTyr), 136.2 
(CAr, q, Phe), 134.1 (CAr, q, Tyr), 129.9, 129.4, 127.9, 120.3, 114.5 (CAr), 94.7 (CCp,1), 85.9 
(CCp’), 85.4 (CCp, 2,5), 84.1 (CCp, 3,4), 56.0 (Cα, Phe), 54.4 (Cα, Tyr), 50.2 (Cα, Leu), 42.0, 41.7 
(Cα, Gly), 37.0 (Cβ, Phe), 36.4 (Cβ, Tyr), 24.2 (Cβ, Leu), 22.8 (CH3, Leu), 22.3 (CH3, Acetyl), 21.2 
(CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.68 5 
92.5% TFA 
5% phenol 
2.5% TIS 
3 h 370 215 mg (86.0 %) 
 
 
 
15: C50H54Fe2N6O9 (994.27 g/mol): MS (ESI, neg): m/z 993.5 [M - H+]-. 1H NMR 
(DMSO-d6, 300.14 MHz): 12.53 (s, br, 1H, COOH), 9.37 (s, 1H, NHFc), 9.04 (s, br, 1H, 
OHTyr), 8.26 (d, 1H, J=7.7Hz, NHLeu), 8.17 (t, 1H, J=5.6 Hz, NHGly), 8.02 (t, 1H, 
J=4.6Hz), 7.98 (m, 1H, NHPhe), 7.77 (d, 1H, J=8.1Hz, NHTyr), 7.58 (d, 2H, J=8.0Hz, 
HAr, Phe), 7.20 (d, 2H, J=8.8Hz, HAr, Phe), 7.16 (d, 2H, J=8.1Hz, HAr, Tyr), 6.66 (d, 2H, 
J=8.0Hz, HAr, Tyr), 4.99 (pseudo-t, 2H, Cp2H2,5), 4.81, 4.72 (s, 1H, Cp1H2,5), 4.59 (m, 
2H, CαHPhe, Tyr), 4.43 (pseudo-t, 2H, Cp2H3,4), 4.28 (pseudo-t, 2H, Cp1H3,4), 4.22 (m, 
1H, CαHLeu), 4.18 (s, 5H, Cp2H), 3.94 (s, 5H, Cp1H), 3.68 (m, 4H, CαHGly), 2.87 (m, 4H, 
CβHPhe, Tyr), 1.62 (m, 1H, CH(CH3)2), 1.55 (dd, 2H, J=6.5Hz, J=11.2Hz, CβHLeu), 0.87 
(dd, 6H, J=6.1Hz, J=16.2Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.8 
(COO), 172.2, 171.0, 169.2, 168.9, 168.2, 167.9 (CON), 155.7 (CArOHTyr), 137.5 (CAr, q, 
Phe), 132.4 (CAr, q, Phe), 129.9, 129.3 (CAr), 128.5 (CAr, q, Tyr), 120.0, 114.9 (CAr), 76.5 
(CCp2-1), 75.5 (CCp1-1), 70.4 (CCp2-3,4), 69.8 (CCp1-3,4), 69.4 (CCp’2), 69.2 (CCp’1), 68.4 
(CCp2, 2,5), 68.2, 67.8 (CCp1, 2,5), (CCp,1), 54.6 (Cα, Phe), 53.6 (Cα, Tyr), 50.3 (Cα, Leu), 42.1, 
41.8 (Cα, Gly), 37.1 (Cβ, Phe), 36.0 (Cβ, Tyr), 24.3 (Cβ, Leu), 22.8 (CH3, Leu), 21.3 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.68 5 
92.5% TFA 
5% phenol 
2.5% TIS 
3 h 370 215 mg (86.0 %) 
 
 
16: C54H54Co2F6N6O13 (1226.23 g/mol): MS (ESI, pos): m/z 999.3 [M - 2 TFA- - H+]+, 
500.3 [M - 2 TFA-]2+. 1H NMR (DMSO-d6, 300.14 MHz): ca. 12.00 (1H, COOH, not 
obs.), 10.43 (s, br, 1H, NHCoCp2), 8.88 (d, 1H, J=8.7Hz, NHTyr), 8.52 (t, 1H, J=5.0Hz, 
NHGly), 8.33 (d, 1H, J=8.2Hz, NHLeu), 8.10 (d, 1H, J=9.18Hz, NHPhe), 8.06 (t, 1H, 
J=5.0Hz, NHGly), 7.60 (d, 2H, J=8.3Hz, HAr, Phe), 7.26 (d, 2H, J=8.5Hz, HAr, Phe), 7.17 (d, 
2H, J=8.5Hz, HAr, Tyr), 6.69 (d, 2H, J=8.5Hz, HAr, Tyr), 6.41 (m, 2H, Cp1H2,5), 6.30, 6.24 
(s, 1H, Cp2H2,5), 5.98 (m, 2H, CpH3,4), 5.89 (s, 5H, Cp1H), 5.89 (m, 2H, Cp2H3,4), 5.55 
(s, 5H, Cp2H), 4.76 (m, 1H, CαHPhe), 4.55 (m, 1H, CαHTyr), 4.19 (m, 1H, CαHLeu), 3.69 
(m, 4H, CαHGly), 2.95 (m, 4H, CβHPhe, Tyr), 1.61 (m, 1H, CH(CH3)2), 1.54 (m, 2H, 
CβHLeu), 0.87 (dd, 6H, J=6.2Hz, J=18.0Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 
MHz): 173.8 (COO), 171.2, 171.0, 168.8, 168.3 (CON), 161.3, 159.8 (CONCoCp), 155.9 
(CArOHTyr), 136.5 (CAr, q, Phe), 134.2 (CAr, q, Tyr), 130.0, 129.5, 128.1 (CAr), 120.2, 115.0 
(CAr), 94.7 (CCp2,1), 92.7 (CCp1,1), 86.0 (CCp1’), 85.9 (CCp1, 2,5), 85.8 (CCp2’), 85.6 (CCp2, 
2,5), 84.2 (CCp2, 3,4), 83.6 (CCp1, 3,4), 56.6 (Cα, Phe), 54.6 (Cα, Tyr), 50.3 (Cα, Leu), 41.9, 41.5 
(Cα, Gly), 37.2 (Cβ, Phe), 36.2 (Cβ, Tyr), 24.3 (Cβ, Leu), 22.8 (CH3, Leu), 21.3 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
92.5% TFA 
5% phenol 
2.5% TIS 
3 h 500 212 mg (86.3 %) 
 
 
17: C39H46FeN6O8 (782.27 g/mol): MS (ESI, pos): m/z 783.3 [M + H+]+, 805.4 [M + 
Na+]+, 821.3 [M  + K+]+, 411.4 [M + H+ + K+]2+. 1H NMR (DMSO-d6, 300.14 MHz): 
9.14 (s, br, 1H, OHTyr), 8.27 (d, 1H, J=7.7Hz, NHLeu), 8.20 (t, 1H, J=4.3Hz, NHGly), 
8.04 (d, 1H, J=8.3Hz, NHPhe), 8.01 (t, 1H, J=5.0Hz, NHGly), 7.79 (d, 1H, J=8.1Hz, 
NHTyr), 7.24 (d, 2H, J=8.0Hz, HAr, Phe), 7.17 (d, 2H, J=7.9Hz, HAr, Phe), 7.03 (d, 2H, 
J=8.0Hz, HAr, Tyr), 6.67 (d, 2H, J=7.9Hz, HAr, Tyr), 4.83, 4.72 (s, 1H, CpH2,5), 4.58 (m, 
2H, CαHPhe, Tyr), 4.30 (s, 2H, CpH3,4), 4.21 (m, 1H, CαHLeu), 3.95 (s, 5H, CpH), 3.69 (m, 
4H, CαHGly), 2.86 (m, 4H, CβHPhe, Tyr), 1.62 (m, 1H, CH(CH3)2), 1.55 (m, 2H, CβHLeu), 
0.87 (dd, 6H, J=6.1Hz, J=16.9Hz, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 
173.8 (COO), 172.2, 170.9, 169.2, 168.9, 168.2 (CON), 155.7 (CArOHTyr), 130.3, 129.9 
(CAr), 128.4 (CAr, q, Tyr), 120.8, 114.9 (CAr), 75.7 (CCp,1), 69.9 (CCp, 3,4), 69.2 (CCp’), 68.6, 
67.7 (CCp, 2,5), 54.6 (Cα, Phe), 53.4 (Cα, Tyr), 50.2 (Cα, Leu), 42.0, 41.6 (Cα, Gly), 36.9 (Cβ, Phe), 
36.0 (Cβ, Tyr), 24.2 (Cβ, Leu), 22.7 (CH3, Leu), 21.3 (CH(CH3)2).  
148 8  Experimental section 
 
H
N
N
H
H
N
N
H
H
N
O
OH
O
O
O
O
Fe
O
OH
H
N
O
Co
O
FF
F
O
 
 
18 
 
 
Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
92.5% TFA 
5% phenol 
2.5% TIS 
3 h 500 212 mg (86.3 %) 
 
 
18: C52H54CoF3FeN6O11 (1110.25 g/mol): MS (ESI, pos): m/z 997.3 [M - TFA-]+, 518.2 
[M - TFA- + K+]2+, 510.2 [M - TFA- + Na+]2+. 1H NMR (DMSO-d6, 300.14 MHz): 
12.58 (s, br, 1H, COOH), 10.42 (s, 1H, NHCoCp2), 9.13 (s, br, 1H, OHTyr), 8.28 (m, 1H, 
NHLeu), 8.20 (m, 1H, NHGly), 8.02 (m, 2H, NHGly, Tyr), 7.78 (m, 1H, NHPhe), 7.60 (m, 
2H, HAr, Phe), 7.26 (m, 2H, HAr, Phe), 7.16 (m, 2H, HAr, Tyr), 6.66 (m, 2H, HAr, Tyr), 6.41 (s, 
2H, CpHCo, 2,5), 5.97 (s, 2H, CpHCo, 3,4), 5.88 (s, 5H, CpHCo), 4.81, 4.71 (s, 1H, CpHFe, 
2,5), 4.58 (m, 2H, CαHPhe, Tyr), 4.28 (m, 2H, CpHFe, 3,4), 4.22 (m, 1H, CαHLeu), 3.94 (s, 5H, 
CpHFe), 3.70 (m, 4H, CαHGly), 2.86 (m, 4H, CβHPhe, Tyr), 1.61 (m, 1H, CH(CH3)2), 1.54 
(m, 2H, CβHLeu), 0.86 (m, 6H, CH(CH3)2). 13C NMR (DMSO-d6, 75.47 MHz): 173.7 
(COO), 172.1, 170.8, 169.1, 168.8, 168.2 (CON), 159.7 (CONCoCp2), 155.6 (CArOHTyr), 
136.2 (CAr, q, Phe), 134.1 (CAr, q, Tyr), 129.8, 129.4 (CAr), 126.4, 120.3, 114.8 (CAr), 94.7 
(CCoCp,1), 85.9 (CCoCp’), 85.5 (CCoCp, 2,5), 84.1 (CCoCp, 3,4), 75.7 (CFeCp,1), 69.7 (CFeCp, 3,4), 
69.1 (CFeCp’), 68.5, 67.7 (CFeCp, 2,5), 54.5 (Cα, Phe), 53.5 (Cα, Tyr), 50.2 (Cα, Leu), 42.0, 41.7 
(Cα, Gly), 37.0 (Cβ, Phe), 35.9 (Cβ, Tyr), 24.2 (Cβ, Leu), 22.7 (CH3, Leu), 21.2 (CH(CH3)2).  
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Synthesis of 4-Iodo-L-phenylalanin 19 
 
C9H10INO2 (M = 290.98 g/mol) 
 
H2N COOH H2N COOH
I
I2 / NaIO3 / NaIO4
HOAc / H2SO4
70 °C, 16 h
 
 
 
4-Iodo-L-phenylalanin was synthesized as reported by Alan W. Schwabacher et al.166 
Some minor changes have been applied to the preparation. 
 
L-Phenylalanine (40.15 g, 243.2 mmol) was dissolved in 220 ml of HOAc and 29.0 ml 
of concentrated H2SO4. The clear and viscous solution was stirred while powdered Io-
dine (24.65 g, 97.1 mmol) and NaIO3 (10.18 g, 51.4 mmol) were added. The mixture 
was heated to 70 °C. Completion was indicated by the I2 color fading from dark red to 
light orange, which took 16 h and the addition of 2 g of NaIO4. HOAc was removed in 
vacuo at 30 °C, and the residual viscous oil was diluted with 400 ml of water and 
washed twice each with 100 ml portions of Et2O and CH2Cl2. The yellow aqueous solu-
tion was decolorized through treatment with 5 g of Norit and after filtration neutralized 
with NaOH to precipitate the crude product, which, after chilling, was filtered and 
rinsed with 800 ml of water and 300 ml of EtOH. The damp precipitate was dried in a 
cabinet desiccator to yield 42.5 g (60.0%). 
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Synthesis of 4-Iodo-L-phenylalaninmethylester 20 
 
C10H12INO2 (M = 304.99 g/mol) 
 
H2N COOH H2N COOMe
II
MeOH / O°C / 12h
SOCl2
 
 
 
In an ice-bath thionylchloride (100 mmol, 11.90 g) was added dropwise to 100 ml of 
Methanol followed by the addition of 40 mmol 4-Iodo-L-Phenylalanin (11.64 g). After 
stirring for 12 hours the solvent was removed at 40°C under reduced pressure to obtain 
the crude product. The slightly green solid was dissolved in as little MeOH as possible 
and the solution was poured into 350 ml of diethylether to precipitate a white solid. Af-
ter filtration and washing with an additional aliquot of 200 ml of diethylether the pure 
product was dried in vacuo. 
 
Yield: 8.25 g (24.25 mmol, 60.5%) 
 
 
20: Anal. calc. for C10H13ClINO2 (340.96 g/mol): C, 35.16; H, 3.48; N, 4.10. Found: C, 
34.52; H, 3.89; N, 4.00. IR (cm-1) in KBr: 2838 (vs, br) υCH, 1738 (vs) υCOO, 1245 (s) 
υC-O, 835 (m) δCH. MS (FAB): m/z 306 [M + Cl]+, 289 [M – Cl – CH3]+. 1H NMR (D2O, 
360.14 MHz): 7.80 (d, 2H, J=8.0Hz, HAr), 7.08 (d, 2H, J=8.0Hz, HAr), 4.43 (t, 1H, 
J=6.7Hz, CαH), 3.38 (s, 3H, CH3), 3.26 (m, 2H, CβHPhe). 13C NMR (D2O, 90.56 MHz): 
170.8 (COO), 139.2, 132.3 (CAr), 134.5 (CAr, q), 94.0 (CAr-I), 54.8 (Cα), 54.5 (CH3), 36.2 
(Cβ) 
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To a stirred solution of 1.89 g of Boc-L-alanine (10 mmol) in THF was added N-
methylmorpholine (1.12 ml, 1.02 g, 10 mmol) followed by the addition of isobutyl 
chloroformiate (1.32 ml, 1.36 g, 10 mmol), resulting in a precipitation of a white solid. 
In a second flask 4-iodo-L-phenylalaninemethylester hydrochloride (3.41 g, 10 mmol) 
was suspended in 50 ml of THF containing triethylamine (1.38 ml, 1.02 g, 10 mmol). 
Both suspensions were mixed and stirred for 60 min. at room temperature. After re-
moval of the white precipitates by filtration the solvent was removed under reduced 
pressure and the residual oil dissolved in 100 ml of CHCl3. The solution was washed 
with H2O (50 ml) and the aqueous solution was back-extracted with three 50ml aliquots 
of CHCl3. The combined CHCl3 solutions were dried over Na2SO4. Evaporation of the 
solvent under reduced pressure yielded 3.68 g of Boc-Ala-Phe(I)-OMe as a white solid. 
The product could be recrystallised from THF/Heptane.  
 
Yield: 3.68 g (77 %) 
 
 
21a: Anal. calc. for C18H25IN2O5 (476.08 g/mol): C, 45.39; H, 5.29; N, 5.88. Found: C, 
44.89; H, 5.26; N, 5.81. IR (cm-1) in KBr: 3336 (s) υNH, 2981 (m) υCH, 1743 (s) υCOO, 
1664 (vs) υCON, 1522 (s) δNH. MS (FAB): m/z 477 [M + 1]+, 463 [M – CH3]+, 421 [M – 
C4H9]+, 377 [M – Boc]+. 1H NMR (DMSO-d6, 360.14 MHz): 8.13 (d, 1H, J=7.5Hz, 
NHPhe), 7.61 (d, 2H, J=7.9Hz, HAr), 7.03 (d, 2H, J=7.5Hz, HAr), 6.85 (d, 1H, J=7.2Hz, 
NHBoc), 4.47 (m, 1H, CαHPhe), 3.95 (m, 1H, CαHAla), 3.60 (s, 3H, CH3), 2.92 (m, 2H, 
CβH), 1.37 (s, 9H, CH3, Boc), 1.11 (d, 3H, J=6.4Hz, CH3, Ala). 13C NMR (DMSO-d6, 
90.56 MHz): 172.7, 171.4 (COO, CON), 154.7 (COBoc), 136.8 (CAr, q), 136.8, 131.5 
(CAr), 92.3 (CAr-I), 77.9 (CBoc, q), 52.8 (Cα, Ala), 51.7 (CH3), 49.4 (Cα, Phe), 35.9 (Cβ), 28.0 
(CH3, Boc), 17.9 (CH3, Ala). UV-Vis (λ in nm, [ε in M-1cm-1]): 232, [15440] 
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The synthesis was carried out in analogy to 21a. 2.31 g (10 mmol) of Boc-L-leucine 
was used. 
 
Yield: 4.26 g (82 %) 
 
 
21b: Anal. calc. for C21H31IN2O5 (518.13 g/mol): C, 48.66; H, 6.03; N, 5.40. Found: C, 
48.33; H, 6.01; N, 5.37. IR (cm-1) in KBr: 3338 (s) υNH, 2955 (m) υCH, 1747 (m) υCOO, 
1658 (vs) υCON, 1521 (s) δNH. MS (FAB): m/z 519 [M + 1]+, 463 [M – C4H9]+, 417 [M – 
Boc]+. 1H NMR (DMSO-d6, 360.14 MHz): 8.12 (d, 1H, J=7.8Hz, NHPhe), 7.61 (d, 2H, 
J=8.1Hz, HAr), 7.04 (d, 2H, J=8.1Hz, HAr), 6.80 (d, 1H, J=8.4Hz, NHBoc), 4.50 (dd, 1H, 
CαHPhe), 3.94 (dd, 1H, CαHAla), 3.61 (s, 3H, CH3), 2.95 (m, 2H, CβHPhe), 1.51 (sep, 1H, 
J=6.6Hz, CH(CH3)), 1.38 (s, 9H, CH3, Boc), 1.30 (m, 2H, CβHLeu), 0.84 (pseudo-t, 6H, 
CH3, Leu). 13C NMR (DMSO-d6, 90.56 MHz): 172.5, 171.6 (COO, CON), 155.1 (COBoc), 
136.9 (CAr, q), 136.9, 131.6 (CAr), 92.3 (CAr-I), 78.1 (CBoc, q), 52.8 (Cα, Ala, Phe), 51.9 
(CH3), 40.0 (Cβ, Leu), 36.1 (Cβ, Phe), 28.2 (CH3, Boc), 24.1, 22.8 (CH3, Leu), 21.7 (C(CH3)2). 
UV-Vis (λ in nm, [ε in M-1cm-1]): 231, [15151] 
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The synthesis was carried out in analogy to 21a. 2.65 g (10 mmol) of Boc-L-
phenylalanine was used. 
 
Yield: 5.03 g (91 %) 
 
 
21c: Anal. calc. for C24H29IN2O5 (552.11 g/mol): C, 52.18; H, 5.29; N, 5.07. Found: C, 
51.59; H, 5.36; N, 5.07. IR (cm-1) in KBr: 3337 (s) υNH, 2980 (m) υCH, 1739 (s) υCOO, 
1662 (vs) υCON, 1521 (s) δNH. MS (FAB): m/z 553 [M + 1]+, 497 [M – C4H9]+, 453 [M – 
Boc]+. 1H NMR (DMSO-d6, 360.14 MHz): 8.33 (d, 1H, J=7.6Hz, NHPhe), 7.62 (d, 2H, 
J=7.5Hz, HAr), 7.22 (m, 5H, HAr), 7.05 (d, 2H, J=7.5Hz, HAr), 6.87 (d, 1H, J=8.6Hz, 
NHBoc), 4.50 (dd, 1H, J=7.1Hz, J=13.2Hz, CαHPhe-I), 4.17 (dd, 1H, J=7.2 Hz, J=13.4Hz, 
CαHPhe), 3.60 (s, 3H, CH3), 2.97 (m, 2H, CβHPhe-I), 2.74 (m, 2H, CβHPhe), 1.29 (s, 9H, 
CH3, Boc). 13C NMR (DMSO-d6, 90.56 MHz): 171.7, 171.5 (COO, CON), 155.0 (COBoc), 
137.9, 136.8 (CAr, q), 136.9, 131.5, 129.0, 127.9, 126.1 (CAr), 92.4 (CAr-I), 78.0 (CBoc, q), 
55.5 (Cα, Phe), 53.1 (Cα, Phe-I), 51.8 (CH3), 37.3 (Cβ, Phe), 36.1 (Cβ, Phe-I), 28.0 (CH3, Boc). 
UV-Vis (λ in nm, [ε in M-1cm-1]): 231, [14153] 
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The synthesis was carried out in analogy to 21a. 2.81 g (10 mmol) of Boc-L-tyrosine 
was used. 
 
Yield: 5.24 g (92 %) 
 
 
21d: Anal. calc. for C24H29IN2O6 (568.11 g/mol): C, 50.71; H, 5.14; N, 4.93. Found: C, 
50.43; H, 5.17; N, 4.88. IR (cm-1) in KBr: 3306 (s) υNH, 2978 (m) υCH, 1709 (s) υCOO, 
1661 (vs) υCON, 1522 (s) δNH. MS (FAB): m/z 569 [M + 1]+, 513 [M – C4H9]+, 469 [M – 
Boc]+. 1H NMR (DMSO-d6, 360.14 MHz): 9.14 (s, OHTyr), 8.25 (d, 1H, J=7.7Hz, 
NHPhe), 7.60 (d, 2H, J=8.0Hz, HAr, Phe), 7.03 (d, 2H, J=8.0Hz, HAr, Phe), 6.98 (d, 2H, 
J=8.2Hz, HAr, Tyr), 6.76 (d, 1H, J=8.6Hz, NHBoc), 6.62 (d, 2H, J=8.1Hz, HAr, Tyr), 4.48 
(dd, 1H, J=7.9Hz, J=13.6Hz, CαHPhe-I), 4.06 (dd, 1H, J=7.6 Hz, J=13.2Hz, CαHPhe), 3.58 
(s, 3H, CH3), 2.94 (m, 2H, CβHPhe-I), 2.62 (m, 2H, CβHPhe), 1.29 (s, 9H, CH3, Boc). 13C 
NMR (DMSO-d6, 90.56 MHz): 172.0, 171.6 (COO, CON), 155.6 (CArOHTyr),  154.9 
(COBoc), 136.7, 127.8 (CAr, q), 136.8, 131.5, 129.9, 114.7 (CAr), 92.4 (CAr-I), 77.9 (CBoc, 
q), 55.7 (Cα, Tyr), 52.9 (Cα, Phe-I), 51.8 (CH3), 36.5 (Cβ, Tyr), 36.0 (Cβ, Phe-I), 28.1 (CH3, Boc). 
UV-Vis (λ in nm, [ε in M-1cm-1]): 229, [19492]; 276, [1172] 
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To a suspension of 2.3 g of ferrocene carboxylic acid (10 mmol) in 50 ml of dried and 
degassed DCM was added under argon 1.78 g of thionyl chloride (15 mmol). The mix-
ture was heated at reflux for 1 hour. The clear and orange solution was allowed to cool 
down and the solvent was removed under reduced pressure, leaving a dark orange solid. 
The latter was dissolved in 50 ml of dried DCM and treated with 1.1 g of 1,1-
diethylpropargylamine (10 mmol) and 1.01 g of NEt3 (10 mmol). After 6 h of stirring at 
ambient temperature and removal of triethylamine hydrochloride by filtration through 
celite, the solvent was removed by rotary evaporation. The remaining orange solid was 
dissolved in 50 ml of chloroform and washed three times with water. After drying over 
Na2SO4 and filtration the solution was rotary evaporated to dryness. The crude product 
could be recrystallised from methanol. 
 
Yield: 2.89 g (89 %) of DEPA-Fc as an orange solid.  
 
 
22: Anal. calc. for C18H21FeNO (323.10 g/mol): C, 66.89; H, 6.55; N, 4.33. Found: C, 
66.65; H, 6.60; N, 4.30. IR (cm-1) in KBr: 3300 (s) υCC, alkyne, 3276 (s) υNH, 2972, 2877 
(m) υCH, 1630 (vs) υCON, 1526 (s) δNH. MS (EI): m/z 323 (100, [M]+), 295 (12, [M – 
Ethyl]+), 267 (10, [M – 2 Ethyl]+), 213 (40, [Fc-CO]+), 185 (22, [Fc]+) . 1H NMR 
(DMSO-d6, 360.14 MHz): 7.08 (s, NH), 4.89 (m, 2H, CpH1,2), 4.33 (m, 2H, CpH3,4), 
4.18 (s, 5H, CpH), 3.19 (s, 1H, CHalkyne), 2.01 (qd, 2H, J=7.3Hz, J=14.5 Hz, CH2, DEPA), 
1.83 (qd, 2H, J=7.3Hz, J=14.6 Hz, CH2, DEPA), 0.95 (t, 6H, J=7.3Hz, CH3,DEPA). 13C 
NMR (DMSO-d6, 90.56 MHz): 168.0 (CON), 85.9, 72.8 (Calkyne), 76.6 (CCp, 1), 69.6 
(CCp, 2,5), 69.0 (CCp’), 68.2 (CCp, 3,4), 55.1 (CDEPA, q), 29.7 (CH2, DEPA), 8.2 (CH3, DEPA). 
UV-Vis (λ in nm, [ε in M-1cm-1]): 259, [3649]; 304, [760]; 444, [232] 
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12 ml of a mixture of dried THF and NEt3 (1:1) was thoroughly degassed in a Schlenck-
tube. To this solution was added 476 mg of Boc-Ala-Phe(I)-OMe (1 mmol) and 356 mg 
(1.1 mmol) of DEPA-Fc. Then was added a mixture of 14 mg of Pd(PPh3)2Cl2 (0.02 
mmol, 2 mol%) and CuI (6 mg, 0.03 mmol, 3 mol%) as a catalyst. The mixture was 
stirred under argon until no more triethylamine hydroiodide precipitated (6h). After re-
moval of the salts by filtration the solvents were removed under reduced pressure and 
the product was purified by column chromatography on silica using ethyl acetate / hex-
ane (2:1, Rf = 0.42). Yield: 504.0 mg (74 %) 
 
23a: Anal. calc. for C36H45FeN3O6 (671.27 g/mol): C, 64.38; H, 6.75; N, 6.26. Found: 
C, 64.26; H, 6.64; N, 5.68. IR (cm-1) in KBr: 3321 (s) υNH, 2974 (m) υCH, 1743 (s) υCOO, 
1653 (vs) υCON, 1508 (s) δNH, 821 (m) δCH. MS (FAB): m/z 671 [M]+, 572 [M - Boc]+, 
213 [Fc-CO]+, 185 [Fc]+. 1H NMR (CDCl3, 360.14 MHz): 7.36 (d, 2H, J=8.0Hz, HAr), 
7.04 (d, 2H, J=8.0Hz, HAr), 6.67 (d, 1H, J=7.5Hz, NHPhe), 5.74 (s, 1H, NHFc), 5.03 (d, 
1H, J=5.6Hz, NHBoc), 4.81 (m, 1H, CαHPhe), 4.64 (m, 2H, CpH1,2), 4.31 (m, 2H, CpH3,4), 
4.21 (s, 5H, CpH), 4.14 (m, 1H, CαHAla), 3.69 (s, 3H, CH3), 3.09 (m, 2H, CβH,Phe), 2.38 
(qd, 2H, J=7.2Hz, J=14.4Hz, CH2, DEPA), 1.91 (qd, 2H, J=7.3Hz, J=14.5Hz, CH2, DEPA), 
1.41 (s, 9H, CH3, Boc), 1.30 (d, 3H, J=7.1Hz, CH3, Ala), 1.09 (t, 6H, J=7.3Hz, CH3, DEPA). 
13C NMR (CDCl3, 90.56 MHz): 172.3, 171.4 (COO, CON), 169.0 (COFc), 155.3 (CO-
Boc), 136.2 (CAr, q), 131.9, 129.2 (CAr), 121.5 (CAr, alkyne), 91.1, 83.3 (Calkyne), 80.0 (CBoc, 
q), 76.8 (CCp, 1), 70.2 (CCp, 2,5), 69.6 (CCp’), 68.0 (CCp, 3,4), 58.4 (CDEPA, q), 53.0 (Cα, Phe), 
52.3 (CH3), 50.0 (Cα, Ala), 36.6 (Cβ, Phe), 30.9 (CH2, DEPA), 28.2 (CH3, Boc), 18.1 (CH3, Ala), 
9.0 (CH3, DEPA). UV-Vis (λ in nm, [ε in M-1cm-1]): 246, [24825]; 256, [22152]; 442, 
[236] 
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The synthesis was carried out in analogy to 23a. 581 mg (1 mmol) of Boc-Leu-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (1:2, Rf = 0.33). 
 
 
Yield: 650.0 mg (91 %) 
 
23b: Anal. calc. for C39H51FeN3O6 (713.31 g/mol): C, 65.63; H, 7.20; N, 5.89. Found: 
C, 65.53; H, 7.41; N, 5.50. IR (cm-1) in KBr: 3318 (s) υNH, 2964 (m) υCH, 1748 (s) υCOO, 
1662 (vs) υCON, 1507 (s) δNH, 822 (m) δCH. MS (FAB): m/z 713 [M]+, 614 [M - Boc]+, 
213 [Fc-CO]+, 185 [Fc]+. 1H NMR (CDCl3, 360.14 MHz): 7.37 (d, 2H, J=8.0Hz, HAr), 
7.06 (d, 2H, J=8.0Hz, HAr), 6.57 (d, 1H, J=7.7Hz, NHPhe), 5.73 (s, 1H, NHFc), ca. 5.00 
(NHBoc, not obs.), 4.83 (m, 1H, CαHPhe), 4.65 (m, 2H, CpH1,2), 4.32 (m, 2H, CpH3,4), 
4.23 (s, 5H, CpH), 4.18 (m, 1H, CαHAla), 3.71 (s, 3H, CH3), 3.11 (m, 2H, CβH,Phe), 2.40 
(qd, 2H, J=7.3Hz, J=14.5Hz, CH2, DEPA), 1.92 (qd, 2H, J=7.2Hz, J=14.3Hz, CH2, DEPA), 
1.43 (s, 9H, CH3, Boc), 1.43 (m, 2H, CβH,Leu), 1.10 (t, 6H, J=7.3Hz, CH3, DEPA), 0.91 (t, 
6H, J=6.0Hz, CH3, Leu). 13C NMR (CDCl3, 90.56 MHz): 172.1, 171.4 (COO, CON), 
169.0 (COFc), 155.5 (COBoc), 136.2 (CAr, q), 131.9, 129.3 (CAr), 121.6 (CAr, alkyne), 91.2, 
83.4 (Calkyne), 80.1 (CBoc, q), 76.9 (CCp, 1), 70.2 (CCp, 2,5), 69.7 (CCp’), 68.1 (CCp, 3,4), 58.6 
(CDEPA, q), 53.2 (Cα, Leu), 53.1 (Cα, Phe), 52.3 (CH3), 41.1 (Cβ, Leu), 37.7 (Cβ, Phe), 31.0 
(CH2, DEPA), 28.2 (CH3, Boc), 24.7 (CH3, Leu), 22.8 (CH(CH3)2), 9.1 (CH3, DEPA). UV-Vis 
(λ in nm, [ε in M-1cm-1]): 246, [28332]; 255, [24239]; 444, [249] 
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The synthesis was carried out in analogy to 23a. 552 mg (1 mmol) of Boc-Phe-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (1:1, Rf = 0.38). 
 
 
Yield: 539.0 mg (72 %) 
 
23c: Anal. calc. for C42H49FeN3O6 (747.30 g/mol): C, 67.47; H, 6.61; N, 5.62. Found: 
C, 66.92; H, 6.42; N, 5.44. IR (cm-1) in KBr: 3316 (s) υNH, 2973 (m) υCH, 1744 (s) υCOO, 
1663 (vs) υCON, 1507 (s) δNH, 821 (m) δCH. MS (FAB): m/z 747 [M]+, 648 [M - Boc]+, 
582 [M - Boc - Cp]+, 213 [Fc-CO]+, 185 [Fc]+. 1H NMR (CDCl3, 360.14 MHz): 7.33 
(d, 2H, J=8.1Hz, HAr, Phe), 7.23 (m, 5H, HAr), 6.94 (d, 2H, J=7.9Hz, HAr), 6.35 (d, 1H, 
J=7.4Hz, NHPhe), 5.73 (s, 1H, NHFc), 4.97 (m, 1H, NHBoc), 4.77 (m, 1H, CαHPhe2), 4.65 
(m, 2H, CpH1,2), 4.33 (m, 2H, CpH3,4), 4.24 (s, 5H, CpH), 4.18 (m, 1H, CαHPhe1), 3.66 
(s, 3H, CH3), 3.04 (m, 4H, CβH), 2.41 (qd, 2H, J=7.2Hz, J=14.4Hz, CH2, DEPA), 1.93 (qd, 
2H, J=7.3Hz, J=14.6Hz, CH2, DEPA), 1.40 (s, 9H, CH3, Boc), 1.11 (t, 6H, J=7.4Hz, CH3, 
DEPA). 13C NMR (CDCl3, 90.56 MHz): 171.0, 170.7 (COO, CON), 169.0 (COFc), 155.2 
(COBoc), 136.4, 136.0 (CAr, q), 131.9, 129.3, 129.1,  128.6, 126.9 (CAr), 121.6 (CAr, alkyne), 
91.2, 83.3 (Calkyne), 80.2 (CBoc, q), 76.9 (CCp, 1), 70.3 (CCp, 2,5), 69.6 (CCp’), 68.0 (CCp, 3,4), 
58.5 (CDEPA, q), 55.7 (Cα, Phe1), 53.1 (Cα, Phe), 52.3 (CH3), 38.1 (Cβ, Phe1), 37.7 (Cβ, Phe2), 
31.0 (CH2, DEPA), 28.2 (CH3, Boc), 9.1 (CH3, DEPA). UV-Vis (λ in nm, [ε in M-1cm-1]): 246, 
[27984]; 256, [24511]; 442, [276] 
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The synthesis was carried out in analogy to 23a. 568 mg (1 mmol) of Boc-Tyr-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (1:1, Rf = 0.33). 
 
 
Yield: 581.0 mg (76 %) 
 
23d: Anal. calc. for C42H49FeN3O7 (763.29 g/mol): C, 66.05; H, 6.47; N, 5.50. Found: 
C, 65.52; H, 6.79; N, 5.02. IR (cm-1) in KBr: 3337 (s) υNH, 2972 (m) υCH, 1740 (s) υCOO, 
1663 (vs) υCON, 1516 (s) δNH, 821 (m) δCH. MS (FAB): m/z 764 [M+1]+, 664 [M - 
Boc]+, 598 [M - Boc - Cp]+, 213 [Fc-CO]+, 185 [Fc]+. 1H NMR (CDCl3, 360.14 MHz): 
8.63 (s, 1H, OHTyr), 7.32 (d, 2H, J=7.9Hz, HAr, Phe), 6.92 (d, 2H, J=7.9Hz, HAr, Phe), 6.81 
(m, br, 4H, HAr, Tyr), 6.26 (d, 1H, J=8.1Hz, NHPhe), 5.82 (s, 1H, NHFc), 4.97 (s, br, 1H, 
NHBoc), 4.84 (dd, 1H, J=7,5Hz, J=13.0Hz, CαHPhe), 4.70 (m, 2H, CpH1,2), 4.35 (m, 2H, 
CpH3,4), 4.31 (m, 1H, CαHTyr), 4.24 (s, 5H, CpH), 3.70 (s, 3H, CH3), 3.13 (m, 2H, 
CβHPhe), 2.80 (m, 2H, CβHTyr), 2.14 (m, 2H, CH2, DEPA), 2.04 (m, 2H, CH2, DEPA), 1.45 (s, 
9H, CH3, Boc), 1.11 (t, 6H, J=7.4Hz, CH3, DEPA). 13C NMR (CDCl3, 90.56 MHz): 171.3, 
171.2 (COO, CON), 170.2 (COFc), 156.3 (CArOHTyr), 155.2 (COBoc), 135.6, 126.4 (CAr, 
q), 131.8, 139.2, 128.9, 115.7 (CAr), 121.6 (CAr, alkyne), 90.7, 83.5 (Calkyne), 80.2 (CBoc, q), 
76.7 (CCp, 1), 70.7 (CCp, 2,5), 69.7 (CCp’), 68.1 (CCp, 3,4), 56.8 (CDEPA, q), 55.3 (Cα, Tyr), 52.7 
(Cα, Phe), 52.3 (CH3), 37.6 (Cβ, Phe), 36.7 (Cβ, Tyr), 31.0 (CH2, DEPA), 28.2 (CH3, Boc), 8.7 
(CH3, DEPA). UV-Vis (λ in nm, [ε in M-1cm-1]): 246, [26010]; 256, [22840]; 442, [231] 
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12 ml of a mixture of dried THF and NEt3 (1:1) was thoroughly degassed in a Schlenck-
tube. To this solution was added 476 mg of Boc-Ala-Phe(I)-OMe (1 mmol) and 231 mg 
(1.1 mmol) of ethynylferrocene. Then was added a mixture of 14 mg of Pd(PPh3)2Cl2 
(0.02 mmol, 2 mol%) and CuI (6 mg, 0.03 mmol, 3 mol%) as a catalyst. The mixture 
was stirred under argon until no more triethylamine hydroiodide precipitated (6h). After 
removal of the salts by filtration the solvents were removed under reduced pressure and 
the product was purified by column chromatography on silica using ethyl acetate / hex-
ane (4:5, Rf = 0.41). Yield: 385.5 mg (69 %) 
 
24a: Anal. calc. for C30H34FeN2O5 (558.18 g/mol): C, 64.52; H, 6.14; N, 5.02. Found: 
C, 62.53; H, 6.24; N, 4.52. IR (cm-1) in KBr: 3315 (s) υNH, 2976 (m) υCH, 1710 (s) υCOO, 
1662 (vs) υCON, 1515 (s) δNH, 820 (m) δCH. MS (EI): m/z 558 (100, [M + 1]+), 502 (21, 
[M – C4H9]+) , 484 (20, [M – OC4H9]+), 458 (18, [M – Boc]+) , 299 (80, [Fc-alkinyl-Ph-
CH2]+). 1H NMR (CDCl3, 360.14 MHz): 7.32 (d, 2H, J=8.0Hz, HAr), 6.99 (d, 2H, 
J=8.0Hz, HAr), 6.55 (d, 1H, J=7.4Hz, NHPhe), 4.90 (m, 1H, NHBoc), 4.77 (dd, 1H, 
J=5.9Hz, J=13.3Hz, CαHPhe), 4.41 (m, 2H, CpH1,2), 4.16 (s, 2H, CpH3,4), 4.16 (s, 5H, 
CpH), 4.09 (m, 1H, CαHAla), 3.64 (s, 3H, CH3), 3.05 (m, 2H, CβH), 1.38 (s, 9H, CH3, 
Boc), 1.25 (d, 3H, J=7.0Hz, CH3, Ala). 13C NMR (CDCl3, 90.56 MHz): 172.3, 171.5 
(COO, CON), 155.3 (COBoc), 135.4 (CAr, q), 131.5, 129.2 (CAr), 122.7 (CAr, alkyne), 88.5, 
85.3 (Calkyne),  80.21 (CBoc, q), 71.3 (CCp, 2,5), 69.9 (CCp’), 68.7 (CCp, 3,4), 65.1 (CCp, 1), 53.0 
(Cα, Phe), 52.3 (CH3), 50.1 (Cα, Ala), 37.7 (Cβ), 28.2 (CH3, Boc), 18.1 (CH3, Ala). UV-Vis (λ 
in nm, [ε in M-1cm-1]): 256, [18335]; 300, [16305]; 445, [563] 
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The synthesis was carried out in analogy to 24a. 518 mg (1 mmol) of Boc-Leu-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (2:5, Rf = 0.29). 
 
 
Yield: 430.0 mg (72 %) 
 
24b: Anal. calc. for C33H40FeN2O5 (600.23 g/mol): C, 66.00; H, 6.71; N, 4.66. Found: 
C, 65.06; H, 6.63; N, 4.40. IR (cm-1) in KBr: 3303 (s) υNH, 2956 (m) υCH, 1709 (s) υCOO, 
1659 (vs) υCON, 1515 (s) δNH, 820 (m) δCH. MS (FAB): m/z 600 [M]+, 545 [M – C4H9]+ , 
501 [M - Boc]+), 299 [Fc-alkinyl-Ph-CH2]+. 1H NMR (CDCl3, 360.14 MHz): 7.32 (d, 
2H, J=8.1Hz, HAr), 7.00 (d, 2H, J=8.0Hz, HAr), 6.59 (d, 1H, J=7.5Hz, NHPhe), 4.86 (d, 
1H, J=7.8Hz, NHBoc), 4.77 (m, 1H, CαHPhe), 4.41 (m, 2H, CpH1,2), 4.16 (s, 2H, CpH3,4), 
4.16 (s, 5H, CpH), 4.16 (m, 1H, CαHAla), 3.63 (s, 3H, CH3), 3.04 (m, 2H, CβH), 1.56 (m, 
1H, CH(CH3)),  1.38 (s, 9H, CH3, Boc), 0.85 (pseudo-t, 6H, J=6.2Hz, CH3, Leu). 13C NMR 
(CDCl3, 90.56 MHz): 172.2, 171.5 (COO, CON), 155.5 (COBoc), 135.4 (CAr, q), 131.4, 
129.2 (CAr), 122.7 (CAr, alkyne), 88.4, 85.4 (Calkyne),  79.9 (CBoc, q), 71.3 (CCp, 2,5), 69.9 
(CCp’), 68.7 (CCp, 3,4), 65.2 (CCp, 1), 53.0 (Cα, Phe), 52.9 (Cα, Leu), 52.2 (CH3), 41.1 (Cβ, Leu), 
37.7 (Cβ, Phe), 28.2 (CH3, Boc), 24.6 (CH3, Leu), 22.8 (CH(CH3)2). UV-Vis (λ in nm, [ε in 
M-1cm-1]): 256, [17927]; 301, [16026]; 445, [582] 
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The synthesis was carried out in analogy to 24a. 552 mg (1 mmol) of Boc-Phe-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (1:2, Rf = 0.33). 
 
 
Yield: 489.0 mg (77 %) 
 
24c: Anal. calc. for C36H38FeN2O5 (634.21 g/mol): C, 68.14; H, 6.04; N, 4.41. Found: 
C, 67.70; H, 6.12; N, 4.29. IR (cm-1) in KBr: 3308 (s) υNH, 2976 (m) υCH, 1696 (s) υCOO, 
1662 (vs) υCON, 1516 (s) δNH, 820 (m) δCH. MS (FAB): m/z 634 [M]+, 579 [M – C4H9]+ , 
535 [M - Boc]+), 299 [Fc-alkinyl-Ph-CH2]+. 1H NMR (CDCl3, 360.14 MHz): 7.35 (d, 
2H, J=8.1Hz, HAr), 7.25 (m, 5H, HAr, Ph), 6.93 (d, 2H, J=8.1Hz, HAr), 6.35 (d, 1H, 
J=7.3Hz, NHPhe), 4.97 (m, 1H, NHBoc), 4.79 (m, 1H, CαHPhe2), 4.48 (m, 2H, CpH1,2), 
4.36 (m, 1H, CαHPhe1), 4.23 (s, 2H, CpH3,4), 4.23 (s, 5H, CpH), 3.67 (s, 3H, CH3), 3.05 
(m, 4H, CβH), 1.41 (s, 9H, CH3, Boc). 13C NMR (CDCl3, 90.56 MHz): 171.1, 170.8 
(COO, CON), 155.2 (COBoc), 136.4, 135.2 (CAr, q), 131.4, 129.3, 129.1, 128.7, 126.9 
(CAr), 122.7 (CAr, alkyne), 88.5, 85.4 (Calkyne),  80.2 (CBoc, q), 71.3 (CCp, 2,5), 69.9 (CCp’), 
68.7 (CCp, 3,4), 65.2 (CCp, 1), 55.0 (Cα, Phe1), 53.1 (Cα, Phe2), 52.2 (CH3), 38.1 (Cβ, Phe1), 37.8 
(Cβ, Phe), 28.2 (CH3, Boc). UV-Vis (λ in nm, [ε in M-1cm-1]): 256, [18338]; 301, [16234]; 
446, [586] 
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The synthesis was carried out in analogy to 24a. 568 mg (1 mmol) of Boc-Tyr-Phe(I)-
OMe was used. The product was purified by column chromatography on silica using 
ethyl acetate / hexane (1:1, Rf = 0.29). 
 
 
Yield: 525.0 mg (81 %) 
 
24d: Anal. calc. for C36H38FeN2O6 (650.21 g/mol): C, 66.47; H, 5.89; N, 4.31. Found: 
C, 64.93; H, 5.92; N, 4.04. IR (cm-1) in KBr: 3334 (s) υNH, 2977 (m) υCH, 1739 (s) υCOO, 
1662 (vs) υCON, 1516 (s) δNH, 822 (m) δCH. MS (FAB): m/z 650 [M]+, 595 [M – C4H9 + 
H]+ , 551 [M - Boc]+), 299 [Fc-alkinyl-Ph-CH2]+. 1H NMR (DMSO-d6, 360.14 MHz): 
9.16 (s, 1H, OHTyr), 8.24 (d, 1H, J=7.7Hz, NHPhe), 7.35 (d, 2H, J=7.9Hz, HAr, Phe), 7.20 
(d, 2H, J=7.9Hz, HAr, Phe), 6.97 (d, 2H, J=8.1Hz, HAr, Tyr), 6.71 (d, 1H, J=8.6Hz, NHBoc), 
6.62 (d, 2H, J=8.1Hz, HAr, Tyr), 4.52 (m, 2H, CpH1,2), 4.49 (m, 1H, CαHTyr), 4.29 (m, 2H, 
CpH3,4), 4.23 (s, 5H, CpH), 4.07 (m, 1H, CαHPhe), 3.58 (s, 3H, CH3), 2.97 (m, 2H, 
CβH,Phe), 2.65 (m, 2H, CβH,Tyr), 1.29 (s, 9H, CH3, Boc). 13C NMR (DMSO-d6, 90.56 
MHz): 171.9, 171.6 (COO, CON), 155.7 (CArOHTyr), 155.0 (COBoc), 137.1, 127.9 (CAr, 
q), 130.9, 130.0, 129.5, 114.7 (CAr), 121.2 (CAr, alkyne), 88.3, 85.3 (Calkyne),  78.0 (CBoc, q), 
71.0 (CCp, 2,5), 69.7 (CCp’), 68.9 (CCp, 3,4), 64.4 (CCp, 1), 55.8 (Cα, Tyr), 53.0 (Cα, Phe), 51.8 
(CH3), 36.6 (Cβ, Phe), 36.5 (Cβ, Tyr), 28.1 (CH3, Boc). UV-Vis (λ in nm, [ε in M-1cm-1]): 
256, [18338]; 301, [16234]; 446, [586] 
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11.63 g (40 mmol) of p-iodo-phenylalanine was dissolved in a mixture of 100 ml of 
H2O and 150 ml of 1,4-dioxane, followed by the addition of 2 equivalents of sodium 
carbonate (8.48 g, 80 mmol) as a base. The mixture was cooled to 5 °C and a solution of 
13.5 g (40 mmol) of Fmoc-ONSu in 50 ml dioxane was added under continuous stir-
ring. After 1 h the reaction mixture was filtered and the solvents were removed by ro-
tary evaporation. The viscous residue was re-dissolved in 250 ml of water and precipi-
tated by the addition of 6 N HCl. Recrystallization from chloroform yielded 17.8 g 
(86.7%) of Fmoc-p-iodo-phenylalanine in high purity. 
 
25: Anal. calc. for C24H20INO4 (513.04 g/mol): C, 56.15; H, 3.93; N, 2.73. Found: C, 
55.17; H, 4.09; N, 2.62. IR (cm-1) in KBr: 3314 (s) υNH, 3063, 2947 (m) υCH, 1693 (vs) 
υCOO, 1539 (s) δNH, 1255 (s) υC-O. MS (FAB): m/z 514 [M + H]+, 388 [M – I + H]+, 203 
[M – C6H5I]+, 165 [Fluorenyl]+. 1H NMR (DMSO-d6, 360.14 MHz): 7.88 (d, 2H, 
J=7.5Hz, HAr, Fl), 7.73 (d, 1H, J=8.5Hz, NH), 7.63 (m, 4H, HAr, Fl, Phe), 7.41 (pseudo-t, 
2H, HAr, Fl), 7.30 (dd, 2H, J=7.9Hz, J=16.8Hz, HAr, Fl), 7.09 (d, 2H, J=8.1Hz, HAr, Phe), 
4.17 (m, 4H, CαHPhe, R3CHFl, CH2, Fl), 3.04, 2.82 (m, 2H, CβHPhe). 13C NMR (DMSO-d6, 
90.56 MHz): 173.0 (COO) 155.8 (CON), 143.7, 140.6, 137.7 (CAr, q), 136.8, 131.5, 
127.5, 126.9, 125.1, 120.0 (CAr), 92.2 (CAr-I), 65.5 (CH2, Fl), 55.1 (Cα, Phe), 46.5 (R3CHFl), 
35.8 (Cβ) 
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 800 288 mg (79.0 %) 
 
 
 
26: C30H38IN5O8 (723.18 g/mol): MS (FAB): m/z 746 [M + Na]+, 724 [M + H]+, 593 
[M – H-Leu-OH]+, 320 [M – H-Phe(I)-Leu-OH]+, 263 [M – H-Gly-Phe(I)-Leu-
OH]+. 1H NMR (DMSO-d6, 360.14 MHz): 12.58 (s, br, 1H, COOH), 9.15 (s, br, 1H, 
OHTyr), 8.27 (d, 1H, J=8.1Hz, NHLeu), 8.22 (t, 1H, J=5.4Hz, NHGly), 8.06 (d, 1H, 
J=8.0Hz, NHTyr), 7.99 (d, 1H, J=8.5Hz, NHI-Phe, 7.93 (t, 1H, J=5.5Hz, NHGly), 7.60 (d, 
2H, J=8.1Hz, HAr, I-Phe), 7.07 (d, 2H, J=8.2Hz, HAr, I-Phe), 7.02 (d, 2H, J=8.3Hz, HAr, Tyr), 
6.63 (d, 2H, J=8.3Hz, HAr, Tyr), 4.54 (dt, 1H, J=3.7Hz, J=9.0Hz, CαHI-Phe), 4.39 (dt, 1H, 
J=4.8Hz, J=9.1Hz, CαHTyr), 4.21 (pseudo-dd, 1H, ), 3.66 (m, 4H, CαHGly), 2.81 (m, 4H, 
CβHPhe, Tyr), 1.61 (m, 1H, CH(CH3)2), 1.54 (m, 2H, CβHLeu), 0.87 (dd, 6H, J=6.2Hz, 
J=17.0Hz, CH(CH3)2). 13C NMR (DMSO-d6, 90.56 MHz): 173.7 (COO), 171.8, 170.7, 
169.3 (CON), 168.9 (CONAc), 168.3 (CON), 155.6 (CArOHTyr), 137.5 (CAr, q, I-Phe), 136.7 
(CAr, I-Phe), 131.7 (CAr, q, Tyr), 129.8, 128.0, 114.8 (CAr), 92.1 (CAr, q, I-Phe), 54.4 (Cα, I-Phe), 
53.2 (Cα, Tyr), 50.2 (Cα, Leu), 42.0, 41.7 (Cα, Gly), 37.0 (Cβ, Phe), 36.5 (Cβ, Tyr), 24.2 (Cβ, Leu), 
22.7 (CH3, Leu), 22.4 (CH3, Ac), 21.2 (CH(CH3)2).  
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Resin Loading (mmol/g) AA excess 
Cleavage 
mixture 
Cleavage 
time mg resin yield 
Wang 0.63 5 
95% TFA 
2.5% H2O 
2.5% TIS 
3 h 800 367 mg (92.7 %) 
 
 
 
27: C35H40IN5O8 (785.19 g/mol): MS (FAB): m/z 808 [M + Na]+, 786 [M + H]+, 655 
[M – H-Leu-OH]+, 508 [M – H-Phe-Leu-OH]+, 451 [M – H-Gly-Phe-Leu-OH]+. 1H 
NMR (DMSO-d6, 360.14 MHz): 12.54 (s, br, 1H, COOH), 9.12 (s, br, 1H, OHTyr), 8.61 
(d, 1H, J=8.2Hz, NHTyr), 8.31 (t, 1H, J=5.5Hz, NHGly), 8.26 (d, 1H, J=7.9Hz, NHLeu), 
8.04 (d, 1H, J=8.4Hz, NHPhe), 7.96 (t, 1H, J=5.5Hz, NHGly), 7.82 (d, 2H, J=8.4Hz, HAr, I-
Ph), 7.57 (d, 2H, J=8.4Hz, HAr, I-Ph), 7.25 (m, 5H, HAr, Phe), 7.09 (d, 2H, J=8.3Hz, HAr, Tyr), 
6.61 (d, 2H, J=8.4Hz, HAr, Tyr), 4.59 (m, 2H, CαHPhe, Tyr), 4.22 (dd, 1H, J=8.4HZ, 
J=14.0Hz, CαHLeu), 3.63 (m, 4H, CαHGly), 2.85 (m, 4H, CβHPhe, Tyr), 1.64 (m, 1H, 
CH(CH3)2), 1.54 (m, 2H, CβHLeu), 0.87 (dd, 6H, J=6.3Hz, J=16.8Hz, CH(CH3)2). 13C 
NMR (DMSO-d6, 90.56 MHz): 173.7 (COO), 171.6, 170.9, 168.8, 168.1 (CON), 165.6 
(CONI-Ph), 155.6 (CArOHTyr), 137.6 (CAr, q, Phe), 136.9 (CAr, I-Ph), 133.4 (CAr, q, I-Ph), 129.9, 
129.3, 129.1 (CAr), 128.3 (CAr, q, Tyr), 127.9, 126.1, 114.8 (CAr), 98.7 (CAr, q, I-Ph), 55.2 
(Cα, Phe), 52.7 (Cα, Phe), 53.4 (Cα, Tyr), 50.2 (Cα, Leu), 42.0, 41.6 (Cα, Gly), 37.5 (Cβ, Phe), 36.1 
(Cβ, Tyr), 24.2 (Cβ, Leu), 22.7 (CH3, Leu), 21.2 (CH(CH3)2).  
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100 mg (0.134 mmol) of Ac-Enk[Phe4(I)]-OH 26 were dissolved in 8 ml of a well de-
gassed mixture of DMF/NEt3 (1:1) in a Schlenck-tube. After complete dissolution 1.1 
equivalents (47.6 mg, 0.147 mmol) of DEPA-Fc 22 were added, followed by another 15 
min. of degassing. 14 mg of CuI and 28 mg of Pd(PPh3)2Cl2 are added and the mixture 
is stirred for 12 hours. The solution was filtered through a syringe filter (22 µm pore 
size), the solvent was evaporated in vacuo and the residual oil was re-dissolved in ace-
tonitrile. The compound was purified by preparative HPLC.  
 
Yield: 58.6 mg ( 47.6%) 
 
 
28: C48H58IN6O9 (918.36 g/mol): MS (ESI, -Q1MS): m/z 917.4 [M - H]-, (+Q1MS): m/z 
919.4 [M + H]+, 941.4 [M + Na]+, 957.5 [M + K]+. 1H NMR (DMSO-d6, 399.90 MHz): 
12.59 (s, br, 1H, COOH), 9.17 (s, 1H, OHTyr), 8.30 (d, 1H, J=7.9Hz, NHLeu), 8.25 (t, 
1H, J=5.6Hz, NHGly), 8.07 (d, 1H, J=8.1Hz, NHTyr), 8.02 (d, 1H, J=8.7Hz, NHPhe, 7.94 
(t, 1H, J=5.5Hz, NHGly), 7.58 (m, 2H, HAr, Phe), 7.25 (d, 2H, 5.8Hz, HAr, Phe), 7.01 (d, 2H, 
J=8.4Hz, HAr, Tyr), 6.63 (d, 2H, J=8.4Hz, HAr, Tyr), 4.92 (pseudo-t, 2H, CpH1,4), 4.56 (dt, 
1H, J=3.8Hz, J=9.5Hz, CαHPhe), 4.38 (dt, 1H, J=4.6Hz, J=9.4Hz, CαHTyr), 4.33 (pseudo-
t, 2H, CpH2,3), 4.19 (s, 5H, CpH), 4.16 (m, 1H, CαHLeu), 3.63 (m, 4H, CαHGly), 2.82 (m, 
4H, CβHPhe, Tyr), 2.10 (m, 2H, CH2, DEPA), 1.90 (m, 2H, CH2, DEPA), 1.76 (s, 3H, CH3, Ace-
tyl), 1.62 (m, 1H, CH(CH3)2), 1.54 (m, 2H, CβHLeu), 1.01 (t, 6H, J=7.3Hz, CH3, DEPA), 
0.87 (dd, 6H, J=6.4Hz, J=2.80Hz, CH(CH3)2). 13C NMR (DMSO-d6, 100.56 MHz): 
173.6 (COO), 171.7, 170.7 (CON), 169.1 (CONAc), 168.6, 168.0, 167.9 (CON), 155.4 
(CArOHTyr), 137.7 (CAr, q, Phe), 130.6 (CAr, q, Tyr), 129.7, 129.1, 127.8, 120.6, 114.5 (CAr), 
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91.6, 82.0 (Calkyne), 76.5 (CCp,1), 69.6 (CCp, 2,5), 68.9 (CCp’), 68.1 (CCp, 3,4), 55.6 (CDEPA, q),  
54.2 (Cα, Phe), 53.0 (Cα, Tyr), 50.0 (Cα, Leu), 41.7, 41.3 (Cα, Gly), 37.2 (Cβ, Phe), 36.3 (Cβ, Tyr), 
29.9 ( CH2, DEPA),  24.0 (Cβ, Leu), 22.5 (CH3, Leu), 22.1 (CH3, Ac), 21.0 (CH(CH3)2), 8.4 
(CH3, DEPA). UV-Vis (λ in nm, [ε in M-1cm-1]): 246, [25165]; 257, [22570]; 444, [272] 
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The synthesis was carried out in analogy to 28. 100 mg (0.127 mmol) of I-Ph-Enk-OH 
27 was used. The product was purified by preparative HPLC. 
 
Yield: 28.0 mg (22.5 %) 
 
29: C53H60FeN6O9 (980.38 g/mol): MS (ESI, -Q1MS): m/z 979.5 [M - H]-. 1H NMR 
(DMSO-d6, 399.90 MHz): 12.58 (s, br, 1H, COOH), 9.16 (s, br, 1H, OHTyr), 8.64 (d, 
1H, J=8.1Hz, NHTyr), 8.35 (t, 1H, J=5.7Hz, NHGly), 8.29 (d, 1H, J=7.9Hz, NHLeu), 8.08 
(d, 1H, J=8.4Hz, NHPhe), 7.99 (t, 1H, J=5.6Hz, NHGly), 7.81 (d, 2H, J=8.3Hz, HAr, Ph), 
7.48 (d, 2H, J=8.3Hz, HAr, Ph), 7.27 (m, 5H, HAr, Phe), 7.11 (d, 2H, J=7.6Hz, HAr, Tyr), 6.63 
(d, 2H, J=8.4Hz, HAr, Tyr), 5.73 (s, 1H, NHFc), 4.95 (m, 2H, CpH1,2), 4.62 (m, 2H, CαH-
Phe, Tyr), 4.37 (m, 2H, CpH3,4), 4.21 (s, 5H, CpH), 4.19 (m, 1H, CαHLeu), 3.69 (m, 4H, 
CαHGly), 2.91 (m, 4H, CβHPhe, Tyr), 2.13 (m, 2H, CH2, Ethyl), 1.97 (m, 2H, CH2, Ethyl), 1.66 
(m, 1H, CH(CH3)2), 1.55 (m, 2H, CβHLeu), 1.05 (t, 6H, CH3, Ethyl), 0.88 (dd, 6H, 
J=6.4Hz, J=22.6Hz, CH(CH3)2). UV-Vis (λ in nm, [ε in M-1cm-1]): 269, [27210]; 442, 
[329] 
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